0001594062-18-000183.txt : 20181106 0001594062-18-000183.hdr.sgml : 20181106 20181106101113 ACCESSION NUMBER: 0001594062-18-000183 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 50 CONFORMED PERIOD OF REPORT: 20180930 FILED AS OF DATE: 20181106 DATE AS OF CHANGE: 20181106 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Qrons Inc. CENTRAL INDEX KEY: 0001689084 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 813623646 STATE OF INCORPORATION: WY FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 000-55800 FILM NUMBER: 181161830 BUSINESS ADDRESS: STREET 1: 777 BRICKELL AVENUE STREET 2: SUITE 500 CITY: MIAMI STATE: FL ZIP: 33131 BUSINESS PHONE: 7866202140 MAIL ADDRESS: STREET 1: 777 BRICKELL AVENUE STREET 2: SUITE 500 CITY: MIAMI STATE: FL ZIP: 33131 FORMER COMPANY: FORMER CONFORMED NAME: BIOLABMART INC. DATE OF NAME CHANGE: 20161102 10-Q 1 form10q.htm 10-Q

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 10-Q

[X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

	For the quarterly period ended: September 30, 2018

[ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

	For the transition period from __________ to __________

000-55800
(Commission File Number)

QRONS INC.
(Exact name of registrant as specified in its charter)

Wyoming	81-3623646
(State or other jurisdiction of incorporation or organization)	(I.R.S. Employer Identification No.)

777 Brickell Avenue, Suite 500, Miami, Florida	33131
(Address of principal executive offices)	(Zip Code)

(786)-620-2140
(Registrant's telephone number, including area code)

(Former name, former address and former fiscal year, if changed since last report)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.

Yes [X] No [ ]

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).

Yes [X] No [ ]

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company" and "emerging growth company" in Rule 12b-2 of the Exchange Act.


Large accelerated filer[ ]	Accelerated filer [ ]
Non-accelerated filer[ ] (Do not check if a smaller reporting company)	Smaller reporting company [X]
	Emerging growth company [X]

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. [ ]

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).

Yes [ ] No [X ]

As of November 5, 2018, there were 12,849,581 shares of the registrant's common stock outstanding.

QRONS INC.

TABLE OF CONTENTS

		Page
	PART I – FINANCIAL INFORMATION

Item 1.	Financial Statements (Unaudited)	3

Item 2.	Management's Discussion and Analysis of Financial Condition and Results of Operations	21

Item 3.	Quantitative and Qualitative Disclosures About Market Risk	27

Item 4.	Controls and Procedures	28

	PART II – OTHER INFORMATION

Item 1.	Legal Proceedings	29

Item 1A.	Risk Factors	29

Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds	29

Item 3.	Defaults Upon Senior Securities	29

Item 4.	Mine Safety Disclosures	29

Item 5.	Other Information	29

Item 6.	Exhibits	30

	SIGNATURES	30

PART I -- FINANCIAL INFORMATION

ITEM 1. FINANCIAL STATEMENTS

QRONS INC.

CONDENSED BALANCE SHEETS

(Unaudited)

	September 30, 2018			December 31, 2017


ASSETS
Current assets
Cash and cash equivalents	$	198,622		$	57,767
Prepaid expenses		54,991			15,812
Total current assets		253,613			73,579

TOTAL ASSETS	$	253,613		$	73,579

LIABILITIES AND STOCKHOLDERS' EQUITY

Current liabilities
Accounts payable and accrued liabilities	$	14,267		$	14,141
Accounts payable and accrued liabilities – related party		2,915			1,410
Convertible note – related party, net of debt discount		25,000			6,665
Derivative liabilities		30,506			31,090
Total current liabilities		72,688			53,306

Total liabilities		72,688			53,306

Stockholders' equity
Series A Preferred Shares: $0.001 par value, authorized 10,000; 2,000 shares issued and outstanding		2			2
Common stock, $0.0001 par value: shares authorized 100,000,000; 12,826,853 and 12,404,910 shares issued and outstanding at September 30, 2018 and December 31, 2017, respectively		1,283			1,240
Additional Paid-in Capital		3,497,774			1,611,711
Accumulated deficit		(3,318,134	)		(1,592,680	)
Total stockholder's equity		180,925			20,273
TOTAL LIABILITIES & STOCKHOLDERS' EQUITY	$	253,613		$	73,579

The accompanying notes are an integral part of these unaudited condensed financial statements.

QRONS INC.

CONDENSED STATEMENTS OF OPERATIONS

(Unaudited)

	Three Months ended						Nine Months ended
	September 30,						September 30,
	2018			2017			2018			2017

Net sales	$	-		$	-		$	-		$	-

Operating expenses:
Research and development expenses		104,798			8,406			237,770			10,120
Professional fees		6,300			8,170			35,449			11,297
General and administrative expenses		423,216			31,643			1,432,980			47,252
Total operating expenses		534,314			48,219			1,706,199			68,669

Income (loss) from operations		(534,314	)		(48,219	)		(1,706,199	)		(68,669	)

Other income (expense)
Interest expense		(6,048	)		(1,785	)		(19,839	)		(7,215	)
Change in derivative liabilities		(2,979	)		(47,954	)		584			(47,954	)
Total Other income (expense)		(9,027	)		(49,739	)		(19,255	)		(55,169	)

Net (loss)	$	(543,341	)	$	(97,958	)	$	(1,725,454	)	$	(123,838	)

Net (loss) per common shares (basic and diluted)	$	(0.04	)	$	(0.00	)	$	(0.14	)	$	(0.00	)

Weighted average shares outstanding
Basic and diluted		12,807,584			11,552,000			12,744,561			11,544,293

The accompanying notes are an integral part of these unaudited condensed financial statements.

QRONS INC.

CONDENSED STATEMENTS OF CASH FLOWS

(Unaudited)

	For the Nine Months ended September 30,
	2018			2017
Cash Flows From Operating Activities
Net loss	$	(1,725,454	)	$	(123,838	)
Adjustments to reconcile net loss to net cash provided from (used by) operating activities:
Stock awards recorded as advisory services		178,000			-
Stock options granted and recorded as administrative expenses and advisory services		1,183,106			-
Accretion of debt discount		18,335			6,599
Change in derivative liabilities		(584	)		47,954
Changes in operating assets and liabilities:
Prepaid expenses		(39,179	)		-
Accounts payable and accrued liabilities		126			6,059
Accounts payable and accrued liabilities, related party		1,505			-
Net cash provided (used by) operating activities		(384,145	)		(63,226	)

Cash Flows From Investing Activities
Net cash provided from (used by) investing activities		-			-

Cash Flows From Financing Activities
Proceeds from convertible note		-			15,000
Proceeds from private placement		525,000			32,000
Financing costs		-			(22,548	)
Net cash provided from financing activities		525,000			24,452

Increase (decrease) in cash and cash equivalents		140,855			(38,774	)

Cash at beginning of period		57,767			155,242
Cash at end of period		198,622			116,468

SUPPLEMENTAL DISCLOSURES
Interest paid	$	-		$	-
Income taxes paid	$	-		$	-

The accompanying notes are an integral part of these unaudited condensed financial statements.

QRONS INC.

NOTES TO UNAUDITED CONDENSED FINANCIAL STATEMENTS

September 30, 2018

Note 1 – Description of Business and Basis of Presentation

Organization and nature of business:

Qrons Inc. ("Qrons" or the "Company") was incorporated under the laws of the State of Wyoming on August 22, 2016 under the name BioLabMart Inc.

On July 6, 2017, the board of directors and a majority of the Company's shareholders approved an amendment to the Company's Articles of Incorporation to change the name of the Company from "BioLabMart Inc." to "Qrons Inc.". On August 8, 2017, the Company filed Amended Articles of Incorporation with the State of Wyoming to effectuate such name change. The Company's common stock was approved by the Financial Industry Regulatory Authority ("FINRA") for quotation on the OTC pink sheets under the symbol "BLMB" as of July 3, 2017. FINRA announced the Company's name change to Qrons Inc. on its Daily List on August 9, 2017. The new name and symbol change to "QRON" for the OTC Market was effective August 10, 2017.

The Company is a preclinical stage biotechnology company developing advanced cell-based solutions to combat neuronal injuries and achieve a breakthrough in the treatment of traumatic brain injuries ("TBIs"), an unmet medical need. We believe that our approach is pushing the boundaries of science by using the latest advances in molecular biology and chemistry. The Company collaborates with universities and scientists in the fields of regenerative medicine, tissue engineering and 3D printable hydrogels to develop a treatment that integrates proprietary, engineered mesenchymal stem cells, 3D printable implant, smart materials and a novel delivery system.

Our headquarters are located at 777 Brickell Avenue, Suite 500, Miami, Florida 33131.

Ariel Agreements

On December 14, 2016, the Company entered into a license and research funding agreement ("License Agreement") with Ariel Scientific Innovations Ltd., formerly known as Ariel University R&D Co., Ltd., ("Ariel"), a wholly owned subsidiary of Ariel University, based in Ariel, Israel. Under the terms of the License Agreement, Professor Danny Baranes, the principal investigator and his research team will carry out further research relating to cell treatment with conditioned medium for neuronal tissue regeneration and repair. In consideration for payments under the License Agreement, the Company received an exclusive worldwide royalty- bearing license in Ariel patents and know-how to develop and commercialize products based on or incorporating conditioned medium for neuronal tissue regeneration and/or repair, resulting from Ariel's research or technology or the Company's research funding (the "Products). Under the License Agreement, the Company is required to use its best efforts to develop and commercialize the Products in accordance with development milestones set forth in the Agreement.

On March 6, 2018, the Company entered into an additional services agreement with Ariel for the services of Professor Gadi Turgeman and his neurobiology research team in their lab.

QRONS INC.

NOTES TO UNAUDITED CONDENSED FINANCIAL STATEMENTS

September 30, 2018

Note 1 – Description of Business and Basis of Presentation (continued)

Dartmouth Agreements

On October 17, 2017, the Company entered into an Option Agreement (the "Agreement") with the Trustees of Dartmouth College which provides for, among other things, the grant to the Company of a one-year exclusive option to negotiate a worldwide, royalty bearing, exclusive license with Dartmouth for 3D printable materials in the field of human and animal health. During the option period, the Company agreed to use all commercially reasonable resources to evaluate the intellectual property and provide quarterly milestone reports and a commercialization plan upon exercise of the option. Pursuant to the Agreement, the Company agreed to finance the prosecution of patents by Dartmouth to protect its intellectual property. Further, the Agreement provides for the payment by the Company of an option fee and certain license fees and royalty payments based upon the Company's product sales, as part of a final negotiated license agreement. The Company exercised its option on March 26, 2018 to negotiate definitive license terms, as it continues further evaluation and research.

On July 12, 2018, the Company entered into a one-year sponsored research agreement (the "Sponsored Research Agreement"), with the Trustees of Dartmouth College ("Dartmouth") pursuant to which the Company will support and fund the cost of research conducted by Dartmouth of mutual interest to the parties in accordance with the Agreement. Intellectual property invented or developed solely by a party shall be owned by such party and intellectual property jointly invented or developed shall be jointly owned. Dartmouth shall retain an irrevocable worldwide right to use intellectual property owned by it resulting from its research under the Agreement on a non-exclusive royalty-free basis for research and education purposes.

The Agreement may be terminated earlier than one year upon written agreement of the parties, a material breach which is not cured within 30 days of notice thereof, if Professor Ke no longer conducts the research under the Agreement and a successor acceptable to both parties is not available, or in the event of an unauthorized assignment of the Company's rights and obligations under the Agreement.

Note 2 – Summary of Significant Accounting Policies

Financial Statement Presentation: The accompanying unaudited condensed financial statements of the Company have been prepared in accordance with the rules and regulations of the Securities and Exchange Commission (the "SEC"), including the instructions to Form 10-Q and Regulation S-X. Certain information and note disclosures normally included in financial statements prepared in accordance with generally accepted accounting principles in the United States of America ("U.S. GAAP"), have been condensed or omitted from these statements pursuant to such rules and regulations and, accordingly, they do not include all the information and notes necessary for comprehensive financial statements and should be read in conjunction with our audited financial statements included in our Annual Report on Form 10-K for the year ended December 31, 2017.

In the opinion of the management of the Company, all adjustments, which are of a normal recurring nature, necessary for a fair statement of the results for the three and nine-month periods have been made. Results for the interim period presented are not necessarily indicative of the results that might be expected for the entire fiscal year.

Fiscal year end: The Company has selected December 31 as its fiscal year end.

Use of Estimates: The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported therein. Due to the inherent uncertainty involved in making estimates, actual results reported in future periods may be based upon amounts that differ from these estimates.

Cash Equivalents: The Company considers all highly liquid investments with maturities of 90 days or less from the date of purchase to be cash equivalents.

Research and Development Costs: The Company charges research and development costs to expense when incurred in accordance with FASB ASC 730, "Research and Development". Research and development costs were $237,770 and $10,120 for the nine-month periods ended September 30, 2018 and September 30, 2017, respectively.

Advertising and Marketing Costs: Advertising and marketing costs are expensed as incurred. The Company incurred $48,832 and $15,657 in advertising or marketing costs during the nine months ended September 30, 2018 and 2017, respectively.

QRONS INC.

NOTES TO UNAUDITED CONDENSED FINANCIAL STATEMENTS

September 30, 2018

Note 2 – Summary of Significant Accounting Policies (continued)

Related parties: For the purposes of these financial statements, parties are considered to be related if one party has the ability, directly or indirectly, to control the party or exercise significant influence over the party in making financial and operating decisions, or vice versa, or where the Company and the party are subject to common control or common significant influence. Related parties may be individuals or other entities.

Stock-Based Compensation and Other Share-Based Payments: The expense attributable to the Company's Directors is recognized over the period the amounts are earned and vested, and the expense attributable to the Company's non-employees is recognized when vested, as described in Note 7, Stock Plan.

Fair Value of Financial Instruments

FASB ASC 820, Fair Value Measurements and Disclosures, defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. FASB ASC 820 also establishes a fair value hierarchy which requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. FASB ASC 820 describes three levels of inputs that may be used to measure fair value:

Level 1 – Quoted prices in active markets for identical assets or liabilities.

Level 2 – Observable inputs other than Level 1 prices, such as quoted prices for similar assets or liabilities; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.

Level 3 – Unobservable inputs that are supported by little or no market activity and that are financial instruments whose values are determined using pricing models, discounted cash flow methodologies, or similar techniques, as well as instruments for which the determination of fair value requires significant judgment or estimation.

If the inputs used to measure the financial assets and liabilities fall within more than one level described above, the categorization is based on the lowest level of input that is significant to the fair value measurement of the instrument.

The following table provides a summary of the fair value of our derivative liabilities as of September 30, 2018 and December 31, 2017:

	Fair value measurements on a recurring basis
	Level 1			Level 2			Level 3
As of September 30, 2018:
Liabilities
Derivative liabilities		$	-		$	-		$	30,506

As of December 31, 2017:
Liabilities
Derivative liabilities		$	-		$	-		$	31,090

QRONS INC.

NOTES TO UNAUDITED CONDENSED FINANCIAL STATEMENTS

September 30, 2018

Note 2 – Summary of Significant Accounting Policies (continued)

Warrants: The Company accounts for common stock warrants in accordance with applicable accounting guidance provided in ASC Topic 815 "Derivatives and Hedging – Contracts in Entity's Own Equity" (ASC Topic 815), as either derivative liabilities or as equity instruments depending on the specific terms of the warrant agreement. For warrants classified as equity instruments we apply the Black Scholes model. Presently all warrants issued and outstanding are accounted for using the equity method.

Income taxes: The Company has adopted ASC Topic 740 – "Income Taxes" ASC Topic 740 requires the use of the asset and liability method of accounting for income taxes. Under the asset and liability method of ASC Topic 740, deferred tax assets and liabilities are recognized for the future tax consequences attributable to temporary differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled.

Basic and Diluted Loss Per Share: In accordance with ASC Topic 260 – "Earnings Per Share", the basic loss per common share is computed by dividing net loss available to common stockholders by the weighted average number of common stock outstanding. Diluted loss per common share is computed similar to basic loss per common share except that the denominator is increased to include the number of additional shares of common stock that would have been outstanding if the potential common stock had been issued and if the additional shares of common stock were dilutive.

Potential common stock consists of the incremental common stock issuable upon the exercise of common stock warrants (using the if-converted method), convertible notes, classes of shares with conversion features, and stock awards and stock options. The computation of basic loss per share for the nine-month period ended September 30, 2018 and 2017 excludes potentially dilutive securities of underlying share purchase warrants, convertible notes, stock options and preferred shares, because their inclusion would be antidilutive. As a result, the computations of net loss per share for each period presented is the same for both basic and fully diluted.

The table below reflects the potentially dilutive securities at each reporting period which have been excluded from the computation of diluted net loss per share:

	September 30, 2018		September 30, 2017
Stock purchase warrants		52,000		566,000
Research Warrants at 3% of issued and outstanding shares		384,806		-
Convertible Notes		28,778		32,178
Series A Preferred shares		700		700
Stock options vested		30,000		-
Stock options not yet vested		690,000		-
Stock awards not yet vested		290,000		-
		1,476,284		598,878

New Accounting Pronouncements: There were various accounting standards and interpretations issued recently, none of which are expected to have a material effect on the Company's operations, financial position or cash flows.

QRONS INC.

NOTES TO UNAUDITED CONDENSED FINANCIAL STATEMENTS

September 30, 2018

Note 3 – Going Concern

The Company has experienced net losses to date, and it has not generated revenue from operations. While the Company has recently raised proceeds, it does not believe its resources will be sufficient to meet its operating and capital needs beyond the fourth quarter of 2018. The Company expects it will require additional capital to fully implement the scope of its proposed business operations, which raises substantial doubt about its ability to continue as a going concern. The Company will have to continue to rely on equity and debt financing. There can be no assurance that financing, whether debt or equity, will always be available to the Company in the amount required at any particular time or for any particular period or, if available, that it can be obtained on favorable terms.

The financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts, or amount and classification of liabilities that might cause results from this uncertainty.

Note 4 – Convertible Note – Related Party and Derivative Liabilities

On September 1, 2016, the Company entered into a convertible debenture agreement with CubeSquare, LLC ("CubeSquare"), of which our Chief Executive Officer is the managing partner and our President is a 25% owner. The Company received proceeds of $10,000 during fiscal 2016 ("Note 1"). The note bears interest at 8% per annum and was due on September 1, 2017. Interest accrues from September 1, 2016 and is payable on maturity. Interest is payable, at the lender's option, in cash or common stock. Any portion of the loan and unpaid interest are convertible at any time at the option of the lender into shares of common stock of the Company at a conversion price of the greater of (i) $0.0625 per share if the Company's shares are not trading on a public market and; (ii) in the event the Company's shares are listed for trading on a public market, the conversion price shall be equal to a 50% discount to the average of the five lowest trading prices during the previous twenty trading days prior to the date of the notice of conversion from the lender.

On September 28, 2017 the Company and CubeSquare amended Note 1 to extend the maturity date from September 1, 2017 to September 1, 2018 and on September 9, 2018, the Company further amended Note 1 to extend the maturity date to September 1, 2019, under the same terms and conditions.

On September 27, 2017, the Company entered into a second convertible debenture agreement with CubeSquare under which the Company received proceeds of $15,000 (Note 2). Note 2 bears interest at 8% per annum and is due on September 27, 2018. Interest shall accrue from September 27, 2017 and shall be payable on maturity. Any portion of the principal and unpaid interest under the note is convertible at any time at the option of CubeSquare into shares of common stock of the Company at a conversion price equal to a 50% discount to the average of the five lowest trading prices during the previous twenty trading days prior to the date of the notice of conversion from CubeSquare. On September 9, 2018, Note 2 was amended to extend the maturity date until September 27, 2019.

The Company analyzed the amendment to Note 1 and Note 2 under ASC 815-10-15-83 and concluded that these two convertible debentures meet the definition of a derivative. We estimated the fair value of the derivative on the inception dates, and subsequently, using the Black-Scholes valuation technique, adjusted for the effect of dilution, because that technique embodies all of the assumptions (including, volatility, expected terms, and risk-free rates) that are necessary to fair value complex derivate instruments.

QRONS INC.

NOTES TO UNAUDITED CONDENSED FINANCIAL STATEMENTS

September 30, 2018

Note 4 – Convertible Note – Related Party and Derivative Liabilities (continued)

The carrying value of these convertible notes is as follows:

	September 30, 2018		December 31, 2017
Face value of certain convertible notes	$	25,000	$	25,000
Less: unamortized discount		-		(18,335	)
Carrying value	$	25,000	$	6,665

Amortization of the discount over the three months ended September 30, 2018 and 2017 totaled $5,541 and $1,571, respectively, which amounts have been recorded as interest expense. Amortization of the discount over the nine months ended September 30, 2018 and 2017 totaled $18,335 and $6,599, respectively, which amounts have been recorded as interest expense.

As a result of the application of ASC No. 815 in the periods ended September 30, 2018 and December 31, 2017 the fair value of the conversion feature is summarized as follows:

Balance at December 31, 2017	$	31,090
Derivative addition associated with convertible notes		-
Change in fair value		(584	)
Balance at September 30, 2018	$	30,506

The fair value at the commitment and re-measurement dates for the Company's derivative liabilities were based upon the following management assumptions as of September 30, 2018 and commitment date:

	Commitment Date		September 30, 2018		December 31, 2017
Expected dividends		0		0		0
Expected volatility	101% ~103%		77% ~ 83%		110% ~ 115%
Expected term	0.92 ~ 1 year		0.92 ~0.99 year		0.67 ~0.74 year
Risk free interest rate		1.33%		2.59%	1.53% ~ 1.65%

Note 5 – License and Research Funding Agreements

On December 14, 2016, the Company entered into the License Agreement with Ariel. Under the terms of the License Agreement, Professor Danny Baranes, the principal investigator and his research team will carry out further research relating to cell treatment with conditioned medium for neuronal tissue regeneration and repair. The Company shall fund the research completed during the research period in the total amount of $100,000. In consideration for payments under the License Agreement, the Company received an exclusive worldwide royalty- bearing license in Ariel patents and know-how to develop and commercialize products based on or incorporating conditioned medium for neuronal tissue regeneration and/or repair, resulting from Ariel's research or technology or the Company's research funding (the "Products). Under the License Agreement, the Company is required to use its best efforts to develop and commercialize the Products in accordance with development milestones set forth in the Agreement.

QRONS INC.

NOTES TO UNAUDITED CONDENSED FINANCIAL STATEMENTS

September 30, 2018

Note 5 – License and Research Funding Agreements (continued)

In addition, upon the occurrence of an Exit Event (as defined in the License Agreement) of the Company or of any affiliate commercializing the products, the Company is obligated to issue to Ariel an immediately exercisable warrant for that number of shares equal to 4% of the issued and outstanding shares of the Company at the time of issuance.

The Company and Ariel entered into Addendum #1, effective December 13, 2017 (the "Addendum") to the License Agreement pursuant to which Ariel was permitted to exercise a portion of the warrant granted pursuant to the License Agreement. On December 13, 2017, the Company issued 119,950 shares of common stock to Ariel, representing 1% of the issued and outstanding shares of the Company on such date, and valued at $335,860. The right to the balance of the shares subject to the warrant remains subject to the terms of the License Agreement and the occurrence of an Exit Event (as described in the License Agreement). In addition, the Addendum provides that Ariel may not request a demand registration until the balance of the shares subject to the warrant is exercised.

In addition to the other payments, the Company will pay Ariel upon the occurrence of the following milestone events, additional payments which shall be due within 6 months of completion of the milestone:

-	Upon successful clinical FDA Phase II completion - $130,000; and
-	Upon successful clinical FDA Phase III completion - $390,000

Upon successful development and commercialization and in recognition of the rights and licenses granted to the Company pursuant to the License Agreement, the Company will be subject to certain royalty payments as specified in the License Agreement.

During the year ended December 31, 2017, the Company incurred total research and development costs of $1,179,777, which amount includes the aforementioned value of 119,950 shares of common stock at $335,860 pursuant to the License Agreement, as well as $812,000 recorded as stock-based compensation related to certain stock awards discussed in Note 6 – Commitments below, granted to various members of the Company's scientific advisory board.

In lieu of extending the research financing and research period under the License Agreement with Ariel beyond the initial 12 months, on December 14, 2017, the Company entered into a 12-month services agreement with Ariel (the "Services Agreement") pursuant to which a team at Ariel University under the direction of Professor Danny Baranes will conduct molecular biology research activities involving the testing of scaffold materials for the Company. As compensation for such services, the Company paid Ariel (i) $17,250 on December 19, 2017 and an additional $17,250 on April 26, 2018. On April 12, 2018, the Services Agreement was amended to provide for the payment by the Company of an additional monthly fee, commencing March 2018, of up to 8,000 Israeli shekels as compensation for additional costs which the Company may request.

On March 6, 2018, the Company entered into an additional service agreement with Ariel for the services of Professor Gadi Turgeman and his stem cells research team in their lab pursuant to which the Company paid Ariel $20,580 on each of March 19, 2018 and August 22, 2018.

On July 12, 2018, the Company entered into the Sponsored Research Agreement with Dartmouth pursuant to which the Company will support and fund the cost of research conducted by Dartmouth of mutual interest to the parties in accordance with the Agreement. Intellectual property invented or developed solely by a party shall be owned by such party and intellectual property jointly invented or developed shall be jointly owned. Dartmouth shall retain an irrevocable worldwide right to use intellectual property owned by it resulting from its research under the Agreement on a non-exclusive royalty-free basis for research and education purposes. The Agreement may be terminated earlier than one year upon written agreement of the parties, a material breach which is not cured within 30 days of notice thereof, if Professor Ke no longer conducts the research under the Agreement and a successor acceptable to both parties is not available, or in the event of an unauthorized assignment of the Company's rights and obligations under the Agreement.

QRONS INC.

NOTES TO UNAUDITED CONDENSED FINANCIAL STATEMENTS

September 30, 2018

Note 6 – Commitments

(1)	Service Agreement with Ariel - Prof. Danny Baranes

On December 14, 2017, the Company entered into a 12-month services agreement pursuant to which a team at Ariel under the direction of Prof. Danny Baranes will conduct molecular biology research activities involving the testing of implant materials for the Company. As compensation for the services provided, the Company will pay Ariel (i) $17,250 within five business days of the execution of the Services Agreement, and (ii) $17,250 by May 1, 2018.

The Services Agreement may be terminated by the non-breaching party upon a material breach that is not cured within 30 days or by the Company upon thirty days' prior written notice to Ariel. Ariel must keep confidential information of the Company confidential for five years after the term of the Services Agreement.

During the year ended December 31, 2017, $17,250 was paid and on April 26, 2018, the remaining installment of $17,250 was paid. During the year ended December 31, 2017, $1,438 was expensed, and during the nine months ended September 30, 2018 $25,875 was expensed, and the remaining $7,187, which amount is reflected on the Company's balance sheets as prepaid expenses, will be expensed in a subsequent period.

On April 12, 2018, the Services Agreement was amended to provide for the payment by the Company of an additional monthly fee, commencing March 2018, of up to 8,000 Israeli shekels as compensation for additional costs which the Company may request. During the nine-month period ended September 30, 2018, the Company paid $14,082 for these additional fees.

(2)	Service Agreement with Ariel - Dr. Gadi Turgeman

On March 6, 2018, the Company entered into a service agreement for the services of Professor Gadi Turgeman and his stem cells research team in their lab. As compensation for the services provided, the Company paid Ariel $20,580 on each of March 19, 2018 and August 22, 2018.

The Services Agreement may be terminated by the non-breaching party upon a material breach that is not cured within 30 days or by the Company upon thirty days' prior written notice to Ariel. Ariel must keep confidential information of the Company confidential for six years after the term of the Services Agreement.

During the nine months ended September 30, 2018, $41,160 was paid and recorded as prepaid expenses, of which $24,010 was expensed in the nine-month period ended September 30, 2018, and the remaining $17,150 will be expensed in a subsequent period.

(3)	Science Advisory Board Member Consulting Agreements (the "Agreements")

As part of its ongoing program of research and development, the Company has retained distinguished scientists and other qualified individuals to advise the Company with respect to its technology and business strategy and to assist it in the research, development and analysis of the Company's technology and products. In furtherance thereof, the Company has retained certain Advisors as members of its Scientific Advisory Board as described below, and the Company and Advisors have entered into agreements with the following terms and conditions:

QRONS INC.

NOTES TO UNAUDITED CONDENSED FINANCIAL STATEMENTS

September 30, 2018

Note 6 – Commitments (continued)

(3)	Science Advisory Board Member Consulting Agreements (the "Agreements") (continued)

Scientific Advisory Board and Consulting Services - Advisor shall provide general consulting services to Company (the "Services") as a member of its Scientific Advisory Board ("SAB"). As a member of the SAB, Advisor agrees to provide the Services as follows: (a) attending meetings of the Company's SAB; (b) performing the duties of a SAB member at such meetings, as established from time to time by the mutual agreement of the Company and the SAB members, including without limitation meeting with Company employees, consultants and other SAB members, reviewing goals of the Company and assisting in developing strategies for achieving such goals, and providing advice, support, theories, techniques and improvements in the Company's scientific research and product development activities; and (c) providing consulting services to Company at its request, including a reasonable amount of informal consultation over the telephone or otherwise as requested by Company. Advisor's consultation with Company will involve services as scientific, technical and business advisor to the Company and its senior team as needed with respect to the field of neuronal injuries and neuro degenerative diseases ("the "Field") and requires the application of unique, special and extraordinary skills and knowledge that Advisor possesses in the Field.

SAB Consulting Compensation - the Company shall grant to Advisor the option to purchase certain number of shares of the common stock of the Company as per the stock option award grant. The options are subject to terms and provisions of the Company's 2016 Stock Option and Stock Award Plan.

On November 15, 2017, the Company entered into Agreements with three Advisors under the terms of which two Advisors are granted an option to purchase 20,000 shares of common stock and one Advisor was granted an option to purchase 30,000 shares of common stock under the 2016 Stock Option and Award Plan subject to certain vesting terms.

On April 16, 2018, the Company entered into a one-year advisory board member consulting agreement with an assistant Professor of Chemistry at Dartmouth College to serve on the Company's Scientific Advisory Board. In consideration for serving on the Scientific Advisory Board, the Company granted an option to purchase 30,000 shares of its common stock under certain vesting terms to the assistant Professor.

On August 15, 2018, the Company entered into an Agreement with an Advisor under the terms of which the Company granted an option to purchase 20,000 shares of common stock under the 2016 Stock Option and Award Plan subject to certain vesting terms.

(4)	Business Advisory Board Agreement

On January 23, 2018, the Company entered into a one-year advisory board member consulting agreement with Pavel Hilman, the controlling shareholder of Conventus Holdings SA, a BVI corporation ("Conventus"), under which Mr. Hilman will serve on the Company's Advisory Board as a business advisor. The Advisory Board Agreement will automatically renew for up to two additional one-year periods, unless earlier terminated by either party upon 30 days' prior written notice to the other party. In consideration for serving on the Advisory Board, the Company awarded 10,000 shares of its common stock to Mr. Hilman under its 2016 Stock Option and Stock Award Plan.

QRONS INC.

NOTES TO UNAUDITED CONDENSED FINANCIAL STATEMENTS

September 30, 2018

Note 6 – Commitments (continued)

(5)	Investor Relations Agreement

On April 23, 2018, the Company entered into a six-month investor relations agreement with an investor relations firm for a monthly consulting fee of $5,000 and the issuance of 75,000 shares of common stock payable on signing the agreement.

On June 23, 2018, the Company gave notice of rescission of the agreement to such firm and requested the return of the consulting fee paid and the 75,000 shares of common stock. As a result, the Company has not recorded any fees for services rendered past June 23, 2018. A total of $10,000 representing April 2018 and May 2018 monthly consulting fees is reflected in the statement of operations and a total of $150,000, the fair market value of the issued shares, was expensed on issue.

(6)	Sponsored Research Agreement

During the nine months ended September 30, 2018, $36,293 was paid and recorded as prepaid expenses, of which $9,073 was expensed in the nine-month period ended September 30, 2018, and the remaining $27,220 will be expensed in a subsequent period.

Note 7 – Stock Plan

2016 Stock Option and Stock Award

On December 14, 2016, the Board adopted the Company's 2016 Stock Option and Stock Award Plan (the "Plan"). The Plan provides for the award of stock options (incentive and non-qualified), stock awards and stock appreciation rights to officers, directors, employees and consultants who provide services to the Company. The terms of awards under the Plan are made by the Administrator of the Plan appointed by the Company's Board of Directors (the "Board"), or in the absence of an Administrator, by the Board. The Company has reserved 10 million shares for issuance under the Plan.

QRONS INC.

NOTES TO UNAUDITED CONDENSED FINANCIAL STATEMENTS

September 30, 2018

Note 7 – Stock Plan (continued)

Stock Awards:

On December 14, 2016, the Board awarded to each of its Science Advisors, Prof. Danny Baranes and Dr. Liat Hammer, a total of 440,000 shares of common stock of which 150,000 shares vested on December 14, 2016, 145,000 shares vested on December 14, 2017, and 145,000 shares will vest on December 14, 2018, provided such advisors are still providing services to the Company.

The value of the vested awards had been recorded as research and development expenses in the respective periods. A total of 290,000 stock awards are expected to vest during the fourth quarter of fiscal 2018.

On January 23, 2018, the Company awarded 10,000 shares of its common stock to Mr. Hilman under its 2016 Stock Option and Stock Award Plan, which shares were fully vested and recorded as advisory services on issuance.

	For the nine months ended September 30, 2018		For the year ended December 31, 2017
Number of shares vested in period		10,000		290,000
Fair market value per share	$	2.80	$	2.80
Stock based compensation recognized	$	28,000	$	812,000

Stock Options:

(a)	Stock Options granted to Science Advisors:

On November 15, 2017, under the 2016 Stock Option and Award Plan, the Board awarded two of its Science Advisors the following three-year stock options: (i) an immediately exercisable option to purchase 6,667 shares of common stock at an exercise price of $2.00 per share, (ii) an option to purchase 6,667 shares of common stock exercisable on November 15, 2018 at an exercise price of $2.00 per share and (iii) an option to purchase 6,666 shares of common stock exercisable on November 15, 2019 at an exercise price of $2.00 per share, provided the advisors are still providing services to the Company.

On November 15, 2017, under the 2016 Stock Option and Award Plan, the Board awarded a Science Advisor, the following three-year stock options: (i) an option to purchase 15,000 shares of common stock, exercisable on November 15, 2018 at an exercise price of $0.40 per share and (ii) an option to purchase 15,000 shares of common stock exercisable on November 15, 2019 at an exercise price of $0.40 per share, provided the advisor is still providing services to the Company.

On April 16, 2018, under the 2016 Stock Option and Award Plan, the Board awarded a Science Advisor, the following three-year stock options: (i) an option to purchase 10,000 shares of common stock, exercisable on April 16, 2018 at an exercise price of $2.00 per share (ii) an option to purchase 10,000 shares of common stock exercisable on April 16, 2019 at an exercise price of $2.00 per share, and (iii) an option to purchase 10,000 shares of common stock exercisable on April 16, 2020 at an exercise price of $2.00 per share, provided the advisor is still providing services to the Company.

On August 15, 2018, under the 2016 Stock Option and Award Plan, the Board granted a Science Advisor an option to purchase an aggregate of 20,000 shares of common stock at an exercise price of $2.00 per share. The option vests as to 6,667 shares on each of August 15, 2018 and August 15, 2019 and as to 6,666 shares on August 15, 2020 and remains exercisable as to each such installment for three years from the date of vesting.

QRONS INC.

NOTES TO UNAUDITED CONDENSED FINANCIAL STATEMENTS

September 30, 2018

Note 7 – Stock Plan (continued)

Stock Options: (continued)

(a)	Stock Options granted to Science Advisors: (continued)

During the year ended December 31, 2017, total recognized compensation in respect of the above stock option compensation was $29,000, which amount has been allocated as advisory services as part of general and administrative expenses.

The Company recorded stock-based compensation in the amount of $48,078 and $122,816 in respect to these options grants during the three and nine months ended September 30, 2018, respectively, which amounts have been allocated as advisory services as part of general and administrative expenses.

As of September 30, 2018, total unrecognized compensation remaining to be recognized in future periods totaled $92,671.

(b)	Stock Options granted to Officers:

On December 4, 2017, the Board granted five-year options to each of its two officers for the purchase of 300,000 shares of the common stock of the Company. The options have an exercise price of $2.00 and vest and become exercisable on December 4, 2018.

During the year ended December 31, 2017, total recognized compensation of $106,029 was recorded as general and administrative expenses.

During the three and nine months ended September 30, 2018, total recognized compensation of $353,430 and $1,060,290, respectively, was recorded as general and administrative expenses.

As of September 30, 2018, total unrecognized compensation remaining to be recognized in future periods totaled $246,755.

The fair value of each option award above is estimated on the date of grant using the Black-Scholes option-pricing model with the following assumptions at the measurement date(s):

	Measurement date
Dividend yield		0%
Expected volatility	114.69 ~ 126.34%
Risk-free interest rate	1.79% ~ 2.68%
Expected life (years)	3 ~ 5
Stock Price	$	2.00 ~ 2.80
Exercise Price	$	0.40 ~ 2.00

QRONS INC.

NOTES TO UNAUDITED CONDENSED FINANCIAL STATEMENTS

September 30, 2018

Note 7 – Stock Plan (continued)

Stock Options: (continued)

A summary of the activity for the Company's stock options for the nine-month period ended September 30, 2018 and for the year ended December 31, 2017, is as follows:

	September 30, 2018				December 31, 2017
			Weighted Average				Weighted Average
	Shares		Exercise Price		Shares		Exercise Price
Outstanding, beginning of period		670,000	$	1.93		-	$	-
Granted		50,000	$	2.00		670,000	$	1.93
Exercised		-	$	-		-	$	-
Canceled		-	$	-		-	$	-
Outstanding, end of period		720,000	$	1.93		670,000	$	1.93
Options exercisable, end of period		30,000	$	2.00		13,334	$	2.00
Options expected to vest, end of period		690,000	$	1.93		656,666	$	1.89
Weighted average fair value of options granted			$	2.30			$	2.36

Note 8 – Capital Stock

Authorized:

The Company has authorized 100,000,000 shares of common stock, par value $0.0001 and 10,000 shares of preferred stock which is designated as Series A Preferred Stock, par value $0.001.

Series A Preferred Stock:

The Series A Preferred Stock is redeemable at the option of the Company at any time, in whole or in part, upon 10 trading days prior notice, at a price of $1.00 per share plus 4% per annum from the date of issuance (the "Stated Value"). The holders of the Series A Preferred Stock are entitled to a liquidation preference equal to the Stated Value, prior to the holders of other preferred stock or common stock. The holders of the Series A Preferred Stock have the right to convert such stock into common stock at a conversion rate equal to the Stated Value as of the conversion date divided by the average closing price of the common stock for the five previous trading days. The Company is required to reserve sufficient number of shares for the conversion of the Series A Preferred Stock. The holders of Class A Preferred Stock shall vote together as a single class with the holders of the Company's common stock and the holders of any other class or series of shares entitled to vote with the common stock, with the holders of Class A Preferred Stock being entitled to 66 2/3% of the total votes on all such matters, regardless of the actual number of shares of Class A Preferred Stock then outstanding.

There was a total of 2,000 shares of Series A Preferred Stock issued and outstanding as at September 30, 2018 and December 31, 2017.

QRONS INC.

NOTES TO UNAUDITED CONDENSED FINANCIAL STATEMENTS

September 30, 2018

Note 8 – Capital Stock (continued)

Common Stock issuances during the nine months ended September 30, 2018:

On January 23, 2018 the Company sold 312,500 shares of its common stock to Conventus and raised $500,000 pursuant to a subscription agreement in a private placement offering. The proceeds of the offering will be used for research and general corporate purposes.

On January 23, 2018, the Company issued 10,000 shares for advisory services (Note 6(4)). The shares were valued at fair market value on the date of issuance for a total of $28,000 or $2.80 per share.

On February 6, 2018, the Company received a warrant exercise notice in respect of 2,000 warrants from a subscriber and issued 1,715 shares of common stock on a cashless exercise basis as per the cashless exercise formula contained in the warrant.

On April 23, 2018, the Company issued 75,000 shares of its common stock in respect of an investor relations services agreement which was rescinded on June 23, 2018 (Note 6(5)). The shares were valued at the fair market value on the date of issuance for a total of $150,000, or $2.00 per share.

On September 16, 2018 the Company sold 22,728 shares of its common stock to an investor and raised $25,000 pursuant to a subscription agreement in a private placement offering. The proceeds of the offering will be used for research and general corporate purposes.

Common Stock issuances as of December 31, 2017:

On December 13, 2017, 119,950 shares were issued to Ariel as an exercise of warrants pursuant to a License Agreement (Note 5 – License and Research Funding Agreement). These shares were valued at $335,860 or $2.80 per share, based on fair market value, and the associated cost was recorded as research and development expenses.

On December 14, 2017, the Company issued 290,000 shares to two Scientific Advisors as a stock award, valued at $812,000, or $2.80 per share, based on fair market value, and recorded the associated cost as research and development expenses. (Note 7 – Stock Plan).

During the year ended December 31, 2017, the Company received aggregate proceeds of $32,000 in private placement subscriptions for a total of 128,000 shares.

During the year ended December 31, 2017 the Company received warrant exercise notices in respect of 512,000 warrants from various subscribers and issued a total of 442,960 shares of common stock on a cashless exercise basis as per the cashless exercise formula in the warrant.

QRONS INC.

NOTES TO UNAUDITED CONDENSED FINANCIAL STATEMENTS

September 30, 2018

Note 8 – Capital Stock (continued)

Share Purchase Warrants

In accordance with authoritative accounting guidance, the fair value of the aforementioned warrants was calculated using the Black-Scholes option-pricing model with the following assumptions at the measurement date(s):

	Measurement date
Dividend yield		0%
Expected volatility	97.90~119.33%
Risk-free interest rate	1.47~1.60%
Expected life (years)	2.71~2.92
Stock Price	$	0.25
Exercise Price	$	0.40

As of September 30, 2018, and December 31, 2017, the following common stock purchase warrants were outstanding:

	Warrants (1)			Weighted Average Exercise Price
Outstanding – December 31, 2016		502,000		$	0.40
Granted		64,000			0.40
Forfeited/Canceled		-			-
Exercised		512,000	(2)		0.40
Outstanding – December 31, 2017		54,000			0.40
Granted		-			-
Forfeited/Canceled		-			-
Exercised		2,000	(3)		0.40
Outstanding – September 30, 2018		52,000		$	0.40

(1) Each two shares of common stock purchased under the private placement provides for one warrant to acquire an additional share of common stock together with the payment of $0.40.

(2) During the year ended December 31, 2017, investors exercised 512,000 share purchase warrants and received 442,960 underlying shares for exercise on a cashless basis.

(3) During the nine-month period ended September 30, 2018, investors exercised 2,000 share purchase warrants and received 1,715 underlying shares for exercise on a cashless basis.

Note 9 – Subsequent Events

On October 8, 2018 the Company sold 22,728 shares of its common stock to an investor and raised $25,000 pursuant to a subscription agreement in a private placement offering. The proceeds of the offering will be used for research and general corporate purposes.

The Company has evaluated subsequent events from the balance sheet date through the date that the financial statements were issued and determined that there are no additional subsequent events to disclose.

ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATION

This Quarterly Report on Report contains predictions, estimates and other forward-looking statements relating to future events or our future financial performance. In some cases, you can identify forward-looking statements by terminology such as "may", "should", "intends", "expects", "plans", "anticipates", "believes", "estimates", "predicts", "potential", or "continue" or the negative of these terms or other comparable terminology. Forward-looking statements involve known and unknown risks, uncertainties and other factors including the risks set forth in the section entitled "Risk Factors" in our Post-Effective Amendment No. 1 to our Registration Statement on Form S-1, as filed with the Securities and Exchange Commission (the "SEC") on March 15, 2018, that may cause our actual results, performance or achievements to be materially different from any future results, performances or achievements expressed or implied by the forward-looking statements.

Forward-looking statements represent our management's beliefs and assumptions only as of the date of this Report. You should read this Report with the understanding that our actual future results may be materially different from what we expect.

All forward-looking statements speak only as of the date on which they are made. We undertake no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they are made, except as required by federal securities and any other applicable law.

The management's discussion and analysis of our financial condition and results of operations are based upon our condensed financial statements, which have been prepared in accordance with accounting principles generally accepted in the United States of America ("U.S. GAAP").

The following discussion of our financial condition and results of operations should be read in conjunction with our unaudited condensed financial statements for the three and nine months ended September 30, 2018 and the notes thereto appearing elsewhere in this Report and the Company's audited financial statements for the fiscal year ended December 31, 2017, as filed with the SEC in its Annual Report on Form 10-K on March 2, 2018, along with the accompanying notes. As used in this Quarterly Report, the terms "we", "us", "our", and the "Company" means BioLabMart Inc. prior to August 8, 2017 and Qrons Inc. since August 8, 2017.

Overview

The Company was incorporated under the laws of the State of Wyoming on August 22, 2016 as BioLabMart Inc. and changed its name to Qrons Inc. on August 8, 2017.

The Company raised an aggregate of $281,000 between November 2, 2016 and January 27, 2017 from 37 accredited investors, $500,000 in January 2018 from an accredited investor, and an aggregate of $50,000 from two accredited investors in September and October 2018, in private placement offerings under Regulation D and Regulation S under the Securities Act of 1933.,

The Company relies primarily on its two co-founders, Jonah Meer and Ido Merfeld, who are its sole officers and directors to manage its day- to-day business. We currently outsource all professional services to third parties in an effort to maintain lower operational costs.

Messrs. Meer and Merfeld, as the holders of the Company's issued and outstanding shares of the Company's Class A Preferred Stock, collectively have 66 2/3% of the voting rights of the Company. Acting together, they will be able to influence the outcome of all corporate actions requiring approval of our stockholders.

The Company's common stock was approved by the Financial Industry Regulatory Authority ("FINRA") for quotation on the OTC pink sheets under the symbol "BLMB" as of July 3, 2017. On July 6, 2017, the Company's board of directors and shareholders approved an amendment to its Articles of Incorporation changing the name of the Company from "BioLabMart Inc." to "Qrons Inc. The Secretary of State of the State of Wyoming approved such name change, effective August 8, 2017. FINRA announced the Company's name change to Qrons Inc. on its Daily List on August 9, 2017. The new name and symbol, "QRON", became effective on August 10, 2017.

License Agreement with Ariel

On December 14, 2016, the Company entered into a license and research funding agreement ("License Agreement") with Ariel University R&D Co., Ltd., ("Ariel"), a wholly owned subsidiary of Ariel University, based in Ariel, Israel. In consideration for payments under the License Agreement, the Company received an exclusive worldwide royalty-bearing license in Ariel patents and know-how to develop and commercialize products for neuronal tissue regeneration and/or repair, resulting from Ariel's research or technology or the Company's research funding.

Services Agreements with Ariel

In lieu of extending the research financing and research period under the License Agreement beyond the initial 12 months, on December 14, 2017, the Company entered into a 12-month services agreement with Ariel (the "Services Agreement") pursuant to which a team at Ariel University under the direction of Prof. Danny Baranes will conduct molecular biology research activities involving the testing of implant materials for the Company. As compensation for such services, the Company paid Ariel (i) $17,250 on December 19, 2017 and (ii) $17,250 on April 26, 2018. On April 12, 2018, the Services Agreement was amended to provide for the payment by the Company of an additional monthly fee, commencing March 2018, of up to 8,000 Israeli shekels as compensation for additional costs which the Company may request.

Option Agreement with Dartmouth

On October 17, 2017, the Company entered into an option agreement (the " Option Agreement") with the Trustees of Dartmouth College ("Dartmouth") which provides for, among other things, the grant to the Company of a one-year exclusive option to negotiate a worldwide, royalty bearing, exclusive license with Dartmouth for 3D printable materials in the field of human and animal health. The Option Agreement provided the opportunity to evaluate the intellectual property, potential products and markets and for further research to develop the intellectual property. The Company exercised its option on March 26, 2018 to negotiate definitive license terms, as it continues further evaluation and research.

Sponsored Research Agreement with Dartmouth

On July 12, 2018, the Company entered into a one-year sponsored research agreement (the "Sponsored Research Agreement"), with Dartmouth pursuant to which the Company will support and fund the cost of research conducted by Dartmouth of mutual interest to the parties in accordance with the Agreement.

Intellectual property invented or developed solely by a party shall be owned by such party and intellectual property jointly invented or developed shall be jointly owned.

Dartmouth shall retain an irrevocable worldwide right to use intellectual property owned by it resulting from its research under the Agreement on a non-exclusive royalty-free basis for research and education purposes.

If either party desires to obtain patent and copyright protection for intellectual property created under the Agreement, such party shall notify the other party and the parties shall agree upon intellectual property protection strategy and cost allocation. Each party shall have the right to grant licenses under jointly-owned patents to third parties, subject to the Company's option to the exclusive right to license Dartmouth intellectual property and/or Dartmouth's ownership in jointly-owned intellectual property upon notification to Dartmouth in accordance with the terms of the Agreement and at the Company's cost. If the Company exercises its option to license intellectual property, Dartmouth shall negotiate exclusively with the Company for 180 days (or such additional period as agreed upon by the parties) for such licenses. The Company will be required to reimburse Dartmouth for the costs of patent prosecution and maintenance in the United States and any foreign country and demonstrate reasonable efforts to commercialize the technology.

Plan of Operations

We have not completed development of our product candidate nor generated any revenue from the sales of products or services.

In the next 12 months, we currently plan on completing development of our product candidate. This will require us to continue working with Dartmouth under the Sponsored Research Agreement in our development of innovative 3D printable biocompatible advanced materials and stem cell delivery techniques. At our Ariel labs our Stem Cells Team will continue development of our proprietary, neuro-regenerative mesenchymal stem cell lines.

Upon completion of the development of our product candidate we will begin testing for efficacy. This will require us to establish an Efficacy Team, in preparation to reach clinical trials.

On January 15, 2018, Ariel filed a provisional patent application related to our neural cell development research. Subject to positive efficacy findings, we currently intend to file for a non-provisional application. On April 9, 2018, we filed a provisional patent application with the U.S. Patent and Trademark Office entitled 'Techniques for Promoting Neuronal Recovery'.

As our research progresses, if and when we achieve functional supporting results, we or Ariel intend to file for additional patents. Under the License Agreement Ariel shall be responsible for the preparation, filing, prosecution and protection of its patents. Such preparation shall be done in consultation with the Company, provided expenses in excess of $1,000 will require Company pre-approval. The Company shall reimburse Ariel for all documented patent-related expenses. We currently estimate the cost of such patent preparation and filing to be approximately $7,000 which we intend to fund with the Company's operating capital.

We will continue exploring sources of additional debt and equity financings as well as available grants.

There is substantial doubt that we can continue as an on-going business after the next twelve months unless we obtain additional capital to pay our expenditures. We do not currently have sufficient resources to accomplish all of the conditions necessary for us to generate revenue.

RESULTS OF OPERATIONS

Three Months Ended September 30, 2018 and September 30, 2017

Revenue

We have not generated any revenue since our inception and do not expect to generate any revenue from the sale of products in the near future.

Net Loss

Our net loss for the three months ended September 30, 2018 and 2017 is as follows:

	For the three months ended September 30,
	2018			2017

Net sales	$	-		$	-

Operating expenses:
Research and development expenses		104,798			8,406
Professional fees		6,300			8,170
General and administrative expenses		423,216			31,643
Total operating expenses		534,314			48,219

Income (loss) from operations		(534,314	)		(48,219	)

Other income (expense)
Interest expense		(6,048	)		(1,785	)
Change in derivative liabilities		(2,979	)		(47,954	)

Net (loss)	$	(543,341	)	$	(97,958	)

Operating Expenses

Total operating expenses for the three months ended September 30, 2018 were $534,314 compared to total operating expenses of $48,219 for the three months ended September 30, 2017. During the three months ended September 30, 2018, the Company incurred $104,798 of research and development expenses which included payroll of $34,563, service fees related to certain research and development agreements of $26,087, fees associated with a sponsored research agreement of $9,073, legal and filing fees related to patents of $710, publication and software fees of $2,163 and purchases of expendable lab supplies and equipment of $32,203, compared to $8,406 of research and development expenses for the three months ended September 30, 2017, which consisted of patent fees of $5,018, and purchases of expendable lab supplies. The Company incurred general and administrative expenses of $423,216 for the three months ended September 30, 2018 compared to general and administrative expenses of $31,643 for the three months ended September 30, 2017. The increase in general and administrative expense during the three months ended September 30, 2018 was primarily due to stock-based compensation costs of $401,208 related to the issuance of stock options to our officers, and members of our advisory board. Professional fees totaled $6,300 for the three months ended September 30, 2018 compared to professional fees of $8,170 during the three months September 30, 2017. Other expense in the three months ended September 30, 2018 included a loss of $2,979 as a result of the change in value of our derivative liabilities and interest expense of $6,048, including accretion of our convertible notes of $5,541. Other expense was $49,739 in the three months ended September 30, 2017, which represents interest expense related to the accretion of our convertible notes, as well as accrued interest, and a loss from the change in the value of our derivative liabilities of $47,954. We had a net loss of $543,341 in the three months ended September 30, 2018 compared to a net loss of $97,958 in the three months ended September 30, 2017.

Nine Months Ended September 30, 2018 and September 30, 2017

Revenue

We have not generated any revenue since our inception and do not expect to generate any revenue from the sale of products in the near future.

Net Loss

Our net loss for the nine months ended September 30, 2018 and 2017 is as follows:

	For the nine months ended September 30,
	2018			2017

Net sales	$	-		$	-

Operating expenses:
Research and development expenses		237,770			10,120
Professional fees		35,449			11,297
General and administrative expenses		1,432,980			47,252
Total operating expenses		1,706,199			68,669

Income (loss) from operations		(1,706,199	)		(68,669	)

Other income (expense)
Interest expense		(19,839	)		(7,215	)
Change in derivative liabilities		584			(47,954	)

Net (loss)	$	(1,725,454	)	$	(123,838	)

Operating Expenses

Total operating expenses for the nine months ended September 30, 2018 were $1,706,199 compared to total operating expenses of $68,669 for the nine months ended September 30, 2017. During the nine months ended September 30, 2018, the Company incurred $237,770 of research and development expenses which included payroll of $88,856, service fees related to certain research and development agreements of $64,167, fees associated with a sponsored research agreement of $9,073, legal and filing fees related to patents of $21,566, publication and software fees of $4,910 and purchases of expendable lab supplies and equipment of $49,199, compared to $10,120 of research and development expenses for the nine months ended September 30, 2017 which consisted of patent fees of $5,018 and purchases of expendable lab supplies. The Company incurred general and administrative expenses of $1,432,980 for the nine months ended September 30, 2018 compared to general and administrative expenses of $47,252 for the nine months ended September 30, 2017. The increase in general and administrative expense during the nine months ended September 30, 2018 was primarily due to stock-based compensation costs of $1,183,106 related to the issuance of stock options to our officers, and $178,000 for stock awards and shares for services to members of our advisory board and investor relations consultants. Professional fees totaled $35,449 for the nine months ended September 30, 2018 compared to professional fees of $11,297 during the nine months September 30, 2017. Other expense in the nine months ended September 30, 2018 included a gain of $584 as a result of the change in value of our derivative liabilities and interest expense of $19,839, including accretion of our convertible notes of $18,335. Other expense was $55,169 in the nine months ended September 30, 2017, which represents interest expense related to the accretion of our convertible notes of $6,599, as well as accrued interest, and a loss from the change in the value of our derivative liabilities of $47,954 We had a net loss of $1,725,454 in the nine months ended September 30, 2018 compared to a net loss of $123,838 in the nine months ended September 30, 2017.

Liquidity and Financial Condition

Our current assets as of September 30, 2018 were $253,613 which consisted of $198,622 in cash and cash equivalents and $54,991 of prepaid expenses. We are in the early stage of development, have experienced net losses to date and have not generated revenue from operations which raises substantial doubt about our ability to continue as a going concern. There are a number of conditions that we must satisfy before we will be able to commercialize our potential product and generate revenue, including successful development of a product candidate, which includes clinical trials, FDA approval, demonstration of effectiveness sufficient to generate commercial orders by customers, establishing production capabilities as well as effective marketing and sales capabilities for our product. We do not currently have sufficient resources to accomplish any of these conditions necessary for us to generate revenue and currently expect to incur increasing operating expenses. We will require substantial additional funds for operations, the service of debt and to fund our business objectives. We will have to continue to rely on equity and debt financing. There can be no assurance that financing, whether debt or equity, will always be available to us in the amount required at any particular time or for any particular period or, if available, that it can be obtained on terms favorable to us. While we secured financing in the amount of $500,000 in January 2018, and additional financing of $50,000 in September and October 2018, without additional financing, we do not believe our resources will be sufficient to meet our operating and capital needs beyond the fourth quarter of 2018.

Working Capital

	At September 30, 2018		At December 31, 2017

Current Assets	$	253,613	$	73,579
Current Liabilities		72,688		53,306
Working Capital	$	180,925	$	20,273

Cash Flows

	At September 30, 2018			At September 30, 2017
Net cash (used in) operating activities	$	(384,145	)	$	(63,226	)
Net cash provided by investing activities		-			-
Net cash provided by financing activities	$	525,000		$	24,452
Net increase (decrease) in cash during period	$	140,855		$	(38,774	)

Operating Activities

Net cash used in operating activities was $384,145 for the nine-month period ended September 30, 2018 compared to $63,226 for the nine-month period ended September 30, 2017. Cash used in operating activities was predominantly the result of our net loss, offset by non-cash items including compensation in the form of stock options totaling $1,183,106, stock awards and stock based compensation totaling $178,000 related to an investor relations agreement and service provided on the Company's advisory board, accretion expense of $18,335, and a gain from the change in the value of derivative liabilities of $584. Changes in operating assets and liabilities includes an increase to accounts payable of $126, an increase to prepaid expenses of $39,179 and an increase to accounts payable related party of $1,505 during the nine months ended September 30, 2018. During the nine months ended September 30, 2017 cash used in operating activities was also a result of our net loss of $123,838, offset by an increase to accounts payable of $6,059, accretion of debt discount totaling $6,599 and a change in our derivative liabilities of $47,954.

Investing Activities

There were no investing activities during the nine-month periods ended September 30, 2018 and 2017.

Financing Activities

Net cash provided by financing activities was $525,000 for the nine-month period ended September 30, 2018 compared to $24,452 for the nine-month period ended September 30, 2017. The Company received proceeds from private placement offerings totaling $525,000 in the nine-month period ended September 30, 2018 as compared to $32,000 in the nine months ended September 30, 2017, which included financing costs of $22,548, with no similar expense in the nine-month period ended September 30, 2018. Further during the nine months ended September 30, 2017, the Company received proceeds of $15,000 from a convertible note, with no similar financing in the nine months ended September 30, 2018.

Going Concern

Our financial statements have been prepared assuming that we will continue as a going concern and, accordingly, do not include adjustments relating to the recoverability and realization of assets and classification of liabilities that may be necessary should we be unable to continue in operation. Our report from our independent registered public accounting firm for the fiscal year ended December 31, 2017 includes an explanatory paragraph stating the Company has experienced net losses to date, and it has not generated revenue from operations, and will need additional working capital to service debt and for ongoing operations. These factors, among others, raise substantial doubt about the Company's ability to continue as a going concern. If we are unable to obtain sufficient funding, our business, prospects, financial condition and results of operations will be materially and adversely effected and we may be unable to continue as a going concern.

Off-Balance Sheet Arrangements

We have no off-balance sheet arrangements.

Critical Accounting Policies and Estimates

The preparation of our financial statements requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. On an on-going basis, management evaluates its estimates and judgments which are based on historical experience and on various other factors that are believed to be reasonable under the circumstances. The results of their evaluation form the basis for making judgments about the carrying values of assets and liabilities. Actual results may differ from these estimates under different assumptions and circumstances. Our significant accounting policies are more fully discussed in note 2 to our financial statements contained herein.

Recent Accounting Pronouncements

There were various accounting standards and interpretations issued recently, none of which are expected to have a material effect on the Company's operations, financial position or cash flows.

ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

We are a smaller reporting company and are not required to provide this information.

ITEM 4. CONTROLS AND PROCEDURES

Evaluation of Disclosure Controls and Procedures

Under the supervision and with the participation of our management, including our principal executive officer and principal financial officer, as of September 30, 2018, we conducted an evaluation of our disclosure controls and procedures, as such term is defined under Rule 13a-15(e) and Rule 15d-15(e) promulgated under the Securities Exchange Act of 1934, as amended. Based on this evaluation, our principal executive officer and principal financial officer have concluded that, based on the material weaknesses discussed below, our disclosure controls and procedures were not effective as of such date to ensure that information required to be disclosed by us in reports filed or submitted under the Securities Exchange Act were recorded, processed, summarized, and reported within the time periods specified in the Securities and Exchange Act Commission's rules and forms and that our disclosure controls are not effectively designed to ensure that information required to be disclosed by us in the reports that we file or submit under the Securities Exchange Act is accumulated and communicated to management, including our principal executive officer and principal financial officer, or persons performing similar functions, as appropriate to allow timely decisions regarding required disclosure.

Our internal controls are not effective for the following reasons: (i) there is an inadequate segregation of duties consistent with control objectives as management is comprised of only two persons, one of which is the Company's principal executive officer and principal financial officer and, (ii) the Company does not have a formal audit committee with a financial expert, and thus the Company lacks the board oversight role within the financial reporting process.

In order to mitigate the foregoing material weakness, we have engaged an outside accounting consultant with significant experience in the preparation of financial statements in conformity with U.S. GAAP to assist us in the preparation of our financial statements to ensure that these financial statements are prepared in conformity to U.S. GAAP. We will continue to monitor the effectiveness of this action and make any changes that our management deems appropriate.

We would need to hire additional staff to provide greater segregation of duties. Currently, it is not feasible to hire additional staff to obtain optimal segregation of duties. Management will reassess this matter in the following year to determine whether improvement in segregation of duty is feasible. In addition, we would need to expand our board to include independent members.

Going forward, we intend to evaluate our processes and procedures and, where practicable and resources permit, implement changes in order to have more effective controls over financial reporting.

Changes in Internal Control over Financial Reporting

During the period covered by this report, there were no changes in our internal controls over financial reporting that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

PART II – OTHER INFORMATION

ITEM 1. LEGAL PROCEEDINGS

There are no pending legal proceedings to which the Company is a party or in which any director, officer or affiliate of the Company, any owner of record or beneficially of more than 5% of any class of voting securities of the Company, or security holder is a party adverse to the Company or has a material interest adverse to the Company. The Company's property is not the subject of any pending legal proceedings.

ITEM 1A. RISK FACTORS

The Company is a smaller reporting company and is not required to provide this information.

ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS

Except as set forth below, there were no sales of equity securities sold during the period covered by this Report:

On August 15, 2018, we granted an option to purchase an aggregate of 20,000 shares of our common stock at an exercise price of $2.00 per share to Igor Korman. The option vests as to 6,667 shares on each of August 15, 2018 and August 15, 2019 and as to 6,666 shares on August 15, 2020 and remains exercisable as to each such installment for three years from the date of vesting.

On September 16, 2018, we sold 22,728 shares of our common stock to an accredited investor for $25,000 pursuant to a subscription agreement.

On October 8, 2018 we sold 22,728 shares our common stock to an accredited investor for $25,000 pursuant to a subscription agreement.

The above issuance did not involve any underwriters, underwriting discounts or commissions, or any public offering and we believe is exempt from the registration requirements of the Securities Act of 1933 by virtue of Section 4(2) thereof and/or Regulation D promulgated thereunder. The purchaser represented to us that he was an accredited investor and was acquiring the shares for investment purposes only and not with a view to, or for sale in connection with, any distribution thereof and that he could bear the risks of the investment.

ITEM 3. DEFAULTS UPON SENIOR SECURITIES

None.

ITEM 4. MINE SAFETY DISCLOSURES

Not Applicable

ITEM 5. OTHER INFORMATION

None.

ITEM 6. EXHIBITS

Exhibit Number	Exhibit

31.1	Certification of the Principal Executive Officer and Principal Financial Officer required by Rule 13a-14(a) or Rule 15d-14(a) under the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
32.1	Certification of the Chief Executive Officer and Chief Financial Officer (Principal Executive Officer and Principal Financial Officer) pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 (18 U.S.C. Section 1350)
101.INS	XBRL INSTANCE DOCUMENT
101.SCH	XBRL TAXONOMY EXTENSION SCHEMA
101.CAL	XBRL TAXONOMY EXTENSION CALCULATION LINKBASE
101.DEF	XBRL TAXONOMY EXTENSION DEFINITION LINKBASE
101.LAB	XBRL TAXONOMY EXTENSION LABEL LINKBASE
101.PRE	XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

	QRONS INC.

Date: November 6, 2018	By:	/s/ Jonah Meer
	Name:	Jonah Meer
	Title:	Chief Executive Officer and Chief Financial Officer (Principal Executive Officer and Principal Financial and Accounting Officer)

EX-31.1 2 ex311.htm CERTIFICATION

Exhibit 31.1

Certification Pursuant to pursuant to Rule 13a-14(a) or Rule 15d-14(a)

of the Securities Exchange Act of 1934, as amended

I, Jonah Meer, (Principal Executive Officer and Principal Financial and Accounting Officer), certify that:

1. I have reviewed this quarterly report on Form 10-Q of Qrons Inc. (the "Company);

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. As the registrant's certifying officer, I am responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15-d-15 (f) for the registrant and I have:

designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under my supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

c)	evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

d)	disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the period covered by this report that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting.

5. As the registrant's certifying officer, I have disclosed, based on my most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of registrant's board of directors (or persons performing the equivalent function):

a)	all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

b)	any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Dated: November 6, 2018	By:	/s/Jonah Meer
		Name: Jonah Meer
		Chief Executive Officer and Chief Financial Officer (Principal Executive Officer and Principal Financial and Accounting Officer)

EX-32.1 3 ex321.htm CERTIFICATION

Exhibit 32.1

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

The undersigned, Jonah Meer, Chief Executive Officer and Chief Financial Officer (Principal Executive Officer and Principal Financial and Accounting Officer) of Qrons Inc. (the "Company"), certifies, pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, 18 U.S.C. Section 1350) that, to his knowledge, the Company's Quarterly Report on Form 10-Q for the quarter ended September 30, 2018 (the "Report"):

(1) fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2) the information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.



/s/Jonah Meer
Jonah Meer
Chief Executive Officer and Chief Financial Officer (Principal Executive Officer and Principal Financial and Accounting Officer)
Date: November 6, 2018

EX-101.INS 4 qron-20180930.xml XBRL INSTANCE DOCUMENT 0001689084 qron:CubesquareLlcMember 2016-09-01 0001689084 qron:CubesquareLlcMember us-gaap:PresidentMember 2016-09-01 0001689084 qron:CubesquareLlcMember 2016-08-16 2016-09-01 0001689084 us-gaap:BoardOfDirectorsChairmanMember 2016-12-14 0001689084 us-gaap:StockOptionMember 2016-12-14 0001689084 us-gaap:BoardOfDirectorsChairmanMember 2016-12-01 2016-12-14 0001689084 us-gaap:LicensingAgreementsMember 2016-12-01 2016-12-14 0001689084 2016-12-31 0001689084 us-gaap:WarrantMember 2016-12-31 0001689084 2017-04-01 2017-06-30 0001689084 qron:CubesquareLlcMember 2017-09-27 0001689084 qron:CubesquareLlcMember 2017-09-20 2017-09-27 0001689084 qron:CubesquareLlcMember 2017-09-22 2017-09-28 0001689084 2017-07-01 2017-09-30 0001689084 2017-01-01 2017-09-30 0001689084 us-gaap:SeriesAPreferredStockMember 2017-01-01 2017-09-30 0001689084 us-gaap:WarrantMember 2017-01-01 2017-09-30 0001689084 us-gaap:ConvertibleDebtSecuritiesMember 2017-01-01 2017-09-30 0001689084 us-gaap:EmployeeStockOptionMember 2017-01-01 2017-09-30 0001689084 qron:ResearchWarrrantsSharesMember 2017-01-01 2017-09-30 0001689084 qron:StockOptionsNotYetVestedMember 2017-01-01 2017-09-30 0001689084 qron:StockAwardsNotYetVestedMember 2017-01-01 2017-09-30 0001689084 2017-09-30 0001689084 us-gaap:StockOptionMember 2017-11-15 0001689084 us-gaap:StockOptionMember 2017-11-01 2017-11-15 0001689084 us-gaap:StockOptionMember 2017-11-01 2017-11-15 0001689084 qron:StockOptionOneMember 2017-11-01 2017-11-15 0001689084 qron:StockOptionsGrantedToOfficersMember 2017-12-04 0001689084 qron:StockOptionsGrantedToOfficersMember 2017-12-03 2017-12-04 0001689084 us-gaap:LicenseAgreementTermsMember 2017-12-13 0001689084 us-gaap:LicenseAgreementTermsMember 2017-12-02 2017-12-13 0001689084 qron:ArielUniversityMember 2017-12-02 2017-12-13 0001689084 qron:TwoScientificAdvistorsMember 2017-12-14 0001689084 qron:ServiceAgreementWithArielMember 2017-12-14 0001689084 us-gaap:BoardOfDirectorsChairmanMember 2017-12-02 2017-12-14 0001689084 qron:TwoScientificAdvistorsMember 2017-12-02 2017-12-14 0001689084 2017-01-01 2017-12-31 0001689084 us-gaap:LicensingAgreementsMember 2017-01-01 2017-12-31 0001689084 us-gaap:WarrantMember 2017-01-01 2017-12-31 0001689084 srt:MaximumMember 2017-01-01 2017-12-31 0001689084 srt:MinimumMember 2017-01-01 2017-12-31 0001689084 us-gaap:GeneralAndAdministrativeExpenseMember 2017-01-01 2017-12-31 0001689084 qron:StockOptionsGrantedToOfficersMember us-gaap:GeneralAndAdministrativeExpenseMember 2017-01-01 2017-12-31 0001689084 2017-12-31 0001689084 us-gaap:WarrantMember 2017-12-31 0001689084 us-gaap:PrivatePlacementMember 2017-12-31 0001689084 us-gaap:FairValueInputsLevel1Member 2017-12-31 0001689084 us-gaap:FairValueInputsLevel2Member 2017-12-31 0001689084 us-gaap:FairValueInputsLevel3Member 2017-12-31 0001689084 us-gaap:StockOptionMember 2018-01-23 0001689084 us-gaap:PrivatePlacementMember 2018-01-23 0001689084 us-gaap:StockOptionMember 2018-01-05 2018-01-23 0001689084 us-gaap:PrivatePlacementMember 2018-01-05 2018-01-23 0001689084 2018-02-02 2018-02-06 0001689084 2018-03-03 2018-03-06 0001689084 qron:ServiceAgreementWithArielMember 2018-03-19 0001689084 2018-04-10 2018-04-12 0001689084 us-gaap:StockOptionMember 2018-04-16 0001689084 us-gaap:StockOptionMember 2018-04-01 2018-04-16 0001689084 2018-04-23 0001689084 2018-04-01 2018-04-23 0001689084 2018-04-26 0001689084 2018-05-01 0001689084 2018-06-16 2018-06-23 0001689084 2018-04-01 2018-06-30 0001689084 qron:SponsoredResearchAgreementMember 2018-07-01 2018-07-12 0001689084 us-gaap:StockOptionMember 2018-08-15 0001689084 us-gaap:StockOptionMember 2018-08-01 2018-08-15 0001689084 qron:ServiceAgreementWithArielMember 2018-08-22 0001689084 qron:CubesquareLlcMember 2018-09-01 2018-09-09 0001689084 us-gaap:PrivatePlacementMember 2018-09-16 0001689084 us-gaap:PrivatePlacementMember 2018-09-01 2018-09-16 0001689084 2018-07-01 2018-09-30 0001689084 us-gaap:GeneralAndAdministrativeExpenseMember 2018-07-01 2018-09-30 0001689084 qron:StockOptionsGrantedToOfficersMember us-gaap:GeneralAndAdministrativeExpenseMember 2018-07-01 2018-09-30 0001689084 2018-01-01 2018-09-30 0001689084 us-gaap:WarrantMember 2018-01-01 2018-09-30 0001689084 us-gaap:SeriesAPreferredStockMember 2018-01-01 2018-09-30 0001689084 us-gaap:WarrantMember 2018-01-01 2018-09-30 0001689084 us-gaap:ConvertibleDebtSecuritiesMember 2018-01-01 2018-09-30 0001689084 us-gaap:EmployeeStockOptionMember 2018-01-01 2018-09-30 0001689084 qron:ResearchWarrrantsSharesMember 2018-01-01 2018-09-30 0001689084 qron:StockOptionsNotYetVestedMember 2018-01-01 2018-09-30 0001689084 qron:StockAwardsNotYetVestedMember 2018-01-01 2018-09-30 0001689084 qron:StockOptionsGrantedToOfficersMember 2018-01-01 2018-09-30 0001689084 qron:ServiceAgreementWithArielMember 2018-01-01 2018-09-30 0001689084 srt:MaximumMember 2018-01-01 2018-09-30 0001689084 srt:MinimumMember 2018-01-01 2018-09-30 0001689084 us-gaap:GeneralAndAdministrativeExpenseMember 2018-01-01 2018-09-30 0001689084 qron:StockOptionsGrantedToOfficersMember us-gaap:GeneralAndAdministrativeExpenseMember 2018-01-01 2018-09-30 0001689084 qron:CommitmentDateMember 2018-01-01 2018-09-30 0001689084 us-gaap:StockOptionMember qron:MeasurementDateMember 2018-01-01 2018-09-30 0001689084 qron:MeasurementDateMember us-gaap:WarrantMember 2018-01-01 2018-09-30 0001689084 us-gaap:InvestorMember 2018-01-01 2018-09-30 0001689084 us-gaap:BoardOfDirectorsChairmanMember qron:DecemberFourteenTwoZeroOneEightMember 2018-01-01 2018-09-30 0001689084 srt:MinimumMember qron:CommitmentDateMember 2018-01-01 2018-09-30 0001689084 srt:MaximumMember qron:CommitmentDateMember 2018-01-01 2018-09-30 0001689084 srt:MaximumMember us-gaap:StockOptionMember qron:MeasurementDateMember 2018-01-01 2018-09-30 0001689084 srt:MinimumMember us-gaap:StockOptionMember qron:MeasurementDateMember 2018-01-01 2018-09-30 0001689084 qron:MeasurementDateMember us-gaap:WarrantMember srt:MaximumMember 2018-01-01 2018-09-30 0001689084 qron:MeasurementDateMember us-gaap:WarrantMember srt:MinimumMember 2018-01-01 2018-09-30 0001689084 qron:StockAwardsNotYetVestedMember qron:FourthQuarterMember 2018-01-01 2018-09-30 0001689084 2018-09-30 0001689084 us-gaap:WarrantMember 2018-09-30 0001689084 qron:ServiceAgreementWithArielMember 2018-09-30 0001689084 us-gaap:FairValueInputsLevel1Member 2018-09-30 0001689084 us-gaap:FairValueInputsLevel2Member 2018-09-30 0001689084 us-gaap:FairValueInputsLevel3Member 2018-09-30 0001689084 qron:MeasurementDateMember us-gaap:WarrantMember 2018-09-30 0001689084 qron:SponsoredResearchAgreementMember 2018-09-30 0001689084 us-gaap:SubsequentEventMember 2018-10-08 0001689084 us-gaap:SubsequentEventMember qron:ServiceAgreementWithArielMember 2018-10-01 2018-10-08 0001689084 us-gaap:SubsequentEventMember 2018-10-01 2018-10-08 0001689084 2018-11-14 xbrli:shares iso4217:USD iso4217:USDxbrli:shares xbrli:pure Qrons Inc. 0001689084 QRON false --12-31 10-Q 2018-09-30 2018 Q3 Non-accelerated Filer 12849581

155242

116468

57767

198622

15812

54991

73579

253613

73579

253613

14141

14267

1410

2915

6665

25000

31090

30506

53306

72688

53306

72688

1240

1283

1611711

3497774

-1592680

-3318134

20273

180925

73579

253613

0.001

10000

2000

0.0001

100000000

12404910

12826853

12404910

12826853

8406

10120

1179777

104798

237770

8170

11297

6300

35449

31643

47252

423216

1432980

48219

68669

534314

1706199

-48219

-68669

-534314

-1706199

1785

7215

6048

19839

-47954

-2979

584

-49739

-55169

-9027

-19255

-97958

-123838

-543341

-1725454

0.00

-0.04

-0.14

11552000

11544293

12807584

12744561

178000 1183106

6599

18335

47954

-584

39179

6059

126

1505

-63226

-384145

32000

525000

22548

24452

525000

-38774

140855

<div> <div style="text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; font-size: 13.33px; font-style: normal; font-weight: 400; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; background-color: #ffffff; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"> <div style="text-align: justify; font-family: 'times new roman', times, serif; font-size: 10pt; font-weight: bold;">Note 2 – Summary of Significant Accounting Policies</div> <div> </div> </div> <div style="text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-weight: 400; margin-bottom: 8pt; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; background-color: #ffffff; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt; font-style: italic; background-color: #ffffff;">Financial Statement Presentation:</font><font style="font-family: 'times new roman', times, serif; font-size: 10pt; background-color: #ffffff;"> </font> <font style="font-family: 'times new roman', times, serif; font-size: 10pt;">The accompanying unaudited condensed financial statements of the Company have been prepared in accordance with the rules and regulations of the Securities and Exchange Commission(the "SEC"), including the instructions to Form 10-Q and Regulation S-X. Certain information and note disclosures normally included in financial statements prepared in accordance with generally accepted accounting principles in the United States of America ("U.S. GAAP"), have been condensed or omitted from these statements pursuant to such rules and regulations and, accordingly, they do not include all the information and notes necessary for comprehensive financial statements and should be read in conjunction with our audited financial statements  included in our Annual Report on Form 10-K for the year ended December 31, 2017.</font></div> <div style="text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-weight: 400; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; background-color: #ffffff; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">In the opinion of the management of the Company, all adjustments, which are of a normal recurring nature, necessary for a fair statement of the results for the three and nine-month periods have been made. Results for the interim period presented are not necessarily indicative of the results that might be expected for the entire fiscal year. </div> <div style="text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; font-size: 13.33px; font-style: normal; font-weight: 400; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; background-color: #ffffff; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"> <div> </div> <div style="text-align: justify; font-family: 'times new roman', times, serif; font-size: 10pt;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt; font-style: italic;">Fiscal year end:</font> The Company has selected December 31 as its fiscal year end.</div> <div> </div> <div style="text-align: justify; font-family: 'times new roman', times, serif; font-size: 10pt;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt; font-style: italic;">Use of Estimates:</font> The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported therein. Due to the inherent uncertainty involved in making estimates, actual results reported in future periods may be based upon amounts that differ from these estimates.</div> <div> </div> <div style="text-align: justify; font-family: 'times new roman', times, serif; font-size: 10pt;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt; font-style: italic;">Cash Equivalents:</font> The Company considers all highly liquid investments with maturities of 90 days or less from the date of purchase to be cash equivalents.</div> <div> </div> <div style="text-align: justify; font-family: 'times new roman', times, serif; font-size: 10pt;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt; font-style: italic;">Research and Development Costs:</font> The Company charges research and development costs to expense when incurred in accordance with FASB ASC 730, "Research and Development". Research and development costs were $237,770 and $10,120 for the nine-month periods ended September 30, 2018 and September 30, 2017, respectively.</div> </div> <div style="text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-weight: 400; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; background-color: #ffffff; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"> </div> <div style="text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-weight: 400; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; background-color: #ffffff; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"> <div style="color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; font-size: 13.33px; font-style: normal; font-weight: 400; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; background-color: #ffffff; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"> <div style="text-align: justify; font-family: 'times new roman', times, serif; font-size: 10pt;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt; font-style: italic;">Advertising and Marketing Costs: </font>Advertising and marketing costs are expensed as incurred. <font style="font-family: 'times new roman', times, serif; font-size: 10pt; background-color: #ffffff;">The Company incurred $48,832 and $15,657 in advertising or marketing costs during the nine months ended September 30, 2018 and 2017, respectively.</font></div> </div> <div style="color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; clear: both; font-family: 'times new roman', times, serif; font-size: 13.33px; font-style: normal; font-weight: 400; margin-top: 10pt; margin-bottom: 10pt; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; background-color: #ffffff; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"> <div style="color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; font-size: 13.33px; font-style: normal; font-weight: 400; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; background-color: #ffffff; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"> <div style="text-align: justify; font-family: 'times new roman', times, serif; font-size: 10pt;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt; font-style: italic;">Related parties:</font> For the purposes of these financial statements, parties are considered to be related if one party has the ability, directly or indirectly, to control the party or exercise significant influence over the party in making financial and operating decisions, or vice versa, or where the Company and the party are subject to common control or common significant influence. Related parties may be individuals or other entities.</div> <div> </div> <div style="text-align: justify; font-family: 'times new roman', times, serif; font-size: 10pt;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt; font-style: italic;">Stock-Based Compensation and Other Share-Based Payments:</font> The expense attributable to the Company's Directors is recognized over the period the amounts are earned and vested, and the expense attributable to the Company's non-employees is recognized when vested, as described in Note 7, <font style="font-family: 'times new roman', times, serif; font-size: 10pt; font-style: italic;">Stock Plan</font>.</div> <div> </div> <div style="text-align: justify; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: italic;">Fair Value of Financial Instruments</div> <div> </div> <div style="text-align: justify; font-family: 'times new roman', times, serif; font-size: 10pt;">FASB ASC 820, Fair Value Measurements and Disclosures, defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. FASB ASC 820 also establishes a fair value hierarchy which requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. FASB ASC 820 describes three levels of inputs that may be used to measure fair value:</div> <div> </div> <div style="text-align: justify; font-family: 'times new roman', times, serif; font-size: 10pt;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt; font-style: italic;">Level 1 </font>– Quoted prices in active markets for identical assets or liabilities.</div> <div> </div> <div style="text-align: justify; font-family: 'times new roman', times, serif; font-size: 10pt;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt; font-style: italic;">Level 2 </font>– Observable inputs other than Level 1 prices, such as quoted prices for similar assets or liabilities; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.</div> <div> </div> <div style="text-align: justify; font-family: 'times new roman', times, serif; font-size: 10pt;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt; font-style: italic;">Level 3 </font>– Unobservable inputs that are supported by little or no market activity and that are financial instruments whose values are determined using pricing models, discounted cash flow methodologies, or similar techniques, as well as instruments for which the determination of fair value requires significant judgment or estimation.</div> <div> </div> <div style="text-align: justify; font-family: 'times new roman', times, serif; font-size: 10pt;">If the inputs used to measure the financial assets and liabilities fall within more than one level described above, the categorization is based on the lowest level of input that is significant to the fair value measurement of the instrument.</div> <div> </div> <div style="text-align: justify; font-family: 'times new roman', times, serif; font-size: 10pt;">The following table provides a summary of the fair value of our derivative liabilities as of September 30, 2018 and December 31, 2017:</div> <div> </div> </div> <table style="width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; font-size: 10pt; word-spacing: 0px; orphans: 2; widows: 2; background-color: #ffffff; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;" cellspacing="0" cellpadding="0"> <tr> <td valign="bottom" style="vertical-align: bottom;"> <div style="text-align: justify; font-family: 'times new roman', times, serif; font-size: 10pt;"> </div> </td> <td valign="bottom" style="vertical-align: bottom;" colspan="11"> <div style="text-align: center; font-family: 'times new roman', times, serif; font-size: 10pt;">Fair value measurements on a recurring basis</div> </td> <td nowrap="nowrap" valign="bottom" style="text-align: left; vertical-align: bottom;"> </td> </tr> <tr> <td valign="bottom" style="padding-bottom: 2px; vertical-align: bottom;"> <div style="text-align: justify; font-family: 'times new roman', times, serif; font-size: 10pt;"> </div> </td> <td valign="bottom" style="vertical-align: bottom; border-bottom-color: #000000; border-bottom-width: 2px; border-bottom-style: solid;" colspan="3"> <div style="text-align: center; font-family: 'times new roman', times, serif; font-size: 10pt;">Level 1</div> </td> <td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; vertical-align: bottom;"> </td> <td valign="bottom" style="vertical-align: bottom; border-bottom-color: #000000; border-bottom-width: 2px; border-bottom-style: solid;" colspan="3"> <div style="text-align: center; font-family: 'times new roman', times, serif; font-size: 10pt;">Level 2</div> </td> <td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; vertical-align: bottom;"> </td> <td valign="bottom" style="vertical-align: bottom; border-bottom-color: #000000; border-bottom-width: 2px; border-bottom-style: solid;" colspan="3"> <div style="text-align: center; font-family: 'times new roman', times, serif; font-size: 10pt;">Level 3</div> </td> <td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; vertical-align: bottom;"> </td> </tr> <tr> <td valign="bottom" style="vertical-align: bottom; background-color: #cceeff;"> <div style="text-align: justify; font-family: 'times new roman', times, serif; font-size: 10pt;">As of September 30, 2018:</div> </td> <td valign="bottom" style="vertical-align: bottom; background-color: #cceeff;" colspan="3"> </td> <td nowrap="nowrap" valign="bottom" style="text-align: left; vertical-align: bottom; background-color: #cceeff;"> </td> <td valign="bottom" style="vertical-align: bottom; background-color: #cceeff;" colspan="3"> </td> <td nowrap="nowrap" valign="bottom" style="text-align: left; vertical-align: bottom; background-color: #cceeff;"> </td> <td valign="bottom" style="vertical-align: bottom; background-color: #cceeff;" colspan="3"> </td> <td nowrap="nowrap" valign="bottom" style="text-align: left; vertical-align: bottom; background-color: #cceeff;"> </td> </tr> <tr> <td valign="bottom" style="vertical-align: bottom; background-color: #ffffff;"> <div style="text-align: justify; font-family: 'times new roman', times, serif; font-size: 10pt;">Liabilities</div> </td> <td valign="bottom" style="vertical-align: bottom; background-color: #ffffff;" colspan="3"> </td> <td nowrap="nowrap" valign="bottom" style="text-align: left; vertical-align: bottom; background-color: #ffffff;"> </td> <td valign="bottom" style="vertical-align: bottom; background-color: #ffffff;" colspan="3"> </td> <td nowrap="nowrap" valign="bottom" style="text-align: left; vertical-align: bottom; background-color: #ffffff;"> </td> <td valign="bottom" style="vertical-align: bottom; background-color: #ffffff;" colspan="3"> </td> <td nowrap="nowrap" valign="bottom" style="text-align: left; vertical-align: bottom; background-color: #ffffff;"> </td> </tr> <tr> <td valign="bottom" style="width: 1003px; padding-bottom: 2px; vertical-align: bottom; background-color: #cceeff;"> <div style="text-align: justify; font-family: 'times new roman', times, serif; font-size: 10pt;">Derivative liabilities</div> </td> <td valign="bottom" style="width: 16px; padding-bottom: 2px; vertical-align: bottom; background-color: #cceeff;"> </td> <td valign="bottom" style="width: 16px; text-align: left; vertical-align: bottom; border-bottom-color: #000000; border-bottom-width: 2px; border-bottom-style: solid; background-color: #cceeff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">$</div> </td> <td valign="bottom" style="width: 142px; text-align: right; vertical-align: bottom; border-bottom-color: #000000; border-bottom-width: 2px; border-bottom-style: solid; background-color: #cceeff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">-</div> </td> <td nowrap="nowrap" valign="bottom" style="width: 16px; text-align: left; padding-bottom: 2px; vertical-align: bottom; background-color: #cceeff;"> </td> <td valign="bottom" style="width: 16px; padding-bottom: 2px; vertical-align: bottom; background-color: #cceeff;"> </td> <td valign="bottom" style="width: 16px; text-align: left; vertical-align: bottom; border-bottom-color: #000000; border-bottom-width: 2px; border-bottom-style: solid; background-color: #cceeff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">$</div> </td> <td valign="bottom" style="width: 141px; text-align: right; vertical-align: bottom; border-bottom-color: #000000; border-bottom-width: 2px; border-bottom-style: solid; background-color: #cceeff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">-</div> </td> <td nowrap="nowrap" valign="bottom" style="width: 15px; text-align: left; padding-bottom: 2px; vertical-align: bottom; background-color: #cceeff;"> </td> <td valign="bottom" style="width: 15px; padding-bottom: 2px; vertical-align: bottom; background-color: #cceeff;"> </td> <td valign="bottom" style="width: 15px; text-align: left; vertical-align: bottom; border-bottom-color: #000000; border-bottom-width: 2px; border-bottom-style: solid; background-color: #cceeff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">$</div> </td> <td valign="bottom" style="width: 141px; text-align: right; vertical-align: bottom; border-bottom-color: #000000; border-bottom-width: 2px; border-bottom-style: solid; background-color: #cceeff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">30,506</div> </td> <td nowrap="nowrap" valign="bottom" style="width: 15px; text-align: left; padding-bottom: 2px; vertical-align: bottom; background-color: #cceeff;"> </td> </tr> <tr> <td valign="bottom" style="width: 1003px; vertical-align: bottom; background-color: #ffffff;"> <div style="text-align: justify; font-family: 'times new roman', times, serif; font-size: 10pt;"> </div> </td> <td valign="bottom" style="width: 16px; vertical-align: bottom; background-color: #ffffff;"> </td> <td valign="bottom" style="width: 16px; text-align: left; vertical-align: bottom; background-color: #ffffff;"> </td> <td valign="bottom" style="width: 142px; text-align: right; vertical-align: bottom; background-color: #ffffff;"> </td> <td nowrap="nowrap" valign="bottom" style="width: 16px; text-align: left; vertical-align: bottom; background-color: #ffffff;"> </td> <td valign="bottom" style="width: 16px; vertical-align: bottom; background-color: #ffffff;"> </td> <td valign="bottom" style="width: 16px; text-align: left; vertical-align: bottom; background-color: #ffffff;"> </td> <td valign="bottom" style="width: 141px; text-align: right; vertical-align: bottom; background-color: #ffffff;"> </td> <td nowrap="nowrap" valign="bottom" style="width: 15px; text-align: left; vertical-align: bottom; background-color: #ffffff;"> </td> <td valign="bottom" style="width: 15px; vertical-align: bottom; background-color: #ffffff;"> </td> <td valign="bottom" style="width: 15px; text-align: left; vertical-align: bottom; background-color: #ffffff;"> </td> <td valign="bottom" style="width: 141px; text-align: right; vertical-align: bottom; background-color: #ffffff;"> </td> <td nowrap="nowrap" valign="bottom" style="width: 15px; text-align: left; vertical-align: bottom; background-color: #ffffff;"> </td> </tr> <tr> <td valign="bottom" style="width: 1003px; vertical-align: bottom; background-color: #cceeff;"> <div style="text-align: justify; font-family: 'times new roman', times, serif; font-size: 10pt;">As of December 31, 2017:</div> </td> <td valign="bottom" style="width: 16px; vertical-align: bottom; background-color: #cceeff;"> </td> <td valign="bottom" style="width: 16px; text-align: left; vertical-align: bottom; background-color: #cceeff;"> </td> <td valign="bottom" style="width: 142px; text-align: right; vertical-align: bottom; background-color: #cceeff;"> </td> <td nowrap="nowrap" valign="bottom" style="width: 16px; text-align: left; vertical-align: bottom; background-color: #cceeff;"> </td> <td valign="bottom" style="width: 16px; vertical-align: bottom; background-color: #cceeff;"> </td> <td valign="bottom" style="width: 16px; text-align: left; vertical-align: bottom; background-color: #cceeff;"> </td> <td valign="bottom" style="width: 141px; text-align: right; vertical-align: bottom; background-color: #cceeff;"> </td> <td nowrap="nowrap" valign="bottom" style="width: 15px; text-align: left; vertical-align: bottom; background-color: #cceeff;"> </td> <td valign="bottom" style="width: 15px; vertical-align: bottom; background-color: #cceeff;"> </td> <td valign="bottom" style="width: 15px; text-align: left; vertical-align: bottom; background-color: #cceeff;"> </td> <td valign="bottom" style="width: 141px; text-align: right; vertical-align: bottom; background-color: #cceeff;"> </td> <td nowrap="nowrap" valign="bottom" style="width: 15px; text-align: left; vertical-align: bottom; background-color: #cceeff;"> </td> </tr> <tr> <td valign="bottom" style="width: 1003px; vertical-align: bottom; background-color: #ffffff;"> <div style="text-align: justify; font-family: 'times new roman', times, serif; font-size: 10pt;">Liabilities</div> </td> <td valign="bottom" style="width: 16px; vertical-align: bottom; background-color: #ffffff;"> </td> <td valign="bottom" style="width: 16px; text-align: left; vertical-align: bottom; background-color: #ffffff;"> </td> <td valign="bottom" style="width: 142px; text-align: right; vertical-align: bottom; background-color: #ffffff;"> </td> <td nowrap="nowrap" valign="bottom" style="width: 16px; text-align: left; vertical-align: bottom; background-color: #ffffff;"> </td> <td valign="bottom" style="width: 16px; vertical-align: bottom; background-color: #ffffff;"> </td> <td valign="bottom" style="width: 16px; text-align: left; vertical-align: bottom; background-color: #ffffff;"> </td> <td valign="bottom" style="width: 141px; text-align: right; vertical-align: bottom; background-color: #ffffff;"> </td> <td nowrap="nowrap" valign="bottom" style="width: 15px; text-align: left; vertical-align: bottom; background-color: #ffffff;"> </td> <td valign="bottom" style="width: 15px; vertical-align: bottom; background-color: #ffffff;"> </td> <td valign="bottom" style="width: 15px; text-align: left; vertical-align: bottom; background-color: #ffffff;"> </td> <td valign="bottom" style="width: 141px; text-align: right; vertical-align: bottom; background-color: #ffffff;"> </td> <td nowrap="nowrap" valign="bottom" style="width: 15px; text-align: left; vertical-align: bottom; background-color: #ffffff;"> </td> </tr> <tr> <td valign="bottom" style="width: 1003px; padding-bottom: 2px; vertical-align: bottom; background-color: #cceeff;"> <div style="text-align: justify; font-family: 'times new roman', times, serif; font-size: 10pt;">Derivative liabilities</div> </td> <td valign="bottom" style="width: 16px; padding-bottom: 2px; vertical-align: bottom; background-color: #cceeff;"> </td> <td valign="bottom" style="width: 16px; text-align: left; vertical-align: bottom; border-bottom-color: #000000; border-bottom-width: 2px; border-bottom-style: solid; background-color: #cceeff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">$</div> </td> <td valign="bottom" style="width: 142px; text-align: right; vertical-align: bottom; border-bottom-color: #000000; border-bottom-width: 2px; border-bottom-style: solid; background-color: #cceeff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">-</div> </td> <td nowrap="nowrap" valign="bottom" style="width: 16px; text-align: left; padding-bottom: 2px; vertical-align: bottom; background-color: #cceeff;"> </td> <td valign="bottom" style="width: 16px; padding-bottom: 2px; vertical-align: bottom; background-color: #cceeff;"> </td> <td valign="bottom" style="width: 16px; text-align: left; vertical-align: bottom; border-bottom-color: #000000; border-bottom-width: 2px; border-bottom-style: solid; background-color: #cceeff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">$</div> </td> <td valign="bottom" style="width: 141px; text-align: right; vertical-align: bottom; border-bottom-color: #000000; border-bottom-width: 2px; border-bottom-style: solid; background-color: #cceeff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">-</div> </td> <td nowrap="nowrap" valign="bottom" style="width: 15px; text-align: left; padding-bottom: 2px; vertical-align: bottom; background-color: #cceeff;"> </td> <td valign="bottom" style="width: 15px; padding-bottom: 2px; vertical-align: bottom; background-color: #cceeff;"> </td> <td valign="bottom" style="width: 15px; text-align: left; vertical-align: bottom; border-bottom-color: #000000; border-bottom-width: 2px; border-bottom-style: solid; background-color: #cceeff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">$</div> </td> <td valign="bottom" style="width: 141px; text-align: right; vertical-align: bottom; border-bottom-color: #000000; border-bottom-width: 2px; border-bottom-style: solid; background-color: #cceeff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">31,090</div> </td> <td nowrap="nowrap" valign="bottom" style="width: 15px; text-align: left; padding-bottom: 2px; vertical-align: bottom; background-color: #cceeff;"> </td> </tr> </table> <div style="text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; font-size: 13.33px; font-style: normal; font-weight: 400; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; background-color: #ffffff; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;"> <br /></font></div> <div style="color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; font-size: 13.33px; font-style: normal; font-weight: 400; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; background-color: #ffffff; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"> <div style="text-align: justify; font-family: 'times new roman', times, serif; font-size: 10pt;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt; font-style: italic;">Warrants: </font>The Company accounts for common stock warrants in accordance with applicable accounting guidance provided in ASC Topic 815 <font style="font-family: 'times new roman', times, serif; font-size: 10pt; font-style: italic;">"Derivatives and Hedging – Contracts in Entity's Own Equity" </font>(ASC Topic 815), as either derivative liabilities or as equity instruments depending on the specific terms of the warrant agreement.  For warrants classified as equity instruments we apply the Black Scholes model.   Presently all warrants issued and outstanding are accounted for using the equity method.</div> <div> </div> <div style="text-align: justify; font-family: 'times new roman', times, serif; font-size: 10pt;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt; font-style: italic;">Income taxes:</font> The Company has adopted ASC Topic 740 – "Income Taxes" ASC Topic 740 requires the use of the asset and liability method of accounting for income taxes. Under the asset and liability method of ASC Topic 740, deferred tax assets and liabilities are recognized for the future tax consequences attributable to temporary differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled.</div> <div> </div> <div style="text-align: justify; font-family: 'times new roman', times, serif; font-size: 10pt;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt; font-style: italic;">Basic and Diluted Loss Per Share</font>: In accordance with ASC Topic 260 – "Earnings Per Share", the basic loss per common share is computed by dividing net loss available to common stockholders by the weighted average number of common stock outstanding. Diluted loss per common share is computed similar to basic loss per common share except that the denominator is increased to include the number of additional shares of common stock that would have been outstanding if the potential common stock had been issued and if the additional shares of common stock were dilutive.</div> <div> </div> <div style="text-align: justify; font-family: 'times new roman', times, serif; font-size: 10pt;">Potential common stock consists of the incremental common stock issuable upon the exercise of common stock warrants (using the if-converted method), convertible notes, classes of shares with conversion features, and stock awards and stock options. The computation of basic loss per share for the nine-month period ended September 30, 2018 and 2017 excludes potentially dilutive securities of underlying share purchase warrants, convertible notes, stock options and preferred shares, because their inclusion would be antidilutive. As a result, the computations of net loss per share for each period presented is the same for both basic and fully diluted.</div> <div> </div> <div style="text-align: justify; font-family: 'times new roman', times, serif; font-size: 10pt;">The table below reflects the potentially dilutive securities at each reporting period which have been excluded from the computation of diluted net loss per share:</div> <div> </div> </div> <table style="width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; font-size: 10pt; word-spacing: 0px; orphans: 2; widows: 2; background-color: #ffffff; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;" cellspacing="0" cellpadding="0"> <tr> <td valign="bottom" style="padding-bottom: 2px; vertical-align: bottom;"> <div style="text-align: justify; font-family: 'times new roman', times, serif; font-size: 10pt;"> </div> </td> <td valign="bottom" style="padding-bottom: 2px; vertical-align: bottom;"> </td> <td valign="bottom" style="vertical-align: bottom; border-bottom-color: #000000; border-bottom-width: 2px; border-bottom-style: solid;" colspan="2"> <div style="text-align: center; font-family: 'times new roman', times, serif; font-size: 10pt;">September 30, 2018</div> </td> <td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; vertical-align: bottom;"> </td> <td valign="bottom" style="padding-bottom: 2px; vertical-align: bottom;"> </td> <td valign="bottom" style="vertical-align: top; border-bottom-color: #000000; border-bottom-width: 2px; border-bottom-style: solid;" colspan="2"> <div style="text-align: center; font-family: 'times new roman', times, serif; font-size: 10pt;">September 30, 2017</div> </td> <td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; vertical-align: bottom;"> </td> </tr> <tr> <td valign="bottom" style="width: 1191px; vertical-align: bottom; background-color: #cceeff;"> <div style="text-align: justify; font-family: 'times new roman', times, serif; font-size: 10pt;">Stock purchase warrants</div> </td> <td valign="bottom" style="width: 16px; vertical-align: bottom; background-color: #cceeff;"> </td> <td valign="bottom" style="width: 16px; text-align: left; vertical-align: bottom; background-color: #cceeff;"> </td> <td valign="bottom" style="width: 142px; text-align: right; vertical-align: bottom; background-color: #cceeff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">52,000</div> </td> <td nowrap="nowrap" valign="bottom" style="width: 16px; text-align: left; vertical-align: bottom; background-color: #cceeff;"> </td> <td valign="bottom" style="width: 15px; vertical-align: bottom; background-color: #cceeff;"> </td> <td valign="bottom" style="width: 15px; text-align: left; vertical-align: bottom; background-color: #cceeff;"> </td> <td valign="bottom" style="width: 141px; text-align: right; vertical-align: bottom; background-color: #cceeff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">566,000</div> </td> <td nowrap="nowrap" valign="bottom" style="width: 15px; text-align: left; vertical-align: bottom; background-color: #cceeff;"> </td> </tr> <tr> <td valign="bottom" style="width: 1191px; vertical-align: bottom; background-color: #ffffff;"> <div style="text-align: justify; font-family: 'times new roman', times, serif; font-size: 10pt;">Research Warrants at 3% of issued and outstanding shares</div> </td> <td valign="bottom" style="width: 16px; vertical-align: bottom; background-color: #ffffff;"> </td> <td valign="bottom" style="width: 16px; text-align: left; vertical-align: bottom; background-color: #ffffff;"> </td> <td valign="bottom" style="width: 142px; text-align: right; vertical-align: bottom; background-color: #ffffff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">384,806</div> </td> <td nowrap="nowrap" valign="bottom" style="width: 16px; text-align: left; vertical-align: bottom; background-color: #ffffff;"> </td> <td valign="bottom" style="width: 15px; vertical-align: bottom; background-color: #ffffff;"> </td> <td valign="bottom" style="width: 15px; text-align: left; vertical-align: bottom; background-color: #ffffff;"> </td> <td valign="bottom" style="width: 141px; text-align: right; vertical-align: bottom; background-color: #ffffff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">-</div> </td> <td nowrap="nowrap" valign="bottom" style="width: 15px; text-align: left; vertical-align: bottom; background-color: #ffffff;"> </td> </tr> <tr> <td valign="bottom" style="width: 1191px; vertical-align: bottom; background-color: #cceeff;"> <div style="text-align: justify; font-family: 'times new roman', times, serif; font-size: 10pt;">Convertible Notes</div> </td> <td valign="bottom" style="width: 16px; vertical-align: bottom; background-color: #cceeff;"> </td> <td valign="bottom" style="width: 16px; text-align: left; vertical-align: bottom; background-color: #cceeff;"> </td> <td valign="bottom" style="width: 142px; text-align: right; vertical-align: bottom; background-color: #cceeff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">28,778</div> </td> <td nowrap="nowrap" valign="bottom" style="width: 16px; text-align: left; vertical-align: bottom; background-color: #cceeff;"> </td> <td valign="bottom" style="width: 15px; vertical-align: bottom; background-color: #cceeff;"> </td> <td valign="bottom" style="width: 15px; text-align: left; vertical-align: bottom; background-color: #cceeff;"> </td> <td valign="bottom" style="width: 141px; text-align: right; vertical-align: bottom; background-color: #cceeff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">32,178</div> </td> <td nowrap="nowrap" valign="bottom" style="width: 15px; text-align: left; vertical-align: bottom; background-color: #cceeff;"> </td> </tr> <tr> <td valign="bottom" style="width: 1191px; vertical-align: bottom; background-color: #ffffff;"> <div style="text-align: justify; font-family: 'times new roman', times, serif; font-size: 10pt;">Series A Preferred shares</div> </td> <td valign="bottom" style="width: 16px; vertical-align: bottom; background-color: #ffffff;"> </td> <td valign="bottom" style="width: 16px; text-align: left; vertical-align: bottom; background-color: #ffffff;"> </td> <td valign="bottom" style="width: 142px; text-align: right; vertical-align: bottom; background-color: #ffffff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">700</div> </td> <td nowrap="nowrap" valign="bottom" style="width: 16px; text-align: left; vertical-align: bottom; background-color: #ffffff;"> </td> <td valign="bottom" style="width: 15px; vertical-align: bottom; background-color: #ffffff;"> </td> <td valign="bottom" style="width: 15px; text-align: left; vertical-align: bottom; background-color: #ffffff;"> </td> <td valign="bottom" style="width: 141px; text-align: right; vertical-align: bottom; background-color: #ffffff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">700</div> </td> <td nowrap="nowrap" valign="bottom" style="width: 15px; text-align: left; vertical-align: bottom; background-color: #ffffff;"> </td> </tr> <tr> <td valign="bottom" style="width: 1191px; vertical-align: bottom; background-color: #cceeff;"> <div style="text-align: justify; font-family: 'times new roman', times, serif; font-size: 10pt;">Stock options vested</div> </td> <td valign="bottom" style="width: 16px; vertical-align: bottom; background-color: #cceeff;"> </td> <td valign="bottom" style="width: 16px; text-align: left; vertical-align: bottom; background-color: #cceeff;"> </td> <td valign="bottom" style="width: 142px; text-align: right; vertical-align: bottom; background-color: #cceeff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">30,000</div> </td> <td nowrap="nowrap" valign="bottom" style="width: 16px; text-align: left; vertical-align: bottom; background-color: #cceeff;"> </td> <td valign="bottom" style="width: 15px; vertical-align: bottom; background-color: #cceeff;"> </td> <td valign="bottom" style="width: 15px; text-align: left; vertical-align: bottom; background-color: #cceeff;"> </td> <td valign="bottom" style="width: 141px; text-align: right; vertical-align: bottom; background-color: #cceeff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">-</div> </td> <td nowrap="nowrap" valign="bottom" style="width: 15px; text-align: left; vertical-align: bottom; background-color: #cceeff;"> </td> </tr> <tr> <td valign="bottom" style="width: 1191px; vertical-align: bottom; background-color: #ffffff;"> <div style="text-align: justify; font-family: 'times new roman', times, serif; font-size: 10pt;">Stock options not yet vested</div> </td> <td valign="bottom" style="width: 16px; vertical-align: bottom; background-color: #ffffff;"> </td> <td valign="bottom" style="width: 16px; text-align: left; vertical-align: bottom; background-color: #ffffff;"> </td> <td valign="bottom" style="width: 142px; text-align: right; vertical-align: bottom; background-color: #ffffff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">690,000</div> </td> <td nowrap="nowrap" valign="bottom" style="width: 16px; text-align: left; vertical-align: bottom; background-color: #ffffff;"> </td> <td valign="bottom" style="width: 15px; vertical-align: bottom; background-color: #ffffff;"> </td> <td valign="bottom" style="width: 15px; text-align: left; vertical-align: bottom; background-color: #ffffff;"> </td> <td valign="bottom" style="width: 141px; text-align: right; vertical-align: bottom; background-color: #ffffff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">-</div> </td> <td nowrap="nowrap" valign="bottom" style="width: 15px; text-align: left; vertical-align: bottom; background-color: #ffffff;"> </td> </tr> <tr> <td valign="bottom" style="width: 1191px; padding-bottom: 2px; vertical-align: bottom; background-color: #cceeff;"> <div style="text-align: justify; font-family: 'times new roman', times, serif; font-size: 10pt;">Stock awards not yet vested</div> </td> <td valign="bottom" style="width: 16px; padding-bottom: 2px; vertical-align: bottom; background-color: #cceeff;"> </td> <td valign="bottom" style="width: 16px; text-align: left; vertical-align: bottom; border-bottom-color: #000000; border-bottom-width: 2px; border-bottom-style: solid; background-color: #cceeff;"> </td> <td valign="bottom" style="width: 142px; text-align: right; vertical-align: bottom; border-bottom-color: #000000; border-bottom-width: 2px; border-bottom-style: solid; background-color: #cceeff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">290,000</div> </td> <td nowrap="nowrap" valign="bottom" style="width: 16px; text-align: left; padding-bottom: 2px; vertical-align: bottom; background-color: #cceeff;"> </td> <td valign="bottom" style="width: 15px; padding-bottom: 2px; vertical-align: bottom; background-color: #cceeff;"> </td> <td valign="bottom" style="width: 15px; text-align: left; vertical-align: bottom; border-bottom-color: #000000; border-bottom-width: 2px; border-bottom-style: solid; background-color: #cceeff;"> </td> <td valign="bottom" style="width: 141px; text-align: right; vertical-align: bottom; border-bottom-color: #000000; border-bottom-width: 2px; border-bottom-style: solid; background-color: #cceeff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">-</div> </td> <td nowrap="nowrap" valign="bottom" style="width: 15px; text-align: left; padding-bottom: 2px; vertical-align: bottom; background-color: #cceeff;"> </td> </tr> <tr> <td valign="bottom" style="width: 1191px; padding-bottom: 2px; vertical-align: bottom; background-color: #ffffff;"> <div style="text-align: justify; font-family: 'times new roman', times, serif; font-size: 10pt;"> </div> </td> <td valign="bottom" style="width: 16px; padding-bottom: 2px; vertical-align: bottom; background-color: #ffffff;"> </td> <td valign="bottom" style="width: 16px; text-align: left; vertical-align: bottom; border-bottom-color: #000000; border-bottom-width: 2px; border-bottom-style: solid; background-color: #ffffff;"> </td> <td valign="bottom" style="width: 142px; text-align: right; vertical-align: bottom; border-bottom-color: #000000; border-bottom-width: 2px; border-bottom-style: solid; background-color: #ffffff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">1,476,284</div> </td> <td nowrap="nowrap" valign="bottom" style="width: 16px; text-align: left; padding-bottom: 2px; vertical-align: bottom; background-color: #ffffff;"> </td> <td valign="bottom" style="width: 15px; padding-bottom: 2px; vertical-align: bottom; background-color: #ffffff;"> </td> <td valign="bottom" style="width: 15px; text-align: left; vertical-align: bottom; border-bottom-color: #000000; border-bottom-width: 2px; border-bottom-style: solid; background-color: #ffffff;"> </td> <td valign="bottom" style="width: 141px; text-align: right; vertical-align: bottom; border-bottom-color: #000000; border-bottom-width: 2px; border-bottom-style: solid; background-color: #ffffff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">598,878</div> </td> <td nowrap="nowrap" valign="bottom" style="width: 15px; text-align: left; padding-bottom: 2px; vertical-align: bottom; background-color: #ffffff;"> </td> </tr> </table> <div style="color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; font-size: 13.33px; font-style: normal; font-weight: 400; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; background-color: #ffffff; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"> <div style="text-align: justify; font-family: 'times new roman', times, serif; font-size: 10pt;"> </div> <div style="text-align: justify; font-family: 'times new roman', times, serif; font-size: 10pt;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt; font-style: italic;">New Accounting Pronouncements: </font>There were various accounting standards and interpretations issued recently, none of which are expected to have a material effect on the Company's operations, financial position or cash flows.</div> </div> </div> </div> </div>

<div> <div style="text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-weight: bold; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">Note 3 – Going Concern</div> <div style="color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; font-size: 13.33px; font-style: normal; font-weight: 400; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"> </div> <div style="text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-weight: 400; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">The Company has experienced net losses to date, and it has not generated revenue from operations.  While the Company has recently raised proceeds, it does not believe its resources will be sufficient to meet its operating and capital needs beyond the fourth quarter of 2018. The Company expects it will require additional capital to fully implement the scope of its proposed business operations, which raises substantial doubt about its ability to continue as a going concern.  The Company will have to continue to rely on equity and debt financing. There can be no assurance that financing, whether debt or equity, will always be available to the Company in the amount required at any particular time or for any particular period or, if available, that it can be obtained on favorable terms.</div> <div style="color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; font-size: 13.33px; font-style: normal; font-weight: 400; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"> </div> <div style="text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-weight: 400; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">The financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts, or amount and classification of liabilities that might cause results from this uncertainty.</div> </div>

<div style="color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; font-size: 13.33px; font-style: normal; font-weight: 400; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; background-color: #ffffff; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"> <div style="text-align: justify; font-family: 'times new roman', times, serif; font-size: 10pt; font-weight: bold;">Note 6 – <font style="font-family: 'times new roman', times, serif; font-size: 10pt; background-color: #ffffff;">Commitments</font></div> <div> </div> </div> <table style="width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; font-size: 10pt; word-spacing: 0px; orphans: 2; widows: 2; background-color: #ffffff; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;" cellspacing="0" cellpadding="0"> <tr> <td style="width: 64px; vertical-align: top; background-color: #ffffff;"> <div style="text-align: justify; font-family: 'times new roman', times, serif; font-size: 10pt;">(1)  </div> </td> <td style="width: 1503px; vertical-align: top; background-color: #ffffff;"> <div style="text-align: justify; font-family: 'times new roman', times, serif; font-size: 10pt;">Service Agreement with Ariel - Prof. Danny Baranes</div> </td> </tr> </table> <div style="color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; font-size: 13.33px; font-style: normal; font-weight: 400; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; background-color: #ffffff; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"> <div> </div> <div style="text-align: justify; font-family: 'times new roman', times, serif; font-size: 10pt;">On December 14, 2017, the Company entered into a 12-month services agreement pursuant to which a team at Ariel under the direction of Prof. Danny Baranes will conduct molecular biology research activities involving the testing of implant materials for the Company. As compensation for the services provided, the Company will pay Ariel (i) $17,250 within five business days of the execution of the Services Agreement, and (ii) $17,250 by May 1, 2018.</div> <div> </div> <div style="text-align: justify; font-family: 'times new roman', times, serif; font-size: 10pt;">The Services Agreement may be terminated by the non-breaching party upon a material breach that is not cured within 30 days or by the Company upon thirty days' prior written notice to Ariel. Ariel must keep confidential information of the Company confidential for five years after the term of the Services Agreement.</div> <div> </div> <div style="text-align: justify; font-family: 'times new roman', times, serif; font-size: 10pt;">During the year ended December 31, 2017, $17,250 was paid and on April 26, 2018, the remaining installment of $17,250 was paid. During the year ended December 31, 2017, $1,438 was expensed, and during the nine months ended September 30, 2018 $25,875 was expensed, and the remaining $7,187, which amount is reflected on the Company's balance sheets as prepaid expenses, will be expensed in a subsequent period.</div> <div> </div> <div style="text-align: justify; font-family: 'times new roman', times, serif; font-size: 10pt;">On April 12, 2018, the Services Agreement was amended to provide for the payment by the Company of an additional monthly fee, commencing March 2018, of up to 8,000 Israeli shekels as compensation for additional costs which the Company may request. During the nine-month period ended September 30, 2018, the Company paid $14,082 for these additional fees.</div> <div> </div> </div> <table style="width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; font-size: 10pt; word-spacing: 0px; orphans: 2; widows: 2; background-color: #ffffff; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;" cellspacing="0" cellpadding="0"> <tr> <td style="width: 64px; vertical-align: top; background-color: #ffffff;"> <div style="text-align: justify; font-family: 'times new roman', times, serif; font-size: 10pt;">(2)  </div> </td> <td style="width: 1503px; vertical-align: top; background-color: #ffffff;"> <div style="text-align: justify; font-family: 'times new roman', times, serif; font-size: 10pt;">Service Agreement with Ariel - Dr. Gadi Turgeman</div> </td> </tr> </table> <div style="color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; font-size: 13.33px; font-style: normal; font-weight: 400; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; background-color: #ffffff; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"> <div> </div> <div style="text-align: justify; font-family: 'times new roman', times, serif; font-size: 10pt;">On March 6, 2018, the Company entered into a service agreement for the services of Professor Gadi Turgeman and his stem cells research team in their lab. <a name="ole_link55"></a><a name="ole_link56"></a>As compensation for the services provided, the Company paid Ariel $20,580 on each of March 19, 2018 and August 22, 2018.</div> <div> </div> <div style="text-align: justify; font-family: 'times new roman', times, serif; font-size: 10pt;">The Services Agreement may be terminated by the non-breaching party upon a material breach that is not cured within 30 days or by the Company upon thirty days' prior written notice to Ariel. Ariel must keep confidential information of the Company confidential for six years after the term of the Services Agreement.</div> <div> </div> <div style="text-align: justify; font-family: 'times new roman', times, serif; font-size: 10pt;"><a name="ole_link57"></a>During the nine months ended September 30, 2018, $41,160 was paid and recorded as prepaid expenses, of which $24,010 was expensed in the nine-month period ended September 30, 2018, and the remaining $17,150 will be expensed in a subsequent period.</div> <div> </div> </div> <table style="width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; font-size: 10pt; word-spacing: 0px; orphans: 2; widows: 2; background-color: #ffffff; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;" cellspacing="0" cellpadding="0"> <tr> <td style="width: 64px; vertical-align: top; background-color: #ffffff;"> <div style="text-align: justify; font-family: 'times new roman', times, serif; font-size: 10pt;">(3)  </div> </td> <td style="width: 1503px; vertical-align: top; background-color: #ffffff;"> <div style="text-align: justify; font-family: 'times new roman', times, serif; font-size: 10pt;">Science Advisory Board Member Consulting Agreements (the "Agreements")</div> </td> </tr> </table> <div style="color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; font-size: 13.33px; font-style: normal; font-weight: 400; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; background-color: #ffffff; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"> <div> </div> <div style="text-align: justify; font-family: 'times new roman', times, serif; font-size: 10pt;">As part of its ongoing program of research and development, the Company has retained distinguished scientists and other qualified individuals to advise the Company with respect to its technology and business strategy and to assist it in the research, development and analysis of the Company's technology and products. In furtherance thereof, the Company has retained certain Advisors as members of its Scientific Advisory Board as described below, and the Company and Advisors have entered into agreements with the following terms and conditions:</div> <div style="text-align: justify; font-family: 'times new roman', times, serif; font-size: 10pt;"> </div> </div> <table style="width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; font-size: 10pt; word-spacing: 0px; orphans: 2; widows: 2; background-color: #ffffff; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;" cellspacing="0" cellpadding="0"> <tr> <td style="width: 64px; vertical-align: top; background-color: #ffffff;"> <div style="text-align: right; font-family: 'times new roman', times, serif; font-size: 10pt;">-</div> </td> <td style="width: 1503px; vertical-align: top; background-color: #ffffff;"> <div style="background-color: #ffffff;"> <div style="text-align: justify; font-family: 'times new roman', times, serif; font-size: 10pt;">Scientific Advisory Board and Consulting Services - Advisor shall provide general consulting services to Company (the "Services") as a member of its Scientific Advisory Board ("SAB"). As a member of the SAB, Advisor agrees to provide the Services as follows: (a) attending meetings of the Company's SAB; (b) performing the duties of a SAB member at such meetings, as established from time to time by the mutual agreement of the Company and the SAB members, including without limitation meeting with Company employees, consultants and other SAB members, reviewing goals of the Company and assisting in developing strategies for achieving such goals, and providing advice, support, theories, techniques and improvements in the Company's scientific research and product development activities; and (c) providing consulting services to Company at its request, including a reasonable amount of informal consultation over the telephone or otherwise as requested by Company. Advisor's consultation with Company will involve services as scientific, technical and business advisor to the Company and its senior team as needed with respect to the field of neuronal injuries and neuro degenerative diseases ("the "Field") and requires the application of unique, special and extraordinary skills and knowledge that Advisor possesses in the Field.</div> <div style="text-align: justify; font-family: 'times new roman', times, serif; font-size: 10pt;"> </div> </div> </td> </tr> <tr> <td style="width: 64px; vertical-align: top; background-color: #ffffff;"> <div style="text-align: right; font-family: 'times new roman', times, serif; font-size: 10pt;">-</div> </td> <td style="width: 1503px; vertical-align: top; background-color: #ffffff;"> <div style="text-align: justify; font-family: 'times new roman', times, serif; font-size: 10pt;">SAB Consulting Compensation - the Company shall grant to Advisor the option to purchase certain number of shares of the common stock of the Company as per the stock option award grant. The options are subject to terms and provisions of the Company's 2016 Stock Option and Stock Award Plan.</div> </td> </tr> </table> <div style="color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; font-size: 13.33px; font-style: normal; font-weight: 400; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; background-color: #ffffff; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"> <div> </div> <div style="text-align: justify; font-family: 'times new roman', times, serif; font-size: 10pt;"><a name="ole_link1"></a><a name="ole_link2"></a>On November 15, 2017, the Company entered into Agreements with three Advisors under the terms of which two Advisors are granted an option to purchase 20,000 shares of common stock and one Advisor was granted an option to purchase 30,000 shares of common stock under the 2016 Stock Option and Award Plan subject to certain vesting terms.</div> <div> </div> <div style="text-align: justify; font-family: 'times new roman', times, serif; font-size: 10pt;">On April 16, 2018, the Company entered into a one-year advisory board member consulting agreement with an assistant Professor of Chemistry at Dartmouth College to serve on the Company's Scientific Advisory Board. In consideration for serving on the Scientific Advisory Board, the Company granted an option to purchase 30,000 shares of its common stock under certain vesting terms to the assistant Professor.</div> <div> </div> <div style="text-align: justify; font-family: 'times new roman', times, serif; font-size: 10pt;">On August 15, 2018, the Company entered into an Agreement with an Advisor under the terms of which the Company granted an option to purchase 20,000 shares of common stock under the 2016 Stock Option and Award Plan subject to certain vesting terms.</div> <div> </div> </div> <table style="width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; font-size: 10pt; word-spacing: 0px; orphans: 2; widows: 2; background-color: #ffffff; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;" cellspacing="0" cellpadding="0"> <tr> <td style="width: 64px; vertical-align: top; background-color: #ffffff;"> <div style="text-align: justify; font-family: 'times new roman', times, serif; font-size: 10pt;">(4)  </div> </td> <td style="width: 1503px; vertical-align: top; background-color: #ffffff;"> <div style="text-align: justify; font-family: 'times new roman', times, serif; font-size: 10pt;">Business Advisory Board Agreement</div> </td> </tr> </table> <div style="color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; font-size: 13.33px; font-style: normal; font-weight: 400; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; background-color: #ffffff; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"> <div> </div> <div style="text-align: justify; font-family: 'times new roman', times, serif; font-size: 10pt;">On January 23, 2018, the Company entered into a one-year advisory board member consulting agreement with Pavel Hilman, the controlling shareholder of Conventus Holdings SA, a BVI corporation ("Conventus"), under which Mr. Hilman will serve on the Company's Advisory Board as a business advisor. The Advisory Board Agreement will automatically renew for up to two additional one-year periods, unless earlier terminated by either party upon 30 days' prior written notice to the other party. In consideration for serving on the Advisory Board, the Company awarded 10,000 shares of its common stock to Mr. Hilman under its 2016 Stock Option and Stock Award Plan.</div> </div> <div> </div> <table style="width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; font-size: 10pt; word-spacing: 0px; orphans: 2; widows: 2; background-color: #ffffff; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;" cellspacing="0" cellpadding="0"> <tr> <td style="width: 65px; vertical-align: top; background-color: #ffffff;"> <div style="text-align: justify; font-family: 'times new roman', times, serif; font-size: 10pt;"><a name="ole_link37"></a> (5)  </div> </td> <td style="width: 1502px; vertical-align: top; background-color: #ffffff;"> <div style="text-align: justify; font-family: 'times new roman', times, serif; font-size: 10pt;"> Investor Relations Agreement</div> </td> </tr> </table> <div style="color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; font-size: 13.33px; font-style: normal; font-weight: 400; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; background-color: #ffffff; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"> <div> </div> <div style="text-align: justify; font-family: 'times new roman', times, serif; font-size: 10pt;">On April 23, 2018, the Company entered into a six-month investor relations agreement with an investor relations firm for a monthly consulting fee of $5,000 and the issuance of 75,000 shares of common stock payable on signing the agreement.</div> <div> </div> <div style="text-align: justify; font-family: 'times new roman', times, serif; font-size: 10pt;">On June 23, 2018, the Company gave notice of rescission of the agreement to such firm and requested the return of the consulting fee paid and the 75,000 shares of common stock. As a result, the Company has not recorded any fees for services rendered past June 23, 2018.  A total of $10,000 representing April 2018 and May 2018 monthly consulting fees is reflected in the statement of operations and a total of $150,000, the fair market value of the issued shares, was expensed on issue.</div> <div> </div> </div> <table style="width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; font-size: 10pt; word-spacing: 0px; orphans: 2; widows: 2; background-color: #ffffff; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;" cellspacing="0" cellpadding="0"> <tr> <td style="width: 65px; vertical-align: top; background-color: #ffffff;"> <div style="text-align: justify; font-family: 'times new roman', times, serif; font-size: 10pt;"> (6)  </div> </td> <td style="width: 1502px; vertical-align: top; background-color: #ffffff;"> <div style="text-align: justify; font-family: 'times new roman', times, serif; font-size: 10pt;"> Sponsored Research Agreement</div> </td> </tr> </table> <div style="color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; font-size: 13.33px; font-style: normal; font-weight: 400; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; background-color: #ffffff; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"> <div> </div> <div style="text-align: justify; font-family: 'times new roman', times, serif; font-size: 10pt;"><a name="ole_link29"></a>On July 12, 2018, the Company entered into a one-year sponsored research agreement (the "Sponsored Research Agreement"), with the Trustees of Dartmouth College ("Dartmouth") pursuant to which the Company will support and fund the cost of research conducted by Dartmouth of mutual interest to the parties in accordance with the Agreement.  Intellectual property invented or developed solely by a party shall be owned by such party and intellectual property jointly invented or developed shall be jointly owned.  Dartmouth shall retain an irrevocable worldwide right to use intellectual property owned by it resulting from its research under the Agreement on a non-exclusive royalty-free basis for research and education purposes. The Company funded $36,293 on August 20, 2018 and will fund additional $18,147 by December 1, 2018 and $18,146 by June 1, 2019, respectively.</div> <div> </div> <div style="text-align: justify; font-family: 'times new roman', times, serif; font-size: 10pt;">The Agreement may be terminated earlier than one year upon written agreement of the parties, a material breach which is not cured within 30 days of notice thereof, if Professor Ke no longer conducts the research under the Agreement and a successor acceptable to both parties is not available, or in the event of an unauthorized assignment of the Company's rights and obligations under the Agreement.</div> <div> </div> <div style="text-align: justify; font-family: 'times new roman', times, serif; font-size: 10pt;">During the nine months ended September 30, 2018, $36,293 was paid and recorded as prepaid expenses, of which $9,073 was expensed in the nine-month period ended September 30, 2018, and the remaining $27,220 will be expensed in a subsequent period.</div> </div>

<div> <div style="color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; font-size: 13.33px; font-style: normal; font-weight: 400; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; background-color: #ffffff; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"> <div style="text-align: justify; font-family: 'times new roman', times, serif; font-size: 10pt; font-weight: bold;">Note 7 – Stock Plan</div> <div> </div> <div style="text-align: justify; font-family: 'times new roman', times, serif; font-size: 10pt;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt; font-style: italic;">2016 Stock Option and Stock Award</font> </div> <div> </div> <div style="text-align: justify; font-family: 'times new roman', times, serif; font-size: 10pt;">On December 14, 2016, the Board adopted the Company's 2016 Stock Option and Stock Award Plan (the "Plan"). The Plan provides for the award of stock options (incentive and non-qualified), stock awards and stock appreciation rights to officers, directors, employees and consultants who provide services to the Company. The terms of awards under the Plan are made by the Administrator of the Plan appointed by the Company's Board of Directors (the "Board"), or in the absence of an Administrator, by the Board. The Company has reserved 10 million shares for issuance under the Plan.</div> <div style="text-align: justify; font-family: 'times new roman', times, serif; font-size: 10pt;"> </div> </div> <div style="color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; font-size: 13.33px; font-style: normal; font-weight: 400; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; background-color: #ffffff; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"> <div style="text-align: justify; font-family: 'times new roman', times, serif; font-size: 10pt;"><u>Stock Awards:</u></div> <div> </div> <div style="text-align: justify; font-family: 'times new roman', times, serif; font-size: 10pt;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt; background-color: #ffffff;">On December 14, 2016, the Board awarded to each of its Science Advisors, Prof. Danny Baranes and Dr. Liat Hammer, a total of 440,000 shares of common stock of which 150,000 shares vested on December 14, 2016, 145,000 shares vested on December 14, 2017, and 145,000 shares will vest on December 14, 2018, provided such advisors are still providing services to the Company.</font></div> <div> </div> <div style="text-align: justify; font-family: 'times new roman', times, serif; font-size: 10pt;">The value of the vested awards had been recorded as research and development expenses in the respective periods.  A total of 290,000 stock awards are expected to vest during the fourth quarter of fiscal 2018.</div> <div> </div> <div style="text-align: justify; font-family: 'times new roman', times, serif; font-size: 10pt;">On January 23, 2018, the Company awarded 10,000 shares of its common stock to Mr. Hilman under its 2016 Stock Option and Stock Award Plan, which shares were fully vested and recorded as advisory services on issuance.  </div> <div> </div> </div> <table style="width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; font-size: 10pt; word-spacing: 0px; orphans: 2; widows: 2; background-color: #ffffff; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;" cellspacing="0" cellpadding="0"> <tr> <td valign="bottom" style="padding-bottom: 2px; vertical-align: top;"> </td> <td valign="bottom" style="padding-bottom: 2px; vertical-align: bottom;"> </td> <td valign="bottom" style="vertical-align: bottom; border-bottom-color: #000000; border-bottom-width: 2px; border-bottom-style: solid;" colspan="2"> <div style="text-align: center; font-family: 'times new roman', times, serif; font-size: 10pt;">For the nine months ended</div> <div style="text-align: center; font-family: 'times new roman', times, serif; font-size: 10pt;">September 30, 2018</div> </td> <td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; vertical-align: bottom;"> </td> <td valign="bottom" style="padding-bottom: 2px; vertical-align: bottom;"> </td> <td valign="bottom" style="vertical-align: bottom; border-bottom-color: #000000; border-bottom-width: 2px; border-bottom-style: solid;" colspan="2"> <div style="text-align: center; font-family: 'times new roman', times, serif; font-size: 10pt;">For the year ended December 31, 2017</div> </td> <td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; vertical-align: bottom;"> </td> </tr> <tr> <td valign="bottom" style="width: 1191px; vertical-align: top; background-color: #cceeff;"> <div style="text-align: justify; font-family: 'times new roman', times, serif; font-size: 10pt;">Number of shares vested in period</div> </td> <td valign="bottom" style="width: 16px; vertical-align: bottom; background-color: #cceeff;"> </td> <td valign="bottom" style="width: 16px; text-align: left; vertical-align: bottom; background-color: #cceeff;"> </td> <td valign="bottom" style="width: 142px; text-align: right; vertical-align: bottom; background-color: #cceeff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">10,000</div> </td> <td nowrap="nowrap" valign="bottom" style="width: 16px; text-align: left; vertical-align: bottom; background-color: #cceeff;"> </td> <td valign="bottom" style="width: 15px; vertical-align: bottom; background-color: #cceeff;"> </td> <td valign="bottom" style="width: 15px; text-align: left; vertical-align: bottom; background-color: #cceeff;"> </td> <td valign="bottom" style="width: 141px; text-align: right; vertical-align: bottom; background-color: #cceeff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">290,000</div> </td> <td nowrap="nowrap" valign="bottom" style="width: 15px; text-align: left; vertical-align: bottom; background-color: #cceeff;"> </td> </tr> <tr> <td valign="bottom" style="width: 1191px; vertical-align: top; background-color: #ffffff;"> <div style="text-align: justify; font-family: 'times new roman', times, serif; font-size: 10pt;">Fair market value per share</div> </td> <td valign="bottom" style="width: 16px; vertical-align: bottom; background-color: #ffffff;"> </td> <td valign="bottom" style="width: 16px; text-align: left; vertical-align: bottom; background-color: #ffffff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">$</div> </td> <td valign="bottom" style="width: 142px; text-align: right; vertical-align: bottom; background-color: #ffffff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">2.80</div> </td> <td nowrap="nowrap" valign="bottom" style="width: 16px; text-align: left; vertical-align: bottom; background-color: #ffffff;"> </td> <td valign="bottom" style="width: 15px; vertical-align: bottom; background-color: #ffffff;"> </td> <td valign="bottom" style="width: 15px; text-align: left; vertical-align: bottom; background-color: #ffffff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">$</div> </td> <td valign="bottom" style="width: 141px; text-align: right; vertical-align: bottom; background-color: #ffffff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">2.80</div> </td> <td nowrap="nowrap" valign="bottom" style="width: 15px; text-align: left; vertical-align: bottom; background-color: #ffffff;"> </td> </tr> <tr> <td valign="bottom" style="width: 1191px; padding-bottom: 2px; vertical-align: top; background-color: #cceeff;"> <div style="text-align: justify; font-family: 'times new roman', times, serif; font-size: 10pt;">Stock based compensation recognized</div> </td> <td valign="bottom" style="width: 16px; padding-bottom: 2px; vertical-align: bottom; background-color: #cceeff;"> </td> <td valign="bottom" style="width: 16px; text-align: left; vertical-align: bottom; border-bottom-color: #000000; border-bottom-width: 2px; border-bottom-style: solid; background-color: #cceeff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">$</div> </td> <td valign="bottom" style="width: 142px; text-align: right; vertical-align: bottom; border-bottom-color: #000000; border-bottom-width: 2px; border-bottom-style: solid; background-color: #cceeff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">28,000</div> </td> <td nowrap="nowrap" valign="bottom" style="width: 16px; text-align: left; padding-bottom: 2px; vertical-align: bottom; background-color: #cceeff;"> </td> <td valign="bottom" style="width: 15px; padding-bottom: 2px; vertical-align: bottom; background-color: #cceeff;"> </td> <td valign="bottom" style="width: 15px; text-align: left; vertical-align: bottom; border-bottom-color: #000000; border-bottom-width: 2px; border-bottom-style: solid; background-color: #cceeff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">$</div> </td> <td valign="bottom" style="width: 141px; text-align: right; vertical-align: bottom; border-bottom-color: #000000; border-bottom-width: 2px; border-bottom-style: solid; background-color: #cceeff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">812,000</div> </td> <td nowrap="nowrap" valign="bottom" style="width: 15px; text-align: left; padding-bottom: 2px; vertical-align: bottom; background-color: #cceeff;"> </td> </tr> </table> <div style="color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; font-size: 13.33px; font-style: normal; font-weight: 400; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; background-color: #ffffff; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"> <div> </div> <div style="text-align: justify; font-family: 'times new roman', times, serif; font-size: 10pt;"><u>Stock Options:</u></div> <div> </div> </div> <table style="width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; font-size: 10pt; word-spacing: 0px; orphans: 2; widows: 2; background-color: #ffffff; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;" cellspacing="0" cellpadding="0"> <tr> <td style="width: 64px; vertical-align: top; background-color: #ffffff;"> <div style="text-align: justify; font-family: 'times new roman', times, serif; font-size: 10pt;">(a)  </div> </td> <td style="width: 1503px; vertical-align: top; background-color: #ffffff;"> <div style="text-align: justify; font-family: 'times new roman', times, serif; font-size: 10pt;">Stock Options granted to Science Advisors:</div> </td> </tr> </table> <div style="color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; font-size: 13.33px; font-style: normal; font-weight: 400; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; background-color: #ffffff; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"> <div> </div> <div style="text-align: justify; font-family: 'times new roman', times, serif; font-size: 10pt;">On November 15, 2017, under the 2016 Stock Option and Award Plan, the Board awarded two of its Science Advisors the following three-year stock options: (i) an immediately exercisable option to purchase 6,667 shares of common stock at an exercise price of $2.00 per share, (ii) an option to purchase 6,667 shares of common stock exercisable on November 15, 2018 at an exercise price of $2.00 per share and (iii) an option to purchase 6,666 shares of common stock exercisable on November 15, 2019 at an exercise price of $2.00 per share, provided the advisors are still providing services to the Company.</div> <div> </div> <div style="text-align: justify; font-family: 'times new roman', times, serif; font-size: 10pt;">On November 15, 2017, under the 2016 Stock Option and Award Plan, the Board awarded a Science Advisor, the following three-year stock options: (i) an option to purchase 15,000 shares of common stock, exercisable on November 15, 2018 at an exercise price of $0.40 per share and (ii) an option to purchase 15,000 shares of common stock exercisable on November 15, 2019 at an exercise price of $0.40 per share, provided the advisor is still providing services to the Company.</div> <div> </div> </div> <div style="text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-weight: 400; margin-bottom: 8pt; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; background-color: #ffffff; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">On </font><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">April 16, 2018</font><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">, under the 2016 Stock Option and Award Plan, the Board awarded a Science Advisor, the following three-year stock options: (i) an option to purchase 10,000 shares of common stock, exercisable on April 16, 2018 at an exercise price of $2.00 per share and (ii) an option to purchase 10,000 shares of common stock exercisable on April 16, 2019 at an exercise price of $2.00 per share, and (iii) an option to purchase 10,000 shares of common stock exercisable on April 16, 2020 at an exercise price of $2.00 per share, provided the advisor is still providing services to the Company. provided the advisor is still providing services to the Company.</font></div> <div style="text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-weight: 400; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; background-color: #ffffff; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">On August 15, 2018, under the 2016 Stock Option and Award Plan, the Board granted a Science Advisor an option to purchase an aggregate of 20,000 shares of  common stock at an exercise price of $2.00 per share. The option vests as to 6,667 shares on each of August 15, 2018 and August 15, 2019 and as to 6,666 shares on August 15, 2020 and remains exercisable as to each such installment for three years from the date of vesting.</div> <div style="color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; clear: both; font-family: 'times new roman', times, serif; font-size: 13.33px; font-style: normal; font-weight: 400; margin-top: 10pt; margin-bottom: 10pt; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; background-color: #ffffff; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"> <div style="text-align: center;"> <div style="text-align: justify; font-family: 'times new roman', times, serif; font-size: 10pt;">During the year ended December 31, 2017, total recognized compensation in respect of the above stock option compensation was $29,000, which amount has been allocated as advisory services as part of general and administrative expenses.</div> </div> </div> <div style="color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; font-size: 13.33px; font-style: normal; font-weight: 400; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; background-color: #ffffff; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"> <div style="text-align: justify; font-family: 'times new roman', times, serif; font-size: 10pt;">The Company recorded stock-based compensation in the amount of $48,078 and $122,816 in respect to these options grants during the three and nine months ended September 30, 2018, respectively, which amounts have been allocated as advisory services as part of general and administrative expenses.</div> <div> </div> <div style="text-align: justify; font-family: 'times new roman', times, serif; font-size: 10pt;">As of September 30, 2018, total unrecognized compensation remaining to be recognized in future periods totaled $92,671.</div> <div> </div> </div> <table style="width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; font-size: 10pt; word-spacing: 0px; orphans: 2; widows: 2; background-color: #ffffff; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;" cellspacing="0" cellpadding="0"> <tr> <td style="width: 64px; vertical-align: top; background-color: #ffffff;"> <div style="text-align: justify; font-family: 'times new roman', times, serif; font-size: 10pt;">(b)  </div> </td> <td style="width: 1503px; vertical-align: top; background-color: #ffffff;"> <div style="text-align: justify; font-family: 'times new roman', times, serif; font-size: 10pt;">Stock Options granted to Officers:</div> </td> </tr> </table> <div style="color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; font-size: 13.33px; font-style: normal; font-weight: 400; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; background-color: #ffffff; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"> <div> </div> <div style="text-align: justify; font-family: 'times new roman', times, serif; font-size: 10pt;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt; background-color: #ffffff;">On December 4, 2017, the Board granted five-year options to each of its two officers</font> for the purchase of 300,000 shares of the common stock of the Company<font style="font-family: 'times new roman', times, serif; font-size: 10pt; background-color: #ffffff;">. The options have an exercise price of $2.00 and vest and become exercisable on December 4, 2018.</font></div> <div style="text-align: justify; font-family: 'times new roman', times, serif; font-size: 10pt;"> </div> <div style="text-align: justify; font-family: 'times new roman', times, serif; font-size: 10pt;">During the year ended December 31, 2017, total recognized compensation of $106,029 was recorded as general and administrative expenses.</div> <div> </div> <div style="text-align: justify; font-family: 'times new roman', times, serif; font-size: 10pt;">During the three and nine months ended September 30, 2018, total recognized compensation of $353,430 and $1,060,290, respectively, was recorded as general and administrative expenses.</div> <div> </div> <div style="text-align: justify; font-family: 'times new roman', times, serif; font-size: 10pt;">As of September 30, 2018, total unrecognized compensation remaining to be recognized in future periods totaled $246,755.<font style="font-family: 'times new roman', times, serif; font-size: 10pt;"><br /></font><font style="font-family: 'times new roman', times, serif; font-size: 10pt;"><br /></font>The fair value of each option award above is estimated on the date of grant <font style="font-family: 'times new roman', times, serif; font-size: 10pt; background-color: #ffffff;">using the Black-Scholes option-pricing model with the following assumptions at the measurement date(s):</font></div> <div style="text-align: justify; font-family: 'times new roman', times, serif; font-size: 10pt;"> </div> </div> <table style="width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; font-size: 10pt; word-spacing: 0px; orphans: 2; widows: 2; background-color: #ffffff; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;" cellspacing="0" cellpadding="0"> <tr> <td style="width: 821px; vertical-align: bottom;"> <div style="text-align: justify; font-family: 'times new roman', times, serif; font-size: 10pt;"> </div> </td> <td style="width: 24px; vertical-align: bottom;"> <div style="text-align: justify; font-family: 'times new roman', times, serif; font-size: 10pt;"> </div> </td> <td style="width: 699px; vertical-align: bottom; border-bottom-color: #000000; border-bottom-width: 2px; border-bottom-style: solid;" colspan="2"> <div style="text-align: center; font-family: 'times new roman', times, serif; font-size: 10pt;">Measurement date</div> </td> <td style="width: 23px; vertical-align: bottom;"> <div style="text-align: justify; font-family: 'times new roman', times, serif; font-size: 10pt;"> </div> </td> </tr> <tr> <td style="width: 821px; vertical-align: bottom; background-color: #cceeff;"> <div style="text-align: justify; font-family: 'times new roman', times, serif; font-size: 10pt;">Dividend yield</div> </td> <td style="width: 24px; vertical-align: bottom; background-color: #cceeff;"> <div style="text-align: justify; font-family: 'times new roman', times, serif; font-size: 10pt;"> </div> </td> <td style="width: 105px; vertical-align: bottom; background-color: #cceeff;"> <div style="text-align: right; font-family: 'times new roman', times, serif; font-size: 10pt;"> </div> </td> <td style="width: 594px; vertical-align: bottom; background-color: #cceeff;"> <div style="text-align: right; font-family: 'times new roman', times, serif; font-size: 10pt;">0%</div> </td> <td style="width: 23px; vertical-align: bottom; background-color: #cceeff;"> <div style="text-align: justify; font-family: 'times new roman', times, serif; font-size: 10pt;"> </div> </td> </tr> <tr> <td style="width: 821px; vertical-align: bottom; background-color: #ffffff;"> <div style="text-align: justify; font-family: 'times new roman', times, serif; font-size: 10pt;">Expected volatility</div> </td> <td style="width: 24px; vertical-align: bottom; background-color: #ffffff;"> <div style="text-align: justify; font-family: 'times new roman', times, serif; font-size: 10pt;"> </div> </td> <td style="width: 699px; vertical-align: bottom; background-color: #ffffff;" colspan="2"> <div style="text-align: right; font-family: 'times new roman', times, serif; font-size: 10pt;">114.69 ~ 126.34%</div> </td> <td style="width: 23px; vertical-align: bottom; background-color: #ffffff;"> <div style="text-align: justify; font-family: 'times new roman', times, serif; font-size: 10pt;"> </div> </td> </tr> <tr> <td style="width: 821px; vertical-align: bottom; background-color: #cceeff;"> <div style="text-align: justify; font-family: 'times new roman', times, serif; font-size: 10pt;">Risk-free interest rate</div> </td> <td style="width: 24px; vertical-align: bottom; background-color: #cceeff;"> <div style="text-align: justify; font-family: 'times new roman', times, serif; font-size: 10pt;"> </div> </td> <td style="width: 699px; vertical-align: bottom; background-color: #cceeff;" colspan="2"> <div style="text-align: right; font-family: 'times new roman', times, serif; font-size: 10pt;">1.79% ~ 2.68%</div> </td> <td style="width: 23px; vertical-align: bottom; background-color: #cceeff;"> <div style="text-align: justify; font-family: 'times new roman', times, serif; font-size: 10pt;"> </div> </td> </tr> <tr> <td style="width: 821px; vertical-align: bottom; background-color: #ffffff;"> <div style="text-align: justify; font-family: 'times new roman', times, serif; font-size: 10pt;">Expected life (years)</div> </td> <td style="width: 24px; vertical-align: bottom; background-color: #ffffff;"> <div style="text-align: justify; font-family: 'times new roman', times, serif; font-size: 10pt;"> </div> </td> <td style="width: 699px; vertical-align: bottom; background-color: #ffffff;" colspan="2"> <div style="text-align: right; font-family: 'times new roman', times, serif; font-size: 10pt;">3 ~ 5</div> </td> <td style="width: 23px; vertical-align: bottom; background-color: #ffffff;"> <div style="text-align: justify; font-family: 'times new roman', times, serif; font-size: 10pt;"> </div> </td> </tr> <tr> <td style="width: 821px; vertical-align: bottom; background-color: #cceeff;"> <div style="text-align: justify; font-family: 'times new roman', times, serif; font-size: 10pt;">Stock Price</div> </td> <td style="width: 24px; vertical-align: bottom; background-color: #cceeff;"> <div style="text-align: justify; font-family: 'times new roman', times, serif; font-size: 10pt;"> </div> </td> <td style="width: 105px; vertical-align: bottom; background-color: #cceeff;"> <div style="text-align: right; font-family: 'times new roman', times, serif; font-size: 10pt;">$</div> </td> <td style="width: 594px; vertical-align: bottom; background-color: #cceeff;"> <div style="text-align: right; font-family: 'times new roman', times, serif; font-size: 10pt;">2.00 ~ 2.80</div> </td> <td style="width: 23px; vertical-align: bottom; background-color: #cceeff;"> <div style="text-align: justify; font-family: 'times new roman', times, serif; font-size: 10pt;"> </div> </td> </tr> <tr> <td style="width: 821px; vertical-align: bottom; background-color: #ffffff;"> <div style="text-align: justify; font-family: 'times new roman', times, serif; font-size: 10pt;">Exercise Price</div> </td> <td style="width: 24px; vertical-align: bottom; background-color: #ffffff;"> <div style="text-align: justify; font-family: 'times new roman', times, serif; font-size: 10pt;"> </div> </td> <td style="width: 105px; vertical-align: bottom; border-bottom-color: #000000; border-bottom-width: 2px; border-bottom-style: solid; background-color: #ffffff;"> <div style="text-align: right; font-family: 'times new roman', times, serif; font-size: 10pt;">$</div> </td> <td style="width: 594px; vertical-align: bottom; border-bottom-color: #000000; border-bottom-width: 2px; border-bottom-style: solid; background-color: #ffffff;"> <div style="text-align: right; font-family: 'times new roman', times, serif; font-size: 10pt;">0.40 ~ 2.00</div> </td> <td style="width: 23px; vertical-align: bottom; background-color: #ffffff;"> <div style="text-align: justify; font-family: 'times new roman', times, serif; font-size: 10pt;"> </div> </td> </tr> </table> <div style="color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; font-size: 13.33px; font-style: normal; font-weight: 400; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; background-color: #ffffff; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"> </div> <div style="color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; font-size: 13.33px; font-style: normal; font-weight: 400; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; background-color: #ffffff; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"> <div style="text-align: justify; font-family: 'times new roman', times, serif; font-size: 10pt;">A summary of the activity for the Company's stock options for the nine-month period ended September 30, 2018 and for the year ended December 31, 2017, is as follows:</div> <div> </div> </div> <table style="width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; font-size: 10pt; word-spacing: 0px; orphans: 2; widows: 2; background-color: #ffffff; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;" cellspacing="0" cellpadding="0"> <tr> <td valign="bottom" style="padding-bottom: 2px; vertical-align: bottom;"> <div style="text-align: justify; font-family: 'times new roman', times, serif; font-size: 10pt;"> </div> </td> <td valign="bottom" style="padding-bottom: 2px; vertical-align: bottom;"> </td> <td valign="bottom" style="vertical-align: top; border-bottom-color: #000000; border-bottom-width: 2px; border-bottom-style: solid;" colspan="6"> <div style="text-align: center; font-family: 'times new roman', times, serif; font-size: 10pt; font-weight: bold;">September 30, 2018</div> </td> <td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; vertical-align: bottom;"> </td> <td valign="bottom" style="padding-bottom: 2px; vertical-align: bottom;"> </td> <td valign="bottom" style="vertical-align: bottom; border-bottom-color: #000000; border-bottom-width: 2px; border-bottom-style: solid;" colspan="6"> <div style="text-align: center; font-family: 'times new roman', times, serif; font-size: 10pt; font-weight: bold;">December 31, 2017</div> </td> <td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; vertical-align: bottom;"> </td> </tr> <tr> <td valign="bottom" style="vertical-align: bottom;"> <div style="text-align: justify; font-family: 'times new roman', times, serif; font-size: 10pt;"> </div> </td> <td valign="bottom" style="vertical-align: bottom;"> </td> <td valign="bottom" style="vertical-align: top;" colspan="2"> </td> <td nowrap="nowrap" valign="bottom" style="text-align: left; vertical-align: bottom;"> </td> <td valign="bottom" style="vertical-align: bottom;"> </td> <td valign="bottom" style="vertical-align: bottom;" colspan="2"> <div style="text-align: center; font-family: 'times new roman', times, serif; font-size: 10pt; font-weight: bold;">Weighted Average</div> </td> <td nowrap="nowrap" valign="bottom" style="text-align: left; vertical-align: bottom;"> </td> <td valign="bottom" style="vertical-align: bottom;"> </td> <td valign="bottom" style="vertical-align: bottom;" colspan="2"> </td> <td nowrap="nowrap" valign="bottom" style="text-align: left; vertical-align: bottom;"> </td> <td valign="bottom" style="vertical-align: bottom;"> </td> <td valign="bottom" style="vertical-align: bottom;" colspan="2"> <div style="text-align: center; font-family: 'times new roman', times, serif; font-size: 10pt; font-weight: bold;">Weighted Average</div> </td> <td nowrap="nowrap" valign="bottom" style="text-align: left; vertical-align: bottom;"> </td> </tr> <tr> <td valign="bottom" style="padding-bottom: 2px; vertical-align: bottom;"> <div style="text-align: justify; font-family: 'times new roman', times, serif; font-size: 10pt;"> </div> </td> <td valign="bottom" style="padding-bottom: 2px; vertical-align: bottom;"> </td> <td valign="bottom" style="vertical-align: bottom; border-bottom-color: #000000; border-bottom-width: 2px; border-bottom-style: solid;" colspan="2"> <div style="text-align: center; font-family: 'times new roman', times, serif; font-size: 10pt; font-weight: bold;">Shares</div> </td> <td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; vertical-align: bottom;"> </td> <td valign="bottom" style="padding-bottom: 2px; vertical-align: bottom;"> </td> <td valign="bottom" style="vertical-align: top; border-bottom-color: #000000; border-bottom-width: 2px; border-bottom-style: solid;" colspan="2"> <div style="text-align: center; font-family: 'times new roman', times, serif; font-size: 10pt; font-weight: bold;">Exercise Price</div> </td> <td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; vertical-align: bottom;"> </td> <td valign="bottom" style="padding-bottom: 2px; vertical-align: bottom;"> </td> <td valign="bottom" style="vertical-align: bottom; border-bottom-color: #000000; border-bottom-width: 2px; border-bottom-style: solid;" colspan="2"> <div style="text-align: center; font-family: 'times new roman', times, serif; font-size: 10pt; font-weight: bold;">Shares</div> </td> <td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; vertical-align: bottom;"> </td> <td valign="bottom" style="padding-bottom: 2px; vertical-align: bottom;"> </td> <td valign="bottom" style="vertical-align: bottom; border-bottom-color: #000000; border-bottom-width: 2px; border-bottom-style: solid;" colspan="2"> <div style="text-align: center; font-family: 'times new roman', times, serif; font-size: 10pt; font-weight: bold;">Exercise Price</div> </td> <td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; vertical-align: bottom;"> </td> </tr> <tr> <td valign="bottom" style="width: 815px; vertical-align: bottom; background-color: #cceeff;"> <div style="text-align: justify; font-family: 'times new roman', times, serif; font-size: 10pt;">Outstanding, beginning of period</div> </td> <td valign="bottom" style="width: 16px; vertical-align: bottom; background-color: #cceeff;"> </td> <td valign="bottom" style="width: 16px; text-align: left; vertical-align: bottom; background-color: #cceeff;"> </td> <td valign="bottom" style="width: 142px; text-align: right; vertical-align: bottom; background-color: #cceeff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">670,000</div> </td> <td nowrap="nowrap" valign="bottom" style="width: 16px; text-align: left; vertical-align: bottom; background-color: #cceeff;"> </td> <td valign="bottom" style="width: 16px; vertical-align: bottom; background-color: #cceeff;"> </td> <td valign="bottom" style="width: 16px; text-align: left; vertical-align: bottom; background-color: #cceeff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">$</div> </td> <td valign="bottom" style="width: 142px; text-align: right; vertical-align: bottom; background-color: #cceeff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">1.93</div> </td> <td nowrap="nowrap" valign="bottom" style="width: 16px; text-align: left; vertical-align: bottom; background-color: #cceeff;"> </td> <td valign="bottom" style="width: 15px; vertical-align: bottom; background-color: #cceeff;"> </td> <td valign="bottom" style="width: 15px; text-align: left; vertical-align: bottom; background-color: #cceeff;"> </td> <td valign="bottom" style="width: 141px; text-align: right; vertical-align: bottom; background-color: #cceeff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">-</div> </td> <td nowrap="nowrap" valign="bottom" style="width: 15px; text-align: left; vertical-align: bottom; background-color: #cceeff;"> </td> <td valign="bottom" style="width: 15px; vertical-align: bottom; background-color: #cceeff;"> </td> <td valign="bottom" style="width: 15px; text-align: left; vertical-align: bottom; background-color: #cceeff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">$</div> </td> <td valign="bottom" style="width: 141px; text-align: right; vertical-align: bottom; background-color: #cceeff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">-</div> </td> <td nowrap="nowrap" valign="bottom" style="width: 15px; text-align: left; vertical-align: bottom; background-color: #cceeff;"> </td> </tr> <tr> <td valign="bottom" style="width: 815px; vertical-align: bottom; background-color: #ffffff;"> <div style="text-align: justify; font-family: 'times new roman', times, serif; font-size: 10pt;">Granted</div> </td> <td valign="bottom" style="width: 16px; vertical-align: bottom; background-color: #ffffff;"> </td> <td valign="bottom" style="width: 16px; text-align: left; vertical-align: bottom; background-color: #ffffff;"> </td> <td valign="bottom" style="width: 142px; text-align: right; vertical-align: bottom; background-color: #ffffff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">50,000</div> </td> <td nowrap="nowrap" valign="bottom" style="width: 16px; text-align: left; vertical-align: bottom; background-color: #ffffff;"> </td> <td valign="bottom" style="width: 16px; vertical-align: bottom; background-color: #ffffff;"> </td> <td valign="bottom" style="width: 16px; text-align: left; vertical-align: bottom; background-color: #ffffff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">$</div> </td> <td valign="bottom" style="width: 142px; text-align: right; vertical-align: bottom; background-color: #ffffff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">2.00</div> </td> <td nowrap="nowrap" valign="bottom" style="width: 16px; text-align: left; vertical-align: bottom; background-color: #ffffff;"> </td> <td valign="bottom" style="width: 15px; vertical-align: bottom; background-color: #ffffff;"> </td> <td valign="bottom" style="width: 15px; text-align: left; vertical-align: bottom; background-color: #ffffff;"> </td> <td valign="bottom" style="width: 141px; text-align: right; vertical-align: bottom; background-color: #ffffff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">670,000</div> </td> <td nowrap="nowrap" valign="bottom" style="width: 15px; text-align: left; vertical-align: bottom; background-color: #ffffff;"> </td> <td valign="bottom" style="width: 15px; vertical-align: bottom; background-color: #ffffff;"> </td> <td valign="bottom" style="width: 15px; text-align: left; vertical-align: bottom; background-color: #ffffff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">$</div> </td> <td valign="bottom" style="width: 141px; text-align: right; vertical-align: bottom; background-color: #ffffff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">1.93</div> </td> <td nowrap="nowrap" valign="bottom" style="width: 15px; text-align: left; vertical-align: bottom; background-color: #ffffff;"> </td> </tr> <tr> <td valign="bottom" style="width: 815px; vertical-align: bottom; background-color: #cceeff;"> <div style="text-align: justify; font-family: 'times new roman', times, serif; font-size: 10pt;">Exercised</div> </td> <td valign="bottom" style="width: 16px; vertical-align: bottom; background-color: #cceeff;"> </td> <td valign="bottom" style="width: 16px; text-align: left; vertical-align: bottom; background-color: #cceeff;"> </td> <td valign="bottom" style="width: 142px; text-align: right; vertical-align: bottom; background-color: #cceeff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">-</div> </td> <td nowrap="nowrap" valign="bottom" style="width: 16px; text-align: left; vertical-align: bottom; background-color: #cceeff;"> </td> <td valign="bottom" style="width: 16px; vertical-align: bottom; background-color: #cceeff;"> </td> <td valign="bottom" style="width: 16px; text-align: left; vertical-align: bottom; background-color: #cceeff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">$</div> </td> <td valign="bottom" style="width: 142px; text-align: right; vertical-align: bottom; background-color: #cceeff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">-</div> </td> <td nowrap="nowrap" valign="bottom" style="width: 16px; text-align: left; vertical-align: bottom; background-color: #cceeff;"> </td> <td valign="bottom" style="width: 15px; vertical-align: bottom; background-color: #cceeff;"> </td> <td valign="bottom" style="width: 15px; text-align: left; vertical-align: bottom; background-color: #cceeff;"> </td> <td valign="bottom" style="width: 141px; text-align: right; vertical-align: bottom; background-color: #cceeff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">-</div> </td> <td nowrap="nowrap" valign="bottom" style="width: 15px; text-align: left; vertical-align: bottom; background-color: #cceeff;"> </td> <td valign="bottom" style="width: 15px; vertical-align: bottom; background-color: #cceeff;"> </td> <td valign="bottom" style="width: 15px; text-align: left; vertical-align: bottom; background-color: #cceeff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">$</div> </td> <td valign="bottom" style="width: 141px; text-align: right; vertical-align: bottom; background-color: #cceeff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">-</div> </td> <td nowrap="nowrap" valign="bottom" style="width: 15px; text-align: left; vertical-align: bottom; background-color: #cceeff;"> </td> </tr> <tr> <td valign="bottom" style="width: 815px; vertical-align: bottom; background-color: #ffffff;"> <div style="text-align: justify; font-family: 'times new roman', times, serif; font-size: 10pt;">Canceled</div> </td> <td valign="bottom" style="width: 16px; vertical-align: bottom; background-color: #ffffff;"> </td> <td valign="bottom" style="width: 16px; text-align: left; vertical-align: bottom; background-color: #ffffff;"> </td> <td valign="bottom" style="width: 142px; text-align: right; vertical-align: bottom; background-color: #ffffff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">-</div> </td> <td nowrap="nowrap" valign="bottom" style="width: 16px; text-align: left; vertical-align: bottom; background-color: #ffffff;"> </td> <td valign="bottom" style="width: 16px; vertical-align: bottom; background-color: #ffffff;"> </td> <td valign="bottom" style="width: 16px; text-align: left; vertical-align: bottom; background-color: #ffffff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">$</div> </td> <td valign="bottom" style="width: 142px; text-align: right; vertical-align: bottom; background-color: #ffffff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">-</div> </td> <td nowrap="nowrap" valign="bottom" style="width: 16px; text-align: left; vertical-align: bottom; background-color: #ffffff;"> </td> <td valign="bottom" style="width: 15px; vertical-align: bottom; background-color: #ffffff;"> </td> <td valign="bottom" style="width: 15px; text-align: left; vertical-align: bottom; background-color: #ffffff;"> </td> <td valign="bottom" style="width: 141px; text-align: right; vertical-align: bottom; background-color: #ffffff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">-</div> </td> <td nowrap="nowrap" valign="bottom" style="width: 15px; text-align: left; vertical-align: bottom; background-color: #ffffff;"> </td> <td valign="bottom" style="width: 15px; vertical-align: bottom; background-color: #ffffff;"> </td> <td valign="bottom" style="width: 15px; text-align: left; vertical-align: bottom; background-color: #ffffff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">$</div> </td> <td valign="bottom" style="width: 141px; text-align: right; vertical-align: bottom; background-color: #ffffff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">-</div> </td> <td nowrap="nowrap" valign="bottom" style="width: 15px; text-align: left; vertical-align: bottom; background-color: #ffffff;"> </td> </tr> <tr> <td valign="bottom" style="width: 815px; vertical-align: bottom; background-color: #cceeff;"> <div style="text-align: justify; font-family: 'times new roman', times, serif; font-size: 10pt;">Outstanding, end of period</div> </td> <td valign="bottom" style="width: 16px; vertical-align: bottom; background-color: #cceeff;"> </td> <td valign="bottom" style="width: 16px; text-align: left; vertical-align: bottom; background-color: #cceeff;"> </td> <td valign="bottom" style="width: 142px; text-align: right; vertical-align: bottom; background-color: #cceeff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">720,000</div> </td> <td nowrap="nowrap" valign="bottom" style="width: 16px; text-align: left; vertical-align: bottom; background-color: #cceeff;"> </td> <td valign="bottom" style="width: 16px; vertical-align: bottom; background-color: #cceeff;"> </td> <td valign="bottom" style="width: 16px; text-align: left; vertical-align: bottom; background-color: #cceeff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">$</div> </td> <td valign="bottom" style="width: 142px; text-align: right; vertical-align: bottom; background-color: #cceeff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">1.93</div> </td> <td nowrap="nowrap" valign="bottom" style="width: 16px; text-align: left; vertical-align: bottom; background-color: #cceeff;"> </td> <td valign="bottom" style="width: 15px; vertical-align: bottom; background-color: #cceeff;"> </td> <td valign="bottom" style="width: 15px; text-align: left; vertical-align: bottom; background-color: #cceeff;"> </td> <td valign="bottom" style="width: 141px; text-align: right; vertical-align: bottom; background-color: #cceeff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">670,000</div> </td> <td nowrap="nowrap" valign="bottom" style="width: 15px; text-align: left; vertical-align: bottom; background-color: #cceeff;"> </td> <td valign="bottom" style="width: 15px; vertical-align: bottom; background-color: #cceeff;"> </td> <td valign="bottom" style="width: 15px; text-align: left; vertical-align: bottom; background-color: #cceeff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">$</div> </td> <td valign="bottom" style="width: 141px; text-align: right; vertical-align: bottom; background-color: #cceeff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">1.93</div> </td> <td nowrap="nowrap" valign="bottom" style="width: 15px; text-align: left; vertical-align: bottom; background-color: #cceeff;"> </td> </tr> <tr> <td valign="bottom" style="width: 815px; vertical-align: bottom; background-color: #ffffff;"> <div style="text-align: justify; font-family: 'times new roman', times, serif; font-size: 10pt;">Options exercisable, end of period</div> </td> <td valign="bottom" style="width: 16px; vertical-align: bottom; background-color: #ffffff;"> </td> <td valign="bottom" style="width: 16px; text-align: left; vertical-align: bottom; background-color: #ffffff;"> </td> <td valign="bottom" style="width: 142px; text-align: right; vertical-align: bottom; background-color: #ffffff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">30,000</div> </td> <td nowrap="nowrap" valign="bottom" style="width: 16px; text-align: left; vertical-align: bottom; background-color: #ffffff;"> </td> <td valign="bottom" style="width: 16px; vertical-align: bottom; background-color: #ffffff;"> </td> <td valign="bottom" style="width: 16px; text-align: left; vertical-align: bottom; background-color: #ffffff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">$</div> </td> <td valign="bottom" style="width: 142px; text-align: right; vertical-align: bottom; background-color: #ffffff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">2.00</div> </td> <td nowrap="nowrap" valign="bottom" style="width: 16px; text-align: left; vertical-align: bottom; background-color: #ffffff;"> </td> <td valign="bottom" style="width: 15px; vertical-align: bottom; background-color: #ffffff;"> </td> <td valign="bottom" style="width: 15px; text-align: left; vertical-align: bottom; background-color: #ffffff;"> </td> <td valign="bottom" style="width: 141px; text-align: right; vertical-align: bottom; background-color: #ffffff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">13,334</div> </td> <td nowrap="nowrap" valign="bottom" style="width: 15px; text-align: left; vertical-align: bottom; background-color: #ffffff;"> </td> <td valign="bottom" style="width: 15px; vertical-align: bottom; background-color: #ffffff;"> </td> <td valign="bottom" style="width: 15px; text-align: left; vertical-align: bottom; background-color: #ffffff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">$</div> </td> <td valign="bottom" style="width: 141px; text-align: right; vertical-align: bottom; background-color: #ffffff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">2.00</div> </td> <td nowrap="nowrap" valign="bottom" style="width: 15px; text-align: left; vertical-align: bottom; background-color: #ffffff;"> </td> </tr> <tr> <td valign="bottom" style="width: 815px; padding-bottom: 2px; vertical-align: bottom; background-color: #cceeff;"> <div style="text-align: justify; font-family: 'times new roman', times, serif; font-size: 10pt;">Options expected to vest, end of period</div> </td> <td valign="bottom" style="width: 16px; padding-bottom: 2px; vertical-align: bottom; background-color: #cceeff;"> </td> <td valign="bottom" style="width: 16px; text-align: left; vertical-align: bottom; border-bottom-color: #000000; border-bottom-width: 2px; border-bottom-style: solid; background-color: #cceeff;"> </td> <td valign="bottom" style="width: 142px; text-align: right; vertical-align: bottom; border-bottom-color: #000000; border-bottom-width: 2px; border-bottom-style: solid; background-color: #cceeff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">690,000</div> </td> <td nowrap="nowrap" valign="bottom" style="width: 16px; text-align: left; padding-bottom: 2px; vertical-align: bottom; background-color: #cceeff;"> </td> <td valign="bottom" style="width: 16px; padding-bottom: 2px; vertical-align: bottom; background-color: #cceeff;"> </td> <td valign="bottom" style="width: 16px; text-align: left; vertical-align: bottom; border-bottom-color: #000000; border-bottom-width: 2px; border-bottom-style: solid; background-color: #cceeff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">$</div> </td> <td valign="bottom" style="width: 142px; text-align: right; vertical-align: bottom; border-bottom-color: #000000; border-bottom-width: 2px; border-bottom-style: solid; background-color: #cceeff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">1.93</div> </td> <td nowrap="nowrap" valign="bottom" style="width: 16px; text-align: left; padding-bottom: 2px; vertical-align: bottom; background-color: #cceeff;"> </td> <td valign="bottom" style="width: 15px; padding-bottom: 2px; vertical-align: bottom; background-color: #cceeff;"> </td> <td valign="bottom" style="width: 15px; text-align: left; vertical-align: bottom; border-bottom-color: #000000; border-bottom-width: 2px; border-bottom-style: solid; background-color: #cceeff;"> </td> <td valign="bottom" style="width: 141px; text-align: right; vertical-align: bottom; border-bottom-color: #000000; border-bottom-width: 2px; border-bottom-style: solid; background-color: #cceeff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">656,666</div> </td> <td nowrap="nowrap" valign="bottom" style="width: 15px; text-align: left; padding-bottom: 2px; vertical-align: bottom; background-color: #cceeff;"> </td> <td valign="bottom" style="width: 15px; padding-bottom: 2px; vertical-align: bottom; background-color: #cceeff;"> </td> <td valign="bottom" style="width: 15px; text-align: left; vertical-align: bottom; border-bottom-color: #000000; border-bottom-width: 2px; border-bottom-style: solid; background-color: #cceeff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">$</div> </td> <td valign="bottom" style="width: 141px; text-align: right; vertical-align: bottom; border-bottom-color: #000000; border-bottom-width: 2px; border-bottom-style: solid; background-color: #cceeff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">1.89</div> </td> <td nowrap="nowrap" valign="bottom" style="width: 15px; text-align: left; padding-bottom: 2px; vertical-align: bottom; background-color: #cceeff;"> </td> </tr> <tr> <td valign="bottom" style="width: 815px; padding-bottom: 4px; vertical-align: bottom; background-color: #ffffff;"> <div style="text-align: justify; font-family: 'times new roman', times, serif; font-size: 10pt;">Weighted average fair value of options granted</div> </td> <td valign="bottom" style="width: 16px; padding-bottom: 4px; vertical-align: bottom; background-color: #ffffff;"> </td> <td valign="bottom" style="width: 16px; text-align: left; padding-bottom: 4px; vertical-align: bottom; background-color: #ffffff;"> </td> <td valign="bottom" style="width: 142px; text-align: right; padding-bottom: 4px; vertical-align: bottom; background-color: #ffffff;"> </td> <td nowrap="nowrap" valign="bottom" style="width: 16px; text-align: left; padding-bottom: 4px; vertical-align: bottom; background-color: #ffffff;"> </td> <td valign="bottom" style="width: 16px; padding-bottom: 4px; vertical-align: bottom; background-color: #ffffff;"> </td> <td valign="bottom" style="width: 16px; text-align: left; vertical-align: bottom; border-bottom-color: #000000; border-bottom-width: 4px; border-bottom-style: double; background-color: #ffffff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">$</div> </td> <td valign="bottom" style="width: 142px; text-align: right; vertical-align: bottom; border-bottom-color: #000000; border-bottom-width: 4px; border-bottom-style: double; background-color: #ffffff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">2.30</div> </td> <td nowrap="nowrap" valign="bottom" style="width: 16px; text-align: left; padding-bottom: 4px; vertical-align: bottom; background-color: #ffffff;"> </td> <td valign="bottom" style="width: 15px; padding-bottom: 4px; vertical-align: bottom; background-color: #ffffff;"> </td> <td valign="bottom" style="width: 15px; text-align: left; padding-bottom: 4px; vertical-align: bottom; background-color: #ffffff;"> </td> <td valign="bottom" style="width: 141px; text-align: right; padding-bottom: 4px; vertical-align: bottom; background-color: #ffffff;"> </td> <td nowrap="nowrap" valign="bottom" style="width: 15px; text-align: left; padding-bottom: 4px; vertical-align: bottom; background-color: #ffffff;"> </td> <td valign="bottom" style="width: 15px; padding-bottom: 4px; vertical-align: bottom; background-color: #ffffff;"> </td> <td valign="bottom" style="width: 15px; text-align: left; vertical-align: bottom; border-bottom-color: #000000; border-bottom-width: 4px; border-bottom-style: double; background-color: #ffffff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">$</div> </td> <td valign="bottom" style="width: 141px; text-align: right; vertical-align: bottom; border-bottom-color: #000000; border-bottom-width: 4px; border-bottom-style: double; background-color: #ffffff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">2.36</div> </td> <td nowrap="nowrap" valign="bottom" style="width: 15px; text-align: left; padding-bottom: 4px; vertical-align: bottom; background-color: #ffffff;"> </td> </tr> </table> </div>

<div style="color: #000000; font-family: 'times new roman', times, serif; font-size: 13.3333330154419px; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; background-color: #ffffff;"> <div style="font-size: 10pt; font-family: 'times new roman', times, serif; font-weight: bold; text-align: justify;">Note 8 – Capital Stock</div> <div> </div> <div style="font-size: 10pt; font-family: 'times new roman', times, serif; text-align: justify;"><u>Authorized:</u></div> <div> </div> <div style="font-size: 10pt; font-family: 'times new roman', times, serif; text-align: justify;">The Company has authorized 100,000,000 shares of common stock, par value $0.0001 and 10,000 shares of preferred stock which is designated as Series A Preferred Stock, par value $0.001.</div> <div> </div> <div style="font-size: 10pt; font-family: 'times new roman', times, serif; text-align: justify;"><u>Series A Preferred Stock:</u></div> <div> </div> <div style="font-size: 10pt; font-family: 'times new roman', times, serif; text-align: justify;">The Series A Preferred Stock is redeemable at the option of the Company at any time, in whole or in part, upon 10 trading days prior notice, at a price of $1.00 per share plus 4% per annum from the date of issuance (the "Stated Value"). The holders of the Series A Preferred Stock are entitled to a liquidation preference equal to the Stated Value, prior to the holders of other preferred stock or common stock. The holders of the Series A Preferred Stock have the right to convert such stock into common stock at a conversion rate equal to the Stated Value as of the conversion date divided by the average closing price of the common stock for the five previous trading days. The Company is required to reserve sufficient number of shares for the conversion of the Series A Preferred Stock. The holders of Class A Preferred Stock shall vote together as a single class with the holders of the Company's common stock and the holders of any other class or series of shares entitled to vote with the common stock, with the holders of Class A Preferred Stock being entitled to 66 2/3% of the total votes on<font style="font-size: 10pt; font-family: 'times new roman', times, serif; font-variant: small-caps;"> </font>all such matters, regardless of the actual number of shares of Class A Preferred Stock then outstanding.</div> <div> </div> <div style="font-size: 10pt; font-family: 'times new roman', times, serif; text-align: justify;">There was a total of 2,000 shares of Series A Preferred Stock issued and outstanding as at September 30, 2018 and December 31, 2017.</div> <div style="font-size: 10pt; font-family: 'times new roman', times, serif; text-align: justify;"> </div> </div> <div style="color: #000000; font-family: 'times new roman', times, serif; font-size: 13.3333330154419px; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; background-color: #ffffff;"> <div style="font-size: 10pt; font-family: 'times new roman', times, serif; text-align: justify;"><u>Common Stock issuances during the nine months ended September 30, 2018:</u></div> <div> </div> <div style="font-size: 10pt; font-family: 'times new roman', times, serif; text-align: justify;"><font style="font-size: 10pt; font-family: 'times new roman', times, serif; background-color: #ffffff;">On January 23, 2018 the Company sold 312,500 shares of its common stock to Conventus and raised $500,000 pursuant to a subscription agreement in a private placement offering. The proceeds of the offering will be used for research and general corporate purposes.</font></div> <div> </div> <div style="font-size: 10pt; font-family: 'times new roman', times, serif; text-align: justify;">On January 23, 2018, the Company issued 10,000 shares for advisory services (Note 6(4)). The shares were valued at fair market value on the date of issuance for a total of $28,000 or $2.80 per share.</div> <div> </div> <div style="font-size: 10pt; font-family: 'times new roman', times, serif; text-align: justify;">On February 6, 2018, <font style="font-size: 10pt; font-family: 'times new roman', times, serif; background-color: #ffffff;">the Company </font>received a warrant exercise notice in respect of 2,000 warrants from a subscriber and issued 1,715 <font style="font-size: 10pt; font-family: 'times new roman', times, serif; background-color: #ffffff;">shares of common stock </font>on a cashless exercise basis as per the cashless exercise formula contained in the warrant.</div> <div> </div> <div style="font-size: 10pt; font-family: 'times new roman', times, serif; text-align: justify;">On April 23, 2018, the Company issued 75,000 shares of its common stock in respect of an investor relations services agreement which was rescinded on June 23, 2018 (Note 6(5)). The shares were valued at the fair market value on the date of issuance for a total of $150,000, or $2.00 per share.</div> <div> </div> <div style="font-size: 10pt; font-family: 'times new roman', times, serif; text-align: justify;"><font style="font-size: 10pt; font-family: 'times new roman', times, serif; background-color: #ffffff;">On September 16, 2018 the Company sold 22,728 shares of its common stock to an investor and raised $25,000 pursuant to a subscription agreement in a private placement offering. The proceeds of the offering will be used for research and general corporate purposes.</font></div> <div style="font-size: 10pt; font-family: 'times new roman', times, serif; text-align: justify;"> </div> <div style="font-size: 10pt; font-family: 'times new roman', times, serif; text-align: justify;"><u>Common Stock issuances as of December 31, 2017:</u></div> <div> </div> <div style="font-size: 10pt; font-family: 'times new roman', times, serif; text-align: justify;">On December 13, 2017, 119,950 shares were issued to Ariel as an exercise of warrants pursuant to a License Agreement (Note 5 – License and Research Funding Agreement). These shares were valued at $335,860 or $2.80 per share, based on fair market value, and the associated cost was recorded as research and development expenses.</div> <div style="font-size: 10pt; font-family: 'times new roman', times, serif; text-align: justify;"> </div> <div style="font-size: 10pt; font-family: 'times new roman', times, serif; text-align: justify;">On December 14, 2017, the Company issued 290,000 shares to <font style="font-size: 10pt; font-family: 'times new roman', times, serif; background-color: #ffffff;">two Scientific Advisors as a stock award, </font>valued at $812,000, or $2.80 per share, based on fair market value, and recorded the associated cost as research and development expenses. (Note 7 – Stock Plan).</div> <div> </div> <div style="font-size: 10pt; font-family: 'times new roman', times, serif; text-align: justify;"><font style="font-size: 10pt; font-family: 'times new roman', times, serif; background-color: #ffffff;">During the year ended December 31, 2017, the Company received aggregate proceeds of $32,000 in private placement subscriptions for a total of 128,000 shares.</font></div> <div> </div> <div style="font-size: 10pt; font-family: 'times new roman', times, serif; text-align: justify;"><font style="font-size: 10pt; font-family: 'times new roman', times, serif; background-color: #ffffff;">During the year ended December 31, 2017 the Company </font>received warrant exercise notices in respect of 512,000 warrants from various subscribers and issued a total of 442,960 <font style="font-size: 10pt; font-family: 'times new roman', times, serif; background-color: #ffffff;">shares of common stock </font>on a cashless exercise basis as per the cashless exercise formula in the warrant.</div> <div> </div> </div> <div style="color: #000000; font-family: 'times new roman', times, serif; font-size: 13.3333330154419px; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; background-color: #ffffff;"> <div style="font-size: 10pt; font-family: 'times new roman', times, serif; font-style: italic; text-align: justify;">Share Purchase Warrants</div> <div> </div> <div style="font-size: 10pt; font-family: 'times new roman', times, serif; text-align: justify;">In accordance with authoritative accounting guidance, <font style="font-size: 10pt; font-family: 'times new roman', times, serif; background-color: #ffffff;">the fair value of the aforementioned warrants was calculated using the Black-Scholes option-pricing model with the following assumptions at the measurement date(s):</font></div> <div> </div> </div> <table style="width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; font-size: 10pt; word-spacing: 0px; widows: 1; background-color: #ffffff; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"> <tr> <td style="vertical-align: bottom; width: 1337px; background-color: #ffffff;"> <div style="font-size: 10pt; font-family: 'times new roman', times, serif; text-align: justify;"> </div> </td> <td style="vertical-align: bottom; width: 8px; background-color: #ffffff;"> <div style="font-size: 10pt; font-family: 'times new roman', times, serif; text-align: justify;"> </div> </td> <td style="vertical-align: bottom; border-bottom-color: #000000; border-bottom-width: 2px; border-bottom-style: solid; width: 213px; background-color: #ffffff;" colspan="2"> <div style="font-size: 10pt; font-family: 'times new roman', times, serif; text-align: center;">Measurement date</div> </td> <td style="vertical-align: bottom; width: 9px; background-color: #ffffff;"> <div style="font-size: 10pt; font-family: 'times new roman', times, serif; text-align: justify;"> </div> </td> </tr> <tr> <td style="vertical-align: bottom; width: 1337px; background-color: #cceeff;"> <div style="font-size: 10pt; font-family: 'times new roman', times, serif; text-align: justify;">Dividend yield</div> </td> <td style="vertical-align: bottom; width: 8px; background-color: #cceeff;"> <div style="font-size: 10pt; font-family: 'times new roman', times, serif; text-align: justify;"> </div> </td> <td style="vertical-align: bottom; width: 21px; background-color: #cceeff;"> <div style="font-size: 10pt; font-family: 'times new roman', times, serif; text-align: right;"> </div> </td> <td style="vertical-align: bottom; width: 192px; background-color: #cceeff;"> <div style="font-size: 10pt; font-family: 'times new roman', times, serif; text-align: right;">0%</div> </td> <td style="vertical-align: bottom; width: 9px; background-color: #cceeff;"> <div style="font-size: 10pt; font-family: 'times new roman', times, serif; text-align: justify;"> </div> </td> </tr> <tr> <td style="vertical-align: bottom; width: 1337px; background-color: #ffffff;"> <div style="font-size: 10pt; font-family: 'times new roman', times, serif; text-align: justify;">Expected volatility</div> </td> <td style="vertical-align: bottom; width: 8px; background-color: #ffffff;"> <div style="font-size: 10pt; font-family: 'times new roman', times, serif; text-align: justify;"> </div> </td> <td style="vertical-align: bottom; width: 213px; background-color: #ffffff;" colspan="2"> <div style="font-size: 10pt; font-family: 'times new roman', times, serif; text-align: right;">97.90~119.33%</div> </td> <td style="vertical-align: bottom; width: 9px; background-color: #ffffff;"> <div style="font-size: 10pt; font-family: 'times new roman', times, serif; text-align: justify;"> </div> </td> </tr> <tr> <td style="vertical-align: bottom; width: 1337px; background-color: #cceeff;"> <div style="font-size: 10pt; font-family: 'times new roman', times, serif; text-align: justify;">Risk-free interest rate</div> </td> <td style="vertical-align: bottom; width: 8px; background-color: #cceeff;"> <div style="font-size: 10pt; font-family: 'times new roman', times, serif; text-align: justify;"> </div> </td> <td style="vertical-align: bottom; width: 213px; background-color: #cceeff;" colspan="2"> <div style="font-size: 10pt; font-family: 'times new roman', times, serif; text-align: right;">1.47~1.60%</div> </td> <td style="vertical-align: bottom; width: 9px; background-color: #cceeff;"> <div style="font-size: 10pt; font-family: 'times new roman', times, serif; text-align: justify;"> </div> </td> </tr> <tr> <td style="vertical-align: bottom; width: 1337px; background-color: #ffffff;"> <div style="font-size: 10pt; font-family: 'times new roman', times, serif; text-align: justify;">Expected life (years)</div> </td> <td style="vertical-align: bottom; width: 8px; background-color: #ffffff;"> <div style="font-size: 10pt; font-family: 'times new roman', times, serif; text-align: justify;"> </div> </td> <td style="vertical-align: bottom; width: 213px; background-color: #ffffff;" colspan="2"> <div style="font-size: 10pt; font-family: 'times new roman', times, serif; text-align: right;">2.71~2.92</div> </td> <td style="vertical-align: bottom; width: 9px; background-color: #ffffff;"> <div style="font-size: 10pt; font-family: 'times new roman', times, serif; text-align: justify;"> </div> </td> </tr> <tr> <td style="vertical-align: bottom; width: 1337px; background-color: #cceeff;"> <div style="font-size: 10pt; font-family: 'times new roman', times, serif; text-align: justify;">Stock Price</div> </td> <td style="vertical-align: bottom; width: 8px; background-color: #cceeff;"> <div style="font-size: 10pt; font-family: 'times new roman', times, serif; text-align: justify;"> </div> </td> <td style="vertical-align: bottom; width: 21px; background-color: #cceeff;"> <div style="font-size: 10pt; font-family: 'times new roman', times, serif; text-align: right;">$</div> </td> <td style="vertical-align: bottom; width: 192px; background-color: #cceeff;"> <div style="font-size: 10pt; font-family: 'times new roman', times, serif; text-align: right;">0.25</div> </td> <td style="vertical-align: bottom; width: 9px; background-color: #cceeff;"> <div style="font-size: 10pt; font-family: 'times new roman', times, serif; text-align: justify;"> </div> </td> </tr> <tr> <td style="vertical-align: bottom; width: 1337px; background-color: #ffffff;"> <div style="font-size: 10pt; font-family: 'times new roman', times, serif; text-align: justify;">Exercise Price</div> </td> <td style="vertical-align: bottom; width: 8px; background-color: #ffffff;"> <div style="font-size: 10pt; font-family: 'times new roman', times, serif; text-align: justify;"> </div> </td> <td style="vertical-align: bottom; border-bottom-color: #000000; border-bottom-width: 2px; border-bottom-style: solid; width: 21px; background-color: #ffffff;"> <div style="font-size: 10pt; font-family: 'times new roman', times, serif; text-align: right;">$</div> </td> <td style="vertical-align: bottom; border-bottom-color: #000000; border-bottom-width: 2px; border-bottom-style: solid; width: 192px; background-color: #ffffff;"> <div style="font-size: 10pt; font-family: 'times new roman', times, serif; text-align: right;">0.40</div> </td> <td style="vertical-align: bottom; width: 9px; background-color: #ffffff;"> <div style="font-size: 10pt; font-family: 'times new roman', times, serif; text-align: justify;"> </div> </td> </tr> </table> <div style="color: #000000; font-family: 'times new roman', times, serif; font-size: 13.3333330154419px; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; background-color: #ffffff;"> <div> </div> <div style="font-size: 10pt; font-family: 'times new roman', times, serif; text-align: justify;">As of September 30, 2018, and December 31, 2017, the following common stock purchase warrants were outstanding:</div> <div> </div> </div> <table style="width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; font-size: 10pt; word-spacing: 0px; widows: 1; background-color: #ffffff; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"> <tr> <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"> <div style="font-size: 10pt; font-family: 'times new roman', times, serif; text-align: justify;"> </div> </td> <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"> </td> <td valign="bottom" style="vertical-align: bottom; border-bottom-color: #000000; border-bottom-width: 2px; border-bottom-style: solid;" colspan="2"> <div style="font-size: 10pt; font-family: 'times new roman', times, serif; text-align: center;">Warrants (1)</div> </td> <td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 21px;"> </td> <td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 15px;"> </td> <td valign="bottom" style="vertical-align: bottom; border-bottom-color: #000000; border-bottom-width: 2px; border-bottom-style: solid;" colspan="2"> <div style="font-size: 10pt; font-family: 'times new roman', times, serif; text-align: center;">Weighted Average Exercise Price</div> </td> <td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;"> </td> </tr> <tr> <td valign="bottom" style="vertical-align: bottom; background-color: #cceeff;"> <div style="font-size: 10pt; font-family: 'times new roman', times, serif; text-align: justify;">Outstanding – December 31, 2016</div> </td> <td valign="bottom" style="vertical-align: bottom; background-color: #cceeff;"> </td> <td valign="bottom" style="vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td> <td valign="bottom" style="vertical-align: bottom; text-align: right; background-color: #cceeff;"> <div style="font-size: 10pt; font-family: 'times new roman', times, serif;">502,000</div> </td> <td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 21px; background-color: #cceeff;"> </td> <td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 15px; background-color: #cceeff;"> </td> <td valign="bottom" style="vertical-align: bottom; text-align: left; background-color: #cceeff;"> <div style="font-size: 10pt; font-family: 'times new roman', times, serif;">$</div> </td> <td valign="bottom" style="vertical-align: bottom; text-align: right; background-color: #cceeff;"> <div style="font-size: 10pt; font-family: 'times new roman', times, serif;">0.40</div> </td> <td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td> </tr> <tr style="height: 32px;"> <td valign="bottom" style="vertical-align: bottom; background-color: #ffffff;"> <div style="font-size: 10pt; font-family: 'times new roman', times, serif; text-align: justify;">Granted</div> </td> <td valign="bottom" style="vertical-align: bottom; background-color: #ffffff;"> </td> <td valign="bottom" style="vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td> <td valign="bottom" style="vertical-align: bottom; text-align: right; background-color: #ffffff;"> <div style="font-size: 10pt; font-family: 'times new roman', times, serif;">64,000</div> </td> <td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 21px; background-color: #ffffff;"> </td> <td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 15px; background-color: #ffffff;"> </td> <td valign="bottom" style="vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td> <td valign="bottom" style="vertical-align: bottom; text-align: right; background-color: #ffffff;"> <div style="font-size: 10pt; font-family: 'times new roman', times, serif;">0.40</div> </td> <td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td> </tr> <tr> <td valign="bottom" style="vertical-align: bottom; background-color: #cceeff;"> <div style="font-size: 10pt; font-family: 'times new roman', times, serif; text-align: justify;">Forfeited/Canceled</div> </td> <td valign="bottom" style="vertical-align: bottom; background-color: #cceeff;"> </td> <td valign="bottom" style="vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td> <td valign="bottom" style="vertical-align: bottom; text-align: right; background-color: #cceeff;"> <div style="font-size: 10pt; font-family: 'times new roman', times, serif;">-</div> </td> <td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 21px; background-color: #cceeff;"> </td> <td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 15px; background-color: #cceeff;"> </td> <td valign="bottom" style="vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td> <td valign="bottom" style="vertical-align: bottom; text-align: right; background-color: #cceeff;"> <div style="font-size: 10pt; font-family: 'times new roman', times, serif;">-</div> </td> <td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td> </tr> <tr> <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1160px; background-color: #ffffff;"> <div style="font-size: 10pt; font-family: 'times new roman', times, serif; text-align: justify;">Exercised</div> </td> <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 16px; background-color: #ffffff;"> </td> <td valign="bottom" style="vertical-align: bottom; border-bottom-color: #000000; border-bottom-width: 2px; border-bottom-style: solid; text-align: left; width: 15px; background-color: #ffffff;"> </td> <td valign="bottom" style="vertical-align: bottom; border-bottom-color: #000000; border-bottom-width: 2px; border-bottom-style: solid; text-align: right; width: 156px; background-color: #ffffff;"> <div style="font-size: 10pt; font-family: 'times new roman', times, serif;">512,000</div> </td> <td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 21px; background-color: #ffffff;"> </td> <td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 15px; background-color: #ffffff;"> <div style="font-size: 10pt; font-family: 'times new roman', times, serif;">(2)</div> </td> <td valign="bottom" style="vertical-align: bottom; border-bottom-color: #000000; border-bottom-width: 2px; border-bottom-style: solid; text-align: left; width: 15px; background-color: #ffffff;"> </td> <td valign="bottom" style="vertical-align: bottom; border-bottom-color: #000000; border-bottom-width: 2px; border-bottom-style: solid; text-align: right; width: 156px; background-color: #ffffff;"> <div style="font-size: 10pt; font-family: 'times new roman', times, serif;">0.40</div> </td> <td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 13px; background-color: #ffffff;"> </td> </tr> <tr> <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1160px; background-color: #cceeff;"> <div style="font-size: 10pt; font-family: 'times new roman', times, serif; text-align: justify;">Outstanding – December 31, 2017</div> </td> <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 16px; background-color: #cceeff;"> </td> <td valign="bottom" style="vertical-align: bottom; border-bottom-color: #000000; border-bottom-width: 2px; border-bottom-style: solid; text-align: left; width: 15px; background-color: #cceeff;"> </td> <td valign="bottom" style="vertical-align: bottom; border-bottom-color: #000000; border-bottom-width: 2px; border-bottom-style: solid; text-align: right; width: 156px; background-color: #cceeff;"> <div style="font-size: 10pt; font-family: 'times new roman', times, serif;">54,000</div> </td> <td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 21px; background-color: #cceeff;"> </td> <td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 15px; background-color: #cceeff;"> </td> <td valign="bottom" style="vertical-align: bottom; border-bottom-color: #000000; border-bottom-width: 2px; border-bottom-style: solid; text-align: left; width: 15px; background-color: #cceeff;"> </td> <td valign="bottom" style="vertical-align: bottom; border-bottom-color: #000000; border-bottom-width: 2px; border-bottom-style: solid; text-align: right; width: 156px; background-color: #cceeff;"> <div style="font-size: 10pt; font-family: 'times new roman', times, serif;">0.40</div> </td> <td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 13px; background-color: #cceeff;"> </td> </tr> <tr> <td valign="bottom" style="vertical-align: bottom; width: 1160px; background-color: #ffffff;"> <div style="font-size: 10pt; font-family: 'times new roman', times, serif; text-align: justify;">Granted</div> </td> <td valign="bottom" style="vertical-align: bottom; width: 16px; background-color: #ffffff;"> </td> <td valign="bottom" style="vertical-align: bottom; text-align: left; width: 15px; background-color: #ffffff;"> </td> <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 156px; background-color: #ffffff;"> <div style="font-size: 10pt; font-family: 'times new roman', times, serif;">-</div> </td> <td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 21px; background-color: #ffffff;"> </td> <td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 15px; background-color: #ffffff;"> </td> <td valign="bottom" style="vertical-align: bottom; text-align: left; width: 15px; background-color: #ffffff;"> </td> <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 156px; background-color: #ffffff;"> <div style="font-size: 10pt; font-family: 'times new roman', times, serif;">-</div> </td> <td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 13px; background-color: #ffffff;"> </td> </tr> <tr> <td valign="bottom" style="vertical-align: bottom; width: 1160px; background-color: #cceeff;"> <div style="font-size: 10pt; font-family: 'times new roman', times, serif; text-align: justify;">Forfeited/Canceled</div> </td> <td valign="bottom" style="vertical-align: bottom; width: 16px; background-color: #cceeff;"> </td> <td valign="bottom" style="vertical-align: bottom; text-align: left; width: 15px; background-color: #cceeff;"> </td> <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 156px; background-color: #cceeff;"> <div style="font-size: 10pt; font-family: 'times new roman', times, serif;">-</div> </td> <td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 21px; background-color: #cceeff;"> </td> <td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 15px; background-color: #cceeff;"> </td> <td valign="bottom" style="vertical-align: bottom; text-align: left; width: 15px; background-color: #cceeff;"> </td> <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 156px; background-color: #cceeff;"> <div style="font-size: 10pt; font-family: 'times new roman', times, serif;">-</div> </td> <td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 13px; background-color: #cceeff;"> </td> </tr> <tr> <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1160px; background-color: #ffffff;"> <div style="font-size: 10pt; font-family: 'times new roman', times, serif; text-align: justify;">Exercised</div> </td> <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 16px; background-color: #ffffff;"> </td> <td valign="bottom" style="vertical-align: bottom; border-bottom-color: #000000; border-bottom-width: 2px; border-bottom-style: solid; text-align: left; width: 15px; background-color: #ffffff;"> </td> <td valign="bottom" style="vertical-align: bottom; border-bottom-color: #000000; border-bottom-width: 2px; border-bottom-style: solid; text-align: right; width: 156px; background-color: #ffffff;"> <div style="font-size: 10pt; font-family: 'times new roman', times, serif;">2,000</div> </td> <td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 21px; background-color: #ffffff;"> </td> <td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 15px; background-color: #ffffff;"> <div style="font-size: 10pt; font-family: 'times new roman', times, serif;">(3)</div> </td> <td valign="bottom" style="vertical-align: bottom; border-bottom-color: #000000; border-bottom-width: 2px; border-bottom-style: solid; text-align: left; width: 15px; background-color: #ffffff;"> </td> <td valign="bottom" style="vertical-align: bottom; border-bottom-color: #000000; border-bottom-width: 2px; border-bottom-style: solid; text-align: right; width: 156px; background-color: #ffffff;"> <div style="font-size: 10pt; font-family: 'times new roman', times, serif;">0.40</div> </td> <td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 13px; background-color: #ffffff;"> </td> </tr> <tr> <td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 1160px; background-color: #cceeff;"> <div style="font-size: 10pt; font-family: 'times new roman', times, serif; text-align: justify;">Outstanding – September 30, 2018</div> </td> <td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 16px; background-color: #cceeff;"> </td> <td valign="bottom" style="vertical-align: bottom; border-bottom-color: #000000; border-bottom-width: 4px; border-bottom-style: double; text-align: left; width: 15px; background-color: #cceeff;"> </td> <td valign="bottom" style="vertical-align: bottom; border-bottom-color: #000000; border-bottom-width: 4px; border-bottom-style: double; text-align: right; width: 156px; background-color: #cceeff;"> <div style="font-size: 10pt; font-family: 'times new roman', times, serif;">52,000</div> </td> <td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 21px; background-color: #cceeff;"> </td> <td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 15px; background-color: #cceeff;"> </td> <td valign="bottom" style="vertical-align: bottom; border-bottom-color: #000000; border-bottom-width: 4px; border-bottom-style: double; text-align: left; width: 15px; background-color: #cceeff;"> <div style="font-size: 10pt; font-family: 'times new roman', times, serif;">$</div> </td> <td valign="bottom" style="vertical-align: bottom; border-bottom-color: #000000; border-bottom-width: 4px; border-bottom-style: double; text-align: right; width: 156px; background-color: #cceeff;"> <div style="font-size: 10pt; font-family: 'times new roman', times, serif;">0.40</div> </td> <td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 13px; background-color: #cceeff;"> </td> </tr> </table> <div style="color: #000000; font-family: 'times new roman', times, serif; font-size: 13.3333330154419px; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; background-color: #ffffff;"> <div> </div> <div style="font-size: 10pt; font-family: 'times new roman', times, serif; text-align: justify;">(1) Each two shares of common stock purchased under the private placement provides for one warrant to acquire an additional share of common stock together with the payment of $0.40.</div> <div> </div> <div style="font-size: 10pt; font-family: 'times new roman', times, serif; text-align: justify;">(2) During the year ended December 31, 2017, investors <font style="font-size: 10pt; font-family: 'times new roman', times, serif; background-color: #ffffff;">exercised 512,000 share purchase warrants and received 442,960 underlying shares for exercise on a cashless basis.</font></div> <div> </div> <div style="font-size: 10pt; font-family: 'times new roman', times, serif; text-align: justify;">(3) During the nine-month period ended September 30, 2018, investors <font style="font-size: 10pt; font-family: 'times new roman', times, serif; background-color: #ffffff;">exercised 2,000 share purchase warrants and received 1,715 underlying shares for exercise on a cashless basis.</font></div> </div>

<div style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-weight: bold; text-align: justify;">Note 9 – Subsequent Events</div> <div style="color: #000000; font-family: 'times new roman', times, serif; font-size: 13.3333330154419px; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px;"> </div> <div style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-align: justify;"><a name="_hlk527967937"></a><font style="font-size: 10pt; font-family: 'times new roman', times, serif; background-color: #ffffff;">On October 8, 2018 the Company sold 22,728 shares of its common stock to an investor and raised $25,000 pursuant to a subscription agreement in a private placement offering. The proceeds of the offering will be used for research and general corporate purposes.</font></div> <div style="color: #000000; font-family: 'times new roman', times, serif; font-size: 13.3333330154419px; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px;"> </div> <div style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-align: justify;">The Company has evaluated subsequent events from the balance sheet date through the date that the financial statements were issued and determined that there are no additional subsequent events to disclose.</div>

<div> <div style="text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-weight: 400; margin-bottom: 8pt; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; background-color: #ffffff; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt; font-style: italic; background-color: #ffffff;">Financial Statement Presentation:</font><font style="font-family: 'times new roman', times, serif; font-size: 10pt; background-color: #ffffff;"> </font> <font style="font-family: 'times new roman', times, serif; font-size: 10pt;">The accompanying unaudited condensed financial statements of the Company have been prepared in accordance with the rules and regulations of the Securities and Exchange Commission(the "SEC"), including the instructions to Form 10-Q and Regulation S-X. Certain information and note disclosures normally included in financial statements prepared in accordance with generally accepted accounting principles in the United States of America ("U.S. GAAP"), have been condensed or omitted from these statements pursuant to such rules and regulations and, accordingly, they do not include all the information and notes necessary for comprehensive financial statements and should be read in conjunction with our audited financial statements  included in our Annual Report on Form 10-K for the year ended December 31, 2017.</font></div> <div style="text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-weight: 400; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; background-color: #ffffff; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">In the opinion of the management of the Company, all adjustments, which are of a normal recurring nature, necessary for a fair statement of the results for the three and nine-month periods have been made. Results for the interim period presented are not necessarily indicative of the results that might be expected for the entire fiscal year.</div> </div>

<div style="text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-weight: 400; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt; font-style: italic;">Advertising and Marketing Costs: </font>Advertising and marketing costs are expensed as incurred. <font style="font-family: 'times new roman', times, serif; font-size: 10pt; background-color: #ffffff;">The Company incurred $48,832 and $15,657 in advertising or marketing costs during the nine months ended September 30, 2018 and 2017, respectively.</font></div>

<div> <table style="width: 1557px; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; font-size: 10pt; word-spacing: 0px; orphans: 2; widows: 2; background-color: #ffffff; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;" cellspacing="0" cellpadding="0"> <tr> <td valign="bottom" style="padding-bottom: 2px; vertical-align: bottom;"> <div style="text-align: justify; font-family: 'times new roman', times, serif; font-size: 10pt;"> </div> </td> <td valign="bottom" style="padding-bottom: 2px; vertical-align: bottom;"> </td> <td valign="bottom" style="vertical-align: top; border-bottom-color: #000000; border-bottom-width: 2px; border-bottom-style: solid;" colspan="6"> <div style="text-align: center; font-family: 'times new roman', times, serif; font-size: 10pt; font-weight: bold;">September 30, 2018</div> </td> <td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; vertical-align: bottom;"> </td> <td valign="bottom" style="padding-bottom: 2px; vertical-align: bottom;"> </td> <td valign="bottom" style="vertical-align: bottom; border-bottom-color: #000000; border-bottom-width: 2px; border-bottom-style: solid;" colspan="6"> <div style="text-align: center; font-family: 'times new roman', times, serif; font-size: 10pt; font-weight: bold;">December 31, 2017</div> </td> <td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; vertical-align: bottom;"> </td> </tr> <tr> <td valign="bottom" style="vertical-align: bottom;"> <div style="text-align: justify; font-family: 'times new roman', times, serif; font-size: 10pt;"> </div> </td> <td valign="bottom" style="vertical-align: bottom;"> </td> <td valign="bottom" style="vertical-align: top;" colspan="2"> </td> <td nowrap="nowrap" valign="bottom" style="text-align: left; vertical-align: bottom;"> </td> <td valign="bottom" style="vertical-align: bottom;"> </td> <td valign="bottom" style="vertical-align: bottom;" colspan="2"> <div style="text-align: center; font-family: 'times new roman', times, serif; font-size: 10pt; font-weight: bold;">Weighted Average</div> </td> <td nowrap="nowrap" valign="bottom" style="text-align: left; vertical-align: bottom;"> </td> <td valign="bottom" style="vertical-align: bottom;"> </td> <td valign="bottom" style="vertical-align: bottom;" colspan="2"> </td> <td nowrap="nowrap" valign="bottom" style="text-align: left; vertical-align: bottom;"> </td> <td valign="bottom" style="vertical-align: bottom;"> </td> <td valign="bottom" style="vertical-align: bottom;" colspan="2"> <div style="text-align: center; font-family: 'times new roman', times, serif; font-size: 10pt; font-weight: bold;">Weighted Average</div> </td> <td nowrap="nowrap" valign="bottom" style="text-align: left; vertical-align: bottom;"> </td> </tr> <tr> <td valign="bottom" style="padding-bottom: 2px; vertical-align: bottom;"> <div style="text-align: justify; font-family: 'times new roman', times, serif; font-size: 10pt;"> </div> </td> <td valign="bottom" style="padding-bottom: 2px; vertical-align: bottom;"> </td> <td valign="bottom" style="vertical-align: bottom; border-bottom-color: #000000; border-bottom-width: 2px; border-bottom-style: solid;" colspan="2"> <div style="text-align: center; font-family: 'times new roman', times, serif; font-size: 10pt; font-weight: bold;">Shares</div> </td> <td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; vertical-align: bottom;"> </td> <td valign="bottom" style="padding-bottom: 2px; vertical-align: bottom;"> </td> <td valign="bottom" style="vertical-align: top; border-bottom-color: #000000; border-bottom-width: 2px; border-bottom-style: solid;" colspan="2"> <div style="text-align: center; font-family: 'times new roman', times, serif; font-size: 10pt; font-weight: bold;">Exercise Price</div> </td> <td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; vertical-align: bottom;"> </td> <td valign="bottom" style="padding-bottom: 2px; vertical-align: bottom;"> </td> <td valign="bottom" style="vertical-align: bottom; border-bottom-color: #000000; border-bottom-width: 2px; border-bottom-style: solid;" colspan="2"> <div style="text-align: center; font-family: 'times new roman', times, serif; font-size: 10pt; font-weight: bold;">Shares</div> </td> <td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; vertical-align: bottom;"> </td> <td valign="bottom" style="padding-bottom: 2px; vertical-align: bottom;"> </td> <td valign="bottom" style="vertical-align: bottom; border-bottom-color: #000000; border-bottom-width: 2px; border-bottom-style: solid;" colspan="2"> <div style="text-align: center; font-family: 'times new roman', times, serif; font-size: 10pt; font-weight: bold;">Exercise Price</div> </td> <td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; vertical-align: bottom;"> </td> </tr> <tr> <td valign="bottom" style="width: 810px; vertical-align: bottom; background-color: #cceeff;"> <div style="text-align: justify; font-family: 'times new roman', times, serif; font-size: 10pt;">Outstanding, beginning of period</div> </td> <td valign="bottom" style="width: 16px; vertical-align: bottom; background-color: #cceeff;"> </td> <td valign="bottom" style="width: 16px; text-align: left; vertical-align: bottom; background-color: #cceeff;"> </td> <td valign="bottom" style="width: 141px; text-align: right; vertical-align: bottom; background-color: #cceeff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">670,000</div> </td> <td nowrap="nowrap" valign="bottom" style="width: 16px; text-align: left; vertical-align: bottom; background-color: #cceeff;"> </td> <td valign="bottom" style="width: 16px; vertical-align: bottom; background-color: #cceeff;"> </td> <td valign="bottom" style="width: 16px; text-align: left; vertical-align: bottom; background-color: #cceeff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">$</div> </td> <td valign="bottom" style="width: 141px; text-align: right; vertical-align: bottom; background-color: #cceeff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">1.93</div> </td> <td nowrap="nowrap" valign="bottom" style="width: 15px; text-align: left; vertical-align: bottom; background-color: #cceeff;"> </td> <td valign="bottom" style="width: 15px; vertical-align: bottom; background-color: #cceeff;"> </td> <td valign="bottom" style="width: 15px; text-align: left; vertical-align: bottom; background-color: #cceeff;"> </td> <td valign="bottom" style="width: 140px; text-align: right; vertical-align: bottom; background-color: #cceeff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">-</div> </td> <td nowrap="nowrap" valign="bottom" style="width: 15px; text-align: left; vertical-align: bottom; background-color: #cceeff;"> </td> <td valign="bottom" style="width: 15px; vertical-align: bottom; background-color: #cceeff;"> </td> <td valign="bottom" style="width: 15px; text-align: left; vertical-align: bottom; background-color: #cceeff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">$</div> </td> <td valign="bottom" style="width: 140px; text-align: right; vertical-align: bottom; background-color: #cceeff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">-</div> </td> <td nowrap="nowrap" valign="bottom" style="width: 15px; text-align: left; vertical-align: bottom; background-color: #cceeff;"> </td> </tr> <tr> <td valign="bottom" style="width: 810px; vertical-align: bottom; background-color: #ffffff;"> <div style="text-align: justify; font-family: 'times new roman', times, serif; font-size: 10pt;">Granted</div> </td> <td valign="bottom" style="width: 16px; vertical-align: bottom; background-color: #ffffff;"> </td> <td valign="bottom" style="width: 16px; text-align: left; vertical-align: bottom; background-color: #ffffff;"> </td> <td valign="bottom" style="width: 141px; text-align: right; vertical-align: bottom; background-color: #ffffff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">50,000</div> </td> <td nowrap="nowrap" valign="bottom" style="width: 16px; text-align: left; vertical-align: bottom; background-color: #ffffff;"> </td> <td valign="bottom" style="width: 16px; vertical-align: bottom; background-color: #ffffff;"> </td> <td valign="bottom" style="width: 16px; text-align: left; vertical-align: bottom; background-color: #ffffff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">$</div> </td> <td valign="bottom" style="width: 141px; text-align: right; vertical-align: bottom; background-color: #ffffff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">2.00</div> </td> <td nowrap="nowrap" valign="bottom" style="width: 15px; text-align: left; vertical-align: bottom; background-color: #ffffff;"> </td> <td valign="bottom" style="width: 15px; vertical-align: bottom; background-color: #ffffff;"> </td> <td valign="bottom" style="width: 15px; text-align: left; vertical-align: bottom; background-color: #ffffff;"> </td> <td valign="bottom" style="width: 140px; text-align: right; vertical-align: bottom; background-color: #ffffff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">670,000</div> </td> <td nowrap="nowrap" valign="bottom" style="width: 15px; text-align: left; vertical-align: bottom; background-color: #ffffff;"> </td> <td valign="bottom" style="width: 15px; vertical-align: bottom; background-color: #ffffff;"> </td> <td valign="bottom" style="width: 15px; text-align: left; vertical-align: bottom; background-color: #ffffff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">$</div> </td> <td valign="bottom" style="width: 140px; text-align: right; vertical-align: bottom; background-color: #ffffff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">1.93</div> </td> <td nowrap="nowrap" valign="bottom" style="width: 15px; text-align: left; vertical-align: bottom; background-color: #ffffff;"> </td> </tr> <tr> <td valign="bottom" style="width: 810px; vertical-align: bottom; background-color: #cceeff;"> <div style="text-align: justify; font-family: 'times new roman', times, serif; font-size: 10pt;">Exercised</div> </td> <td valign="bottom" style="width: 16px; vertical-align: bottom; background-color: #cceeff;"> </td> <td valign="bottom" style="width: 16px; text-align: left; vertical-align: bottom; background-color: #cceeff;"> </td> <td valign="bottom" style="width: 141px; text-align: right; vertical-align: bottom; background-color: #cceeff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">-</div> </td> <td nowrap="nowrap" valign="bottom" style="width: 16px; text-align: left; vertical-align: bottom; background-color: #cceeff;"> </td> <td valign="bottom" style="width: 16px; vertical-align: bottom; background-color: #cceeff;"> </td> <td valign="bottom" style="width: 16px; text-align: left; vertical-align: bottom; background-color: #cceeff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">$</div> </td> <td valign="bottom" style="width: 141px; text-align: right; vertical-align: bottom; background-color: #cceeff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">-</div> </td> <td nowrap="nowrap" valign="bottom" style="width: 15px; text-align: left; vertical-align: bottom; background-color: #cceeff;"> </td> <td valign="bottom" style="width: 15px; vertical-align: bottom; background-color: #cceeff;"> </td> <td valign="bottom" style="width: 15px; text-align: left; vertical-align: bottom; background-color: #cceeff;"> </td> <td valign="bottom" style="width: 140px; text-align: right; vertical-align: bottom; background-color: #cceeff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">-</div> </td> <td nowrap="nowrap" valign="bottom" style="width: 15px; text-align: left; vertical-align: bottom; background-color: #cceeff;"> </td> <td valign="bottom" style="width: 15px; vertical-align: bottom; background-color: #cceeff;"> </td> <td valign="bottom" style="width: 15px; text-align: left; vertical-align: bottom; background-color: #cceeff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">$</div> </td> <td valign="bottom" style="width: 140px; text-align: right; vertical-align: bottom; background-color: #cceeff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">-</div> </td> <td nowrap="nowrap" valign="bottom" style="width: 15px; text-align: left; vertical-align: bottom; background-color: #cceeff;"> </td> </tr> <tr> <td valign="bottom" style="width: 810px; vertical-align: bottom; background-color: #ffffff;"> <div style="text-align: justify; font-family: 'times new roman', times, serif; font-size: 10pt;">Canceled</div> </td> <td valign="bottom" style="width: 16px; vertical-align: bottom; background-color: #ffffff;"> </td> <td valign="bottom" style="width: 16px; text-align: left; vertical-align: bottom; background-color: #ffffff;"> </td> <td valign="bottom" style="width: 141px; text-align: right; vertical-align: bottom; background-color: #ffffff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">-</div> </td> <td nowrap="nowrap" valign="bottom" style="width: 16px; text-align: left; vertical-align: bottom; background-color: #ffffff;"> </td> <td valign="bottom" style="width: 16px; vertical-align: bottom; background-color: #ffffff;"> </td> <td valign="bottom" style="width: 16px; text-align: left; vertical-align: bottom; background-color: #ffffff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">$</div> </td> <td valign="bottom" style="width: 141px; text-align: right; vertical-align: bottom; background-color: #ffffff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">-</div> </td> <td nowrap="nowrap" valign="bottom" style="width: 15px; text-align: left; vertical-align: bottom; background-color: #ffffff;"> </td> <td valign="bottom" style="width: 15px; vertical-align: bottom; background-color: #ffffff;"> </td> <td valign="bottom" style="width: 15px; text-align: left; vertical-align: bottom; background-color: #ffffff;"> </td> <td valign="bottom" style="width: 140px; text-align: right; vertical-align: bottom; background-color: #ffffff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">-</div> </td> <td nowrap="nowrap" valign="bottom" style="width: 15px; text-align: left; vertical-align: bottom; background-color: #ffffff;"> </td> <td valign="bottom" style="width: 15px; vertical-align: bottom; background-color: #ffffff;"> </td> <td valign="bottom" style="width: 15px; text-align: left; vertical-align: bottom; background-color: #ffffff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">$</div> </td> <td valign="bottom" style="width: 140px; text-align: right; vertical-align: bottom; background-color: #ffffff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">-</div> </td> <td nowrap="nowrap" valign="bottom" style="width: 15px; text-align: left; vertical-align: bottom; background-color: #ffffff;"> </td> </tr> <tr> <td valign="bottom" style="width: 810px; vertical-align: bottom; background-color: #cceeff;"> <div style="text-align: justify; font-family: 'times new roman', times, serif; font-size: 10pt;">Outstanding, end of period</div> </td> <td valign="bottom" style="width: 16px; vertical-align: bottom; background-color: #cceeff;"> </td> <td valign="bottom" style="width: 16px; text-align: left; vertical-align: bottom; background-color: #cceeff;"> </td> <td valign="bottom" style="width: 141px; text-align: right; vertical-align: bottom; background-color: #cceeff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">720,000</div> </td> <td nowrap="nowrap" valign="bottom" style="width: 16px; text-align: left; vertical-align: bottom; background-color: #cceeff;"> </td> <td valign="bottom" style="width: 16px; vertical-align: bottom; background-color: #cceeff;"> </td> <td valign="bottom" style="width: 16px; text-align: left; vertical-align: bottom; background-color: #cceeff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">$</div> </td> <td valign="bottom" style="width: 141px; text-align: right; vertical-align: bottom; background-color: #cceeff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">1.93</div> </td> <td nowrap="nowrap" valign="bottom" style="width: 15px; text-align: left; vertical-align: bottom; background-color: #cceeff;"> </td> <td valign="bottom" style="width: 15px; vertical-align: bottom; background-color: #cceeff;"> </td> <td valign="bottom" style="width: 15px; text-align: left; vertical-align: bottom; background-color: #cceeff;"> </td> <td valign="bottom" style="width: 140px; text-align: right; vertical-align: bottom; background-color: #cceeff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">670,000</div> </td> <td nowrap="nowrap" valign="bottom" style="width: 15px; text-align: left; vertical-align: bottom; background-color: #cceeff;"> </td> <td valign="bottom" style="width: 15px; vertical-align: bottom; background-color: #cceeff;"> </td> <td valign="bottom" style="width: 15px; text-align: left; vertical-align: bottom; background-color: #cceeff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">$</div> </td> <td valign="bottom" style="width: 140px; text-align: right; vertical-align: bottom; background-color: #cceeff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">1.93</div> </td> <td nowrap="nowrap" valign="bottom" style="width: 15px; text-align: left; vertical-align: bottom; background-color: #cceeff;"> </td> </tr> <tr> <td valign="bottom" style="width: 810px; vertical-align: bottom; background-color: #ffffff;"> <div style="text-align: justify; font-family: 'times new roman', times, serif; font-size: 10pt;">Options exercisable, end of period</div> </td> <td valign="bottom" style="width: 16px; vertical-align: bottom; background-color: #ffffff;"> </td> <td valign="bottom" style="width: 16px; text-align: left; vertical-align: bottom; background-color: #ffffff;"> </td> <td valign="bottom" style="width: 141px; text-align: right; vertical-align: bottom; background-color: #ffffff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">30,000</div> </td> <td nowrap="nowrap" valign="bottom" style="width: 16px; text-align: left; vertical-align: bottom; background-color: #ffffff;"> </td> <td valign="bottom" style="width: 16px; vertical-align: bottom; background-color: #ffffff;"> </td> <td valign="bottom" style="width: 16px; text-align: left; vertical-align: bottom; background-color: #ffffff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">$</div> </td> <td valign="bottom" style="width: 141px; text-align: right; vertical-align: bottom; background-color: #ffffff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">2.00</div> </td> <td nowrap="nowrap" valign="bottom" style="width: 15px; text-align: left; vertical-align: bottom; background-color: #ffffff;"> </td> <td valign="bottom" style="width: 15px; vertical-align: bottom; background-color: #ffffff;"> </td> <td valign="bottom" style="width: 15px; text-align: left; vertical-align: bottom; background-color: #ffffff;"> </td> <td valign="bottom" style="width: 140px; text-align: right; vertical-align: bottom; background-color: #ffffff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">13,334</div> </td> <td nowrap="nowrap" valign="bottom" style="width: 15px; text-align: left; vertical-align: bottom; background-color: #ffffff;"> </td> <td valign="bottom" style="width: 15px; vertical-align: bottom; background-color: #ffffff;"> </td> <td valign="bottom" style="width: 15px; text-align: left; vertical-align: bottom; background-color: #ffffff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">$</div> </td> <td valign="bottom" style="width: 140px; text-align: right; vertical-align: bottom; background-color: #ffffff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">2.00</div> </td> <td nowrap="nowrap" valign="bottom" style="width: 15px; text-align: left; vertical-align: bottom; background-color: #ffffff;"> </td> </tr> <tr> <td valign="bottom" style="width: 810px; padding-bottom: 2px; vertical-align: bottom; background-color: #cceeff;"> <div style="text-align: justify; font-family: 'times new roman', times, serif; font-size: 10pt;">Options expected to vest, end of period</div> </td> <td valign="bottom" style="width: 16px; padding-bottom: 2px; vertical-align: bottom; background-color: #cceeff;"> </td> <td valign="bottom" style="width: 16px; text-align: left; vertical-align: bottom; border-bottom-color: #000000; border-bottom-width: 2px; border-bottom-style: solid; background-color: #cceeff;"> </td> <td valign="bottom" style="width: 141px; text-align: right; vertical-align: bottom; border-bottom-color: #000000; border-bottom-width: 2px; border-bottom-style: solid; background-color: #cceeff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">690,000</div> </td> <td nowrap="nowrap" valign="bottom" style="width: 16px; text-align: left; padding-bottom: 2px; vertical-align: bottom; background-color: #cceeff;"> </td> <td valign="bottom" style="width: 16px; padding-bottom: 2px; vertical-align: bottom; background-color: #cceeff;"> </td> <td valign="bottom" style="width: 16px; text-align: left; vertical-align: bottom; border-bottom-color: #000000; border-bottom-width: 2px; border-bottom-style: solid; background-color: #cceeff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">$</div> </td> <td valign="bottom" style="width: 141px; text-align: right; vertical-align: bottom; border-bottom-color: #000000; border-bottom-width: 2px; border-bottom-style: solid; background-color: #cceeff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">1.93</div> </td> <td nowrap="nowrap" valign="bottom" style="width: 15px; text-align: left; padding-bottom: 2px; vertical-align: bottom; background-color: #cceeff;"> </td> <td valign="bottom" style="width: 15px; padding-bottom: 2px; vertical-align: bottom; background-color: #cceeff;"> </td> <td valign="bottom" style="width: 15px; text-align: left; vertical-align: bottom; border-bottom-color: #000000; border-bottom-width: 2px; border-bottom-style: solid; background-color: #cceeff;"> </td> <td valign="bottom" style="width: 140px; text-align: right; vertical-align: bottom; border-bottom-color: #000000; border-bottom-width: 2px; border-bottom-style: solid; background-color: #cceeff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">656,666</div> </td> <td nowrap="nowrap" valign="bottom" style="width: 15px; text-align: left; padding-bottom: 2px; vertical-align: bottom; background-color: #cceeff;"> </td> <td valign="bottom" style="width: 15px; padding-bottom: 2px; vertical-align: bottom; background-color: #cceeff;"> </td> <td valign="bottom" style="width: 15px; text-align: left; vertical-align: bottom; border-bottom-color: #000000; border-bottom-width: 2px; border-bottom-style: solid; background-color: #cceeff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">$</div> </td> <td valign="bottom" style="width: 140px; text-align: right; vertical-align: bottom; border-bottom-color: #000000; border-bottom-width: 2px; border-bottom-style: solid; background-color: #cceeff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">1.89</div> </td> <td nowrap="nowrap" valign="bottom" style="width: 15px; text-align: left; padding-bottom: 2px; vertical-align: bottom; background-color: #cceeff;"> </td> </tr> <tr> <td valign="bottom" style="width: 810px; padding-bottom: 4px; vertical-align: bottom; background-color: #ffffff;"> <div style="text-align: justify; font-family: 'times new roman', times, serif; font-size: 10pt;">Weighted average fair value of options granted</div> </td> <td valign="bottom" style="width: 16px; padding-bottom: 4px; vertical-align: bottom; background-color: #ffffff;"> </td> <td valign="bottom" style="width: 16px; text-align: left; padding-bottom: 4px; vertical-align: bottom; background-color: #ffffff;"> </td> <td valign="bottom" style="width: 141px; text-align: right; padding-bottom: 4px; vertical-align: bottom; background-color: #ffffff;"> </td> <td nowrap="nowrap" valign="bottom" style="width: 16px; text-align: left; padding-bottom: 4px; vertical-align: bottom; background-color: #ffffff;"> </td> <td valign="bottom" style="width: 16px; padding-bottom: 4px; vertical-align: bottom; background-color: #ffffff;"> </td> <td valign="bottom" style="width: 16px; text-align: left; vertical-align: bottom; border-bottom-color: #000000; border-bottom-width: 4px; border-bottom-style: double; background-color: #ffffff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">$</div> </td> <td valign="bottom" style="width: 141px; text-align: right; vertical-align: bottom; border-bottom-color: #000000; border-bottom-width: 4px; border-bottom-style: double; background-color: #ffffff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">2.30</div> </td> <td nowrap="nowrap" valign="bottom" style="width: 15px; text-align: left; padding-bottom: 4px; vertical-align: bottom; background-color: #ffffff;"> </td> <td valign="bottom" style="width: 15px; padding-bottom: 4px; vertical-align: bottom; background-color: #ffffff;"> </td> <td valign="bottom" style="width: 15px; text-align: left; padding-bottom: 4px; vertical-align: bottom; background-color: #ffffff;"> </td> <td valign="bottom" style="width: 140px; text-align: right; padding-bottom: 4px; vertical-align: bottom; background-color: #ffffff;"> </td> <td nowrap="nowrap" valign="bottom" style="width: 15px; text-align: left; padding-bottom: 4px; vertical-align: bottom; background-color: #ffffff;"> </td> <td valign="bottom" style="width: 15px; padding-bottom: 4px; vertical-align: bottom; background-color: #ffffff;"> </td> <td valign="bottom" style="width: 15px; text-align: left; vertical-align: bottom; border-bottom-color: #000000; border-bottom-width: 4px; border-bottom-style: double; background-color: #ffffff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">$</div> </td> <td valign="bottom" style="width: 140px; text-align: right; vertical-align: bottom; border-bottom-color: #000000; border-bottom-width: 4px; border-bottom-style: double; background-color: #ffffff;"> <div style="font-family: 'times new roman', times, serif; font-size: 10pt;">2.36</div> </td> <td nowrap="nowrap" valign="bottom" style="width: 15px; text-align: left; padding-bottom: 4px; vertical-align: bottom; background-color: #ffffff;"> </td> </tr> </table> </div>

<div> <table style="width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; font-size: 10pt; word-spacing: 0px; orphans: 2; widows: 2; background-color: #ffffff; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;" cellspacing="0" cellpadding="0"> <tr> <td style="width: 1337px; vertical-align: bottom; background-color: #ffffff;"> <div style="text-align: justify; font-family: 'times new roman', times, serif; font-size: 10pt;"> </div> </td> <td style="width: 8px; vertical-align: bottom; background-color: #ffffff;"> <div style="text-align: justify; font-family: 'times new roman', times, serif; font-size: 10pt;"> </div> </td> <td style="width: 213px; vertical-align: bottom; border-bottom-color: #000000; border-bottom-width: 2px; border-bottom-style: solid; background-color: #ffffff;" colspan="2"> <div style="text-align: center; font-family: 'times new roman', times, serif; font-size: 10pt;">Measurement date</div> </td> <td style="width: 9px; vertical-align: bottom; background-color: #ffffff;"> <div style="text-align: justify; font-family: 'times new roman', times, serif; font-size: 10pt;"> </div> </td> </tr> <tr> <td style="width: 1337px; vertical-align: bottom; background-color: #cceeff;"> <div style="text-align: justify; font-family: 'times new roman', times, serif; font-size: 10pt;">Dividend yield</div> </td> <td style="width: 8px; vertical-align: bottom; background-color: #cceeff;"> <div style="text-align: justify; font-family: 'times new roman', times, serif; font-size: 10pt;"> </div> </td> <td style="width: 21px; vertical-align: bottom; background-color: #cceeff;"> <div style="text-align: right; font-family: 'times new roman', times, serif; font-size: 10pt;"> </div> </td> <td style="width: 192px; vertical-align: bottom; background-color: #cceeff;"> <div style="text-align: right; font-family: 'times new roman', times, serif; font-size: 10pt;">0%</div> </td> <td style="width: 9px; vertical-align: bottom; background-color: #cceeff;"> <div style="text-align: justify; font-family: 'times new roman', times, serif; font-size: 10pt;"> </div> </td> </tr> <tr> <td style="width: 1337px; vertical-align: bottom; background-color: #ffffff;"> <div style="text-align: justify; font-family: 'times new roman', times, serif; font-size: 10pt;">Expected volatility</div> </td> <td style="width: 8px; vertical-align: bottom; background-color: #ffffff;"> <div style="text-align: justify; font-family: 'times new roman', times, serif; font-size: 10pt;"> </div> </td> <td style="width: 213px; vertical-align: bottom; background-color: #ffffff;" colspan="2"> <div style="text-align: right; font-family: 'times new roman', times, serif; font-size: 10pt;">97.90~119.33%</div> </td> <td style="width: 9px; vertical-align: bottom; background-color: #ffffff;"> <div style="text-align: justify; font-family: 'times new roman', times, serif; font-size: 10pt;"> </div> </td> </tr> <tr> <td style="width: 1337px; vertical-align: bottom; background-color: #cceeff;"> <div style="text-align: justify; font-family: 'times new roman', times, serif; font-size: 10pt;">Risk-free interest rate</div> </td> <td style="width: 8px; vertical-align: bottom; background-color: #cceeff;"> <div style="text-align: justify; font-family: 'times new roman', times, serif; font-size: 10pt;"> </div> </td> <td style="width: 213px; vertical-align: bottom; background-color: #cceeff;" colspan="2"> <div style="text-align: right; font-family: 'times new roman', times, serif; font-size: 10pt;">1.47~1.60%</div> </td> <td style="width: 9px; vertical-align: bottom; background-color: #cceeff;"> <div style="text-align: justify; font-family: 'times new roman', times, serif; font-size: 10pt;"> </div> </td> </tr> <tr> <td style="width: 1337px; vertical-align: bottom; background-color: #ffffff;"> <div style="text-align: justify; font-family: 'times new roman', times, serif; font-size: 10pt;">Expected life (years)</div> </td> <td style="width: 8px; vertical-align: bottom; background-color: #ffffff;"> <div style="text-align: justify; font-family: 'times new roman', times, serif; font-size: 10pt;"> </div> </td> <td style="width: 213px; vertical-align: bottom; background-color: #ffffff;" colspan="2"> <div style="text-align: right; font-family: 'times new roman', times, serif; font-size: 10pt;">2.71~2.92</div> </td> <td style="width: 9px; vertical-align: bottom; background-color: #ffffff;"> <div style="text-align: justify; font-family: 'times new roman', times, serif; font-size: 10pt;"> </div> </td> </tr> <tr> <td style="width: 1337px; vertical-align: bottom; background-color: #cceeff;"> <div style="text-align: justify; font-family: 'times new roman', times, serif; font-size: 10pt;">Stock Price</div> </td> <td style="width: 8px; vertical-align: bottom; background-color: #cceeff;"> <div style="text-align: justify; font-family: 'times new roman', times, serif; font-size: 10pt;"> </div> </td> <td style="width: 21px; vertical-align: bottom; background-color: #cceeff;"> <div style="text-align: right; font-family: 'times new roman', times, serif; font-size: 10pt;">$</div> </td> <td style="width: 192px; vertical-align: bottom; background-color: #cceeff;"> <div style="text-align: right; font-family: 'times new roman', times, serif; font-size: 10pt;">0.25</div> </td> <td style="width: 9px; vertical-align: bottom; background-color: #cceeff;"> <div style="text-align: justify; font-family: 'times new roman', times, serif; font-size: 10pt;"> </div> </td> </tr> <tr> <td style="width: 1337px; vertical-align: bottom; background-color: #ffffff;"> <div style="text-align: justify; font-family: 'times new roman', times, serif; font-size: 10pt;">Exercise Price</div> </td> <td style="width: 8px; vertical-align: bottom; background-color: #ffffff;"> <div style="text-align: justify; font-family: 'times new roman', times, serif; font-size: 10pt;"> </div> </td> <td style="width: 21px; vertical-align: bottom; border-bottom-color: #000000; border-bottom-width: 2px; border-bottom-style: solid; background-color: #ffffff;"> <div style="text-align: right; font-family: 'times new roman', times, serif; font-size: 10pt;">$</div> </td> <td style="width: 192px; vertical-align: bottom; border-bottom-color: #000000; border-bottom-width: 2px; border-bottom-style: solid; background-color: #ffffff;"> <div style="text-align: right; font-family: 'times new roman', times, serif; font-size: 10pt;">0.40</div> </td> <td style="width: 9px; vertical-align: bottom; background-color: #ffffff;"> <div style="text-align: justify; font-family: 'times new roman', times, serif; font-size: 10pt;"> </div> </td> </tr> </table> </div> <div> </div> <table style="width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; font-size: 10pt; word-spacing: 0px; widows: 1; background-color: #ffffff; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"> <tr> <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"> <div style="font-size: 10pt; font-family: 'times new roman', times, serif; text-align: justify;"> </div> </td> <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"> </td> <td valign="bottom" style="vertical-align: bottom; border-bottom-color: #000000; border-bottom-width: 2px; border-bottom-style: solid;" colspan="2"> <div style="font-size: 10pt; font-family: 'times new roman', times, serif; text-align: center;">Warrants (1)</div> </td> <td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 21px;"> </td> <td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 15px;"> </td> <td valign="bottom" style="vertical-align: bottom; border-bottom-color: #000000; border-bottom-width: 2px; border-bottom-style: solid;" colspan="2"> <div style="font-size: 10pt; font-family: 'times new roman', times, serif; text-align: center;">Weighted Average Exercise Price</div> </td> <td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;"> </td> </tr> <tr> <td valign="bottom" style="vertical-align: bottom; background-color: #cceeff;"> <div style="font-size: 10pt; font-family: 'times new roman', times, serif; text-align: justify;">Outstanding – December 31, 2016</div> </td> <td valign="bottom" style="vertical-align: bottom; background-color: #cceeff;"> </td> <td valign="bottom" style="vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td> <td valign="bottom" style="vertical-align: bottom; text-align: right; background-color: #cceeff;"> <div style="font-size: 10pt; font-family: 'times new roman', times, serif;">502,000</div> </td> <td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 21px; background-color: #cceeff;"> </td> <td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 15px; background-color: #cceeff;"> </td> <td valign="bottom" style="vertical-align: bottom; text-align: left; background-color: #cceeff;"> <div style="font-size: 10pt; font-family: 'times new roman', times, serif;">$</div> </td> <td valign="bottom" style="vertical-align: bottom; text-align: right; background-color: #cceeff;"> <div style="font-size: 10pt; font-family: 'times new roman', times, serif;">0.40</div> </td> <td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td> </tr> <tr style="height: 32px;"> <td valign="bottom" style="vertical-align: bottom; background-color: #ffffff;"> <div style="font-size: 10pt; font-family: 'times new roman', times, serif; text-align: justify;">Granted</div> </td> <td valign="bottom" style="vertical-align: bottom; background-color: #ffffff;"> </td> <td valign="bottom" style="vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td> <td valign="bottom" style="vertical-align: bottom; text-align: right; background-color: #ffffff;"> <div style="font-size: 10pt; font-family: 'times new roman', times, serif;">64,000</div> </td> <td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 21px; background-color: #ffffff;"> </td> <td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 15px; background-color: #ffffff;"> </td> <td valign="bottom" style="vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td> <td valign="bottom" style="vertical-align: bottom; text-align: right; background-color: #ffffff;"> <div style="font-size: 10pt; font-family: 'times new roman', times, serif;">0.40</div> </td> <td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td> </tr> <tr> <td valign="bottom" style="vertical-align: bottom; background-color: #cceeff;"> <div style="font-size: 10pt; font-family: 'times new roman', times, serif; text-align: justify;">Forfeited/Canceled</div> </td> <td valign="bottom" style="vertical-align: bottom; background-color: #cceeff;"> </td> <td valign="bottom" style="vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td> <td valign="bottom" style="vertical-align: bottom; text-align: right; background-color: #cceeff;"> <div style="font-size: 10pt; font-family: 'times new roman', times, serif;">-</div> </td> <td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 21px; background-color: #cceeff;"> </td> <td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 15px; background-color: #cceeff;"> </td> <td valign="bottom" style="vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td> <td valign="bottom" style="vertical-align: bottom; text-align: right; background-color: #cceeff;"> <div style="font-size: 10pt; font-family: 'times new roman', times, serif;">-</div> </td> <td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td> </tr> <tr> <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1160px; background-color: #ffffff;"> <div style="font-size: 10pt; font-family: 'times new roman', times, serif; text-align: justify;">Exercised</div> </td> <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 16px; background-color: #ffffff;"> </td> <td valign="bottom" style="vertical-align: bottom; border-bottom-color: #000000; border-bottom-width: 2px; border-bottom-style: solid; text-align: left; width: 15px; background-color: #ffffff;"> </td> <td valign="bottom" style="vertical-align: bottom; border-bottom-color: #000000; border-bottom-width: 2px; border-bottom-style: solid; text-align: right; width: 156px; background-color: #ffffff;"> <div style="font-size: 10pt; font-family: 'times new roman', times, serif;">512,000</div> </td> <td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 21px; background-color: #ffffff;"> </td> <td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 15px; background-color: #ffffff;"> <div style="font-size: 10pt; font-family: 'times new roman', times, serif;">(2)</div> </td> <td valign="bottom" style="vertical-align: bottom; border-bottom-color: #000000; border-bottom-width: 2px; border-bottom-style: solid; text-align: left; width: 15px; background-color: #ffffff;"> </td> <td valign="bottom" style="vertical-align: bottom; border-bottom-color: #000000; border-bottom-width: 2px; border-bottom-style: solid; text-align: right; width: 156px; background-color: #ffffff;"> <div style="font-size: 10pt; font-family: 'times new roman', times, serif;">0.40</div> </td> <td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 13px; background-color: #ffffff;"> </td> </tr> <tr> <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1160px; background-color: #cceeff;"> <div style="font-size: 10pt; font-family: 'times new roman', times, serif; text-align: justify;">Outstanding – December 31, 2017</div> </td> <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 16px; background-color: #cceeff;"> </td> <td valign="bottom" style="vertical-align: bottom; border-bottom-color: #000000; border-bottom-width: 2px; border-bottom-style: solid; text-align: left; width: 15px; background-color: #cceeff;"> </td> <td valign="bottom" style="vertical-align: bottom; border-bottom-color: #000000; border-bottom-width: 2px; border-bottom-style: solid; text-align: right; width: 156px; background-color: #cceeff;"> <div style="font-size: 10pt; font-family: 'times new roman', times, serif;">54,000</div> </td> <td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 21px; background-color: #cceeff;"> </td> <td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 15px; background-color: #cceeff;"> </td> <td valign="bottom" style="vertical-align: bottom; border-bottom-color: #000000; border-bottom-width: 2px; border-bottom-style: solid; text-align: left; width: 15px; background-color: #cceeff;"> </td> <td valign="bottom" style="vertical-align: bottom; border-bottom-color: #000000; border-bottom-width: 2px; border-bottom-style: solid; text-align: right; width: 156px; background-color: #cceeff;"> <div style="font-size: 10pt; font-family: 'times new roman', times, serif;">0.40</div> </td> <td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 13px; background-color: #cceeff;"> </td> </tr> <tr> <td valign="bottom" style="vertical-align: bottom; width: 1160px; background-color: #ffffff;"> <div style="font-size: 10pt; font-family: 'times new roman', times, serif; text-align: justify;">Granted</div> </td> <td valign="bottom" style="vertical-align: bottom; width: 16px; background-color: #ffffff;"> </td> <td valign="bottom" style="vertical-align: bottom; text-align: left; width: 15px; background-color: #ffffff;"> </td> <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 156px; background-color: #ffffff;"> <div style="font-size: 10pt; font-family: 'times new roman', times, serif;">-</div> </td> <td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 21px; background-color: #ffffff;"> </td> <td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 15px; background-color: #ffffff;"> </td> <td valign="bottom" style="vertical-align: bottom; text-align: left; width: 15px; background-color: #ffffff;"> </td> <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 156px; background-color: #ffffff;"> <div style="font-size: 10pt; font-family: 'times new roman', times, serif;">-</div> </td> <td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 13px; background-color: #ffffff;"> </td> </tr> <tr> <td valign="bottom" style="vertical-align: bottom; width: 1160px; background-color: #cceeff;"> <div style="font-size: 10pt; font-family: 'times new roman', times, serif; text-align: justify;">Forfeited/Canceled</div> </td> <td valign="bottom" style="vertical-align: bottom; width: 16px; background-color: #cceeff;"> </td> <td valign="bottom" style="vertical-align: bottom; text-align: left; width: 15px; background-color: #cceeff;"> </td> <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 156px; background-color: #cceeff;"> <div style="font-size: 10pt; font-family: 'times new roman', times, serif;">-</div> </td> <td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 21px; background-color: #cceeff;"> </td> <td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 15px; background-color: #cceeff;"> </td> <td valign="bottom" style="vertical-align: bottom; text-align: left; width: 15px; background-color: #cceeff;"> </td> <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 156px; background-color: #cceeff;"> <div style="font-size: 10pt; font-family: 'times new roman', times, serif;">-</div> </td> <td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 13px; background-color: #cceeff;"> </td> </tr> <tr> <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1160px; background-color: #ffffff;"> <div style="font-size: 10pt; font-family: 'times new roman', times, serif; text-align: justify;">Exercised</div> </td> <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 16px; background-color: #ffffff;"> </td> <td valign="bottom" style="vertical-align: bottom; border-bottom-color: #000000; border-bottom-width: 2px; border-bottom-style: solid; text-align: left; width: 15px; background-color: #ffffff;"> </td> <td valign="bottom" style="vertical-align: bottom; border-bottom-color: #000000; border-bottom-width: 2px; border-bottom-style: solid; text-align: right; width: 156px; background-color: #ffffff;"> <div style="font-size: 10pt; font-family: 'times new roman', times, serif;">2,000</div> </td> <td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 21px; background-color: #ffffff;"> </td> <td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 15px; background-color: #ffffff;"> <div style="font-size: 10pt; font-family: 'times new roman', times, serif;">(3)</div> </td> <td valign="bottom" style="vertical-align: bottom; border-bottom-color: #000000; border-bottom-width: 2px; border-bottom-style: solid; text-align: left; width: 15px; background-color: #ffffff;"> </td> <td valign="bottom" style="vertical-align: bottom; border-bottom-color: #000000; border-bottom-width: 2px; border-bottom-style: solid; text-align: right; width: 156px; background-color: #ffffff;"> <div style="font-size: 10pt; font-family: 'times new roman', times, serif;">0.40</div> </td> <td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 13px; background-color: #ffffff;"> </td> </tr> <tr> <td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 1160px; background-color: #cceeff;"> <div style="font-size: 10pt; font-family: 'times new roman', times, serif; text-align: justify;">Outstanding – September 30, 2018</div> </td> <td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 16px; background-color: #cceeff;"> </td> <td valign="bottom" style="vertical-align: bottom; border-bottom-color: #000000; border-bottom-width: 4px; border-bottom-style: double; text-align: left; width: 15px; background-color: #cceeff;"> </td> <td valign="bottom" style="vertical-align: bottom; border-bottom-color: #000000; border-bottom-width: 4px; border-bottom-style: double; text-align: right; width: 156px; background-color: #cceeff;"> <div style="font-size: 10pt; font-family: 'times new roman', times, serif;">52,000</div> </td> <td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 21px; background-color: #cceeff;"> </td> <td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 15px; background-color: #cceeff;"> </td> <td valign="bottom" style="vertical-align: bottom; border-bottom-color: #000000; border-bottom-width: 4px; border-bottom-style: double; text-align: left; width: 15px; background-color: #cceeff;"> <div style="font-size: 10pt; font-family: 'times new roman', times, serif;">$</div> </td> <td valign="bottom" style="vertical-align: bottom; border-bottom-color: #000000; border-bottom-width: 4px; border-bottom-style: double; text-align: right; width: 156px; background-color: #cceeff;"> <div style="font-size: 10pt; font-family: 'times new roman', times, serif;">0.40</div> </td> <td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 13px; background-color: #cceeff;"> </td> </tr> </table> <div style="color: #000000; font-family: 'times new roman', times, serif; font-size: 13.3333330154419px; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; background-color: #ffffff;"> <div> </div> <div style="font-size: 10pt; font-family: 'times new roman', times, serif; text-align: justify;">(1) Each two shares of common stock purchased under the private placement provides for one warrant to acquire an additional share of common stock together with the payment of $0.40.</div> <div> </div> <div style="font-size: 10pt; font-family: 'times new roman', times, serif; text-align: justify;">(2) During the year ended December 31, 2017, investors <font style="font-size: 10pt; font-family: 'times new roman', times, serif; background-color: #ffffff;">exercised 512,000 share purchase warrants and received 442,960 underlying shares for exercise on a cashless basis.</font></div> <div> </div> <div style="font-size: 10pt; font-family: 'times new roman', times, serif; text-align: justify;">(3) During the nine-month period ended September 30, 2018, investors <font style="font-size: 10pt; font-family: 'times new roman', times, serif; background-color: #ffffff;">exercised 2,000 share purchase warrants and received 1,715 underlying shares for exercise on a cashless basis.</font></div> </div>

31090

30506

598878

700

566000

32178

1476284

700

52000

28778

30000

384806

690000

290000

15657

48832

0.03

25000

18335

584

0.00 0.00 0.00 1.15 1.10 0.83 0.77 1.01 1.03 P0Y8M26D P0Y8M2D P0Y11M26D P0Y11M1D P0Y11M1D P1Y 0.0165 0.0153 0.0259 0.0133

0.25

10000

15000

0.08

(i) $0.0625 per share if the Company's shares are not trading on a public market and; (ii) in the event the Company's shares are listed for trading on a public market, the conversion price shall be equal to a 50% discount to the average of the five lowest trading prices during the previous twenty trading days prior to the date of the notice of conversion from the lender.

Any portion of the principal and unpaid interest under the note is convertible at any time at the option of CubeSquare into shares of common stock of the Company at a conversion price equal to a 50% discount to the average of the five lowest trading prices during the previous twenty trading days prior to the date of the notice of conversion from CubeSquare.

2017-09-01

Note 1 to extend the maturity date from September 1, 2017 to September 1, 2018 and on September 9, 2018, the Company further amended Note 1 to extend the maturity date to September 1, 2019, under the same terms and conditions.

Note 2 was amended to extend the maturity date until September 27, 2019.

1571

6599

5541

18335

100000

0.04 Upon successful clinical FDA Phase II completion - $130,000; and Upon successful clinical FDA Phase III completion - $390,000

119950

812000

29000

106029

48078

353430

122816

1060290

P6M

119950

75000

335860

0.01

The Company entered into an additional service agreement with Ariel for the services of Professor Gadi Turgeman and his stem cells research team in their lab pursuant to which the Company paid Ariel $20,580 on each of March 19, 2018 and August 22, 2018. The Company paid Ariel (i) $17,250 on December 19, 2017 and an additional $17,250 on April 26, 2018. On April 12, 2018, the Services Agreement was amended to provide for the payment by the Company of an additional monthly fee, commencing March 2018, of up to 8,000 Israeli shekels as compensation for additional costs which the Company may request.

17250

20580

17250

20580

1438

25875

7187

20000

64000

10000

30000

20000

The Company of an additional monthly fee, commencing March 2018, of up to 8,000 Israeli shekels as compensation for additional costs which the Company may request.

41160

36293

24010

9073

17150

27220

5000

The Company issued 10,000 shares for advisory services (Note 6(4)). The shares were valued at fair market value on the date of issuance for a total of $28,000 or $2.80 per share. The Company issued 75,000 shares of its common stock in respect of an investor relations services agreement which was rescinded on June 23, 2018 (Note 6(5)). The shares were valued at the fair market value on the date of issuance for a total of $150,000, or $2.00 per share. The Company gave notice of rescission of the agreement to such firm and requested the return of the consulting fee paid and the 75,000 shares of common stock. As a result, the Company has not recorded any fees for services rendered past June 23, 2018. A total of $10,000 representing April 2018 and May 2018 monthly consulting fees is reflected in the statement of operations and a total of $150,000, the fair market value of the issued shares, was expensed on issue.

290000

10000

2.80 2.80

812000

28000

0.00

1.2634

1.1469

1.1933

0.9790

0.0268

0.0179

0.0160

0.0147

P5Y

P3Y

P2Y11M1D

P2Y8M16D

2.80 2.00

0.40

2.00

670000

720000

670000

50000

13334

30000

656666

690000

1.93

2.00

1.89

1.93

2.36

2.30

10000000

440000

10000

150000

145000

290000

Under the 2016 Stock Option and Award Plan, the Board awarded two of its Science Advisors the following three-year stock options: (i) an immediately exercisable option to purchase 6,667 shares of common stock at an exercise price of $2.00 per share, (ii) an option to purchase 6,667 shares of common stock exercisable on November 15, 2018 at an exercise price of $2.00 per share and (iii) an option to purchase 6,666 shares of common stock exercisable on November 15, 2019 at an exercise price of $2.00 per share, provided the advisors are still providing services to the Company.

Under the 2016 Stock Option and Award Plan, the Board awarded a Science Advisor, the following three-year stock options: (i) an option to purchase 15,000 shares of common stock, exercisable on November 15, 2018 at an exercise price of $0.40 per share and (ii) an option to purchase 15,000 shares of common stock exercisable on November 15, 2019 at an exercise price of $0.40 per share, provided the advisor is still providing services to the Company.

Under the 2016 Stock Option and Award Plan, the Board awarded a Science Advisor, the following three-year stock options: (i) an option to purchase 10,000 shares of common stock, exercisable on April 16, 2018 at an exercise price of $2.00 per share and (ii) an option to purchase 10,000 shares of common stock exercisable on April 16, 2019 at an exercise price of $2.00 per share, and (iii) an option to purchase 10,000 shares of common stock exercisable on April 16, 2020 at an exercise price of $2.00 per share, provided the advisor is still providing services to the Company. provided the advisor is still providing services to the Company.

Under the 2016 Stock Option and Award Plan, the Board granted a Science Advisor an option to purchase an aggregate of 20,000 shares of common stock at an exercise price of $2.00 per share. The option vests as to 6,667 shares on each of August 15, 2018 and August 15, 2019 and as to 6,666 shares on August 15, 2020 and remains exercisable as to each such installment for three years from the date of vesting.

92671 246755

P5Y

2018-12-04

300000

0.25

0.40

502000

54000

52000

512000

2000

0.40 0.40 0.40 0.40 0.40 0.40

119950

290000

335860

812000

2.80 2.80

312500

22728

32000

500000

25000

128000

The Company received a warrant exercise notice in respect of 2,000 warrants from a subscriber and issued 1,715 shares of common stock on a cashless exercise basis as per the cashless exercise formula contained in the warrant.

442960 1715 true true false 14082 The Company entered into a one-year sponsored research agreement (the "Sponsored Research Agreement"), with the Trustees of Dartmouth College ("Dartmouth") pursuant to which the Company will support and fund the cost of research conducted by Dartmouth of mutual interest to the parties in accordance with the Agreement. Intellectual property invented or developed solely by a party shall be owned by such party and intellectual property jointly invented or developed shall be jointly owned. Dartmouth shall retain an irrevocable worldwide right to use intellectual property owned by it resulting from its research under the Agreement on a non-exclusive royalty-free basis for research and education purposes. The Company funded $36,293 on August 20, 2018 and will fund additional $18,147 by December 1, 2018 and $18,146 by June 1, 2019, respectively.

2018-09-27

0.40 Each two shares of common stock purchased under the private placement provides for one warrant to acquire an additional share of common stock together with the payment of $0.40. During the year ended December 31, 2017, investors exercised 512,000 share purchase warrants and received 442,960 underlying shares for exercise on a cashless basis. During the nine-month period ended September 30, 2018, investors exercised 2,000 share purchase warrants and received 1,715 underlying shares for exercise on a cashless basis.

EX-101.SCH 5 qron-20180930.xsd XBRL TAXONOMY EXTENSION SCHEMA 001 - Document - Document and Entity Information link:presentationLink link:definitionLink link:calculationLink 002 - Statement - Condensed Balance Sheets (Unaudited) link:presentationLink link:definitionLink link:calculationLink 003 - Statement - Condensed Balance Sheets (Unaudited) (Parenthetical) link:presentationLink link:definitionLink link:calculationLink 004 - Statement - Condensed Statements of Operations (Unaudited) link:presentationLink link:definitionLink link:calculationLink 005 - Statement - Condensed Statements of Cash Flows (Unaudited) link:presentationLink link:definitionLink link:calculationLink 006 - Disclosure - Description of Business and Basis of Presentation link:presentationLink link:definitionLink link:calculationLink 007 - Disclosure - Summary of Significant Accounting Policies link:presentationLink link:definitionLink link:calculationLink 008 - Disclosure - Going Concern link:presentationLink link:definitionLink link:calculationLink 009 - Disclosure - Convertible Note - Related Party and Derivative Liabilities link:presentationLink link:definitionLink link:calculationLink 010 - Disclosure - License and Research Funding Agreements link:presentationLink link:definitionLink link:calculationLink 011 - Disclosure - Commitments link:presentationLink link:definitionLink link:calculationLink 012 - Disclosure - Stock Plan link:presentationLink link:definitionLink link:calculationLink 013 - Disclosure - Capital Stock link:presentationLink link:definitionLink link:calculationLink 014 - Disclosure - Subsequent Events link:presentationLink link:definitionLink link:calculationLink 015 - Disclosure - Summary of Significant Accounting Policies (Policies) link:presentationLink link:definitionLink link:calculationLink 016 - Disclosure - Summary of Significant Accounting Policies (Tables) link:presentationLink link:definitionLink link:calculationLink 017 - Disclosure - Convertible Note - Related Party and Derivative Liabilities (Tables) link:presentationLink link:definitionLink link:calculationLink 018 - Disclosure - Stock Plan (Tables) link:presentationLink link:definitionLink link:calculationLink 019 - Disclosure - Capital Stock (Tables) link:presentationLink link:definitionLink link:calculationLink 020 - Disclosure - Summary of Significant Accounting Policies (Details) link:presentationLink link:definitionLink link:calculationLink 021 - Disclosure - Summary of Significant Accounting Policies (Details 1) link:presentationLink link:definitionLink link:calculationLink 022 - Disclosure - Summary of Significant Accounting Policies (Details Textual) link:presentationLink link:definitionLink link:calculationLink 023 - Disclosure - Convertible Note - Related Party and Derivative Liabilities (Details) link:presentationLink link:definitionLink link:calculationLink 024 - Disclosure - Convertible Note - Related Party and Derivative Liabilities (Details 1) link:presentationLink link:definitionLink link:calculationLink 025 - Disclosure - Convertible Note - Related Party and Derivative Liabilities (Details 2) link:presentationLink link:definitionLink link:calculationLink 026 - Disclosure - Convertible Note - Related Party and Derivative Liabilities (Details Textual) link:presentationLink link:definitionLink link:calculationLink 027 - Disclosure - License and Research Funding Agreements (Details) link:presentationLink link:definitionLink link:calculationLink 028 - Disclosure - Commitments (Details) link:presentationLink link:definitionLink link:calculationLink 029 - Disclosure - Stock Plan (Details) link:presentationLink link:definitionLink link:calculationLink 030 - Disclosure - Stock Plan (Details 1) link:presentationLink link:definitionLink link:calculationLink 031 - Disclosure - Stock Plan (Details 2) link:presentationLink link:definitionLink link:calculationLink 032 - Disclosure - Stock Plan (Details Textual) link:presentationLink link:definitionLink link:calculationLink 033 - Disclosure - Capital Stock (Details) link:presentationLink link:definitionLink link:calculationLink 034 - Disclosure - Capital Stock (Details 1) link:presentationLink link:definitionLink link:calculationLink 035 - Disclosure - Capital Stock (Details Textual) link:presentationLink link:definitionLink link:calculationLink 036 - Disclosure - Subsequent Events (Details) link:presentationLink link:definitionLink link:calculationLink EX-101.CAL 6 qron-20180930_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE EX-101.DEF 7 qron-20180930_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE EX-101.LAB 8 qron-20180930_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Document and Entity Information [Abstract] Entity Registrant Name Entity Central Index Key Trading Symbol Amendment Flag Current Fiscal Year End Date Document Type Document Period End Date Document Fiscal Year Focus Document Fiscal Period Focus Entity Filer Category Entity Small Business Entity Emerging Growth Company Entity Ex Transition Period Entity Common Stock, Shares Outstanding Statement of Financial Position [Abstract] Assets [Abstract] ASSETS Assets, Current [Abstract] Current assets Cash and Cash Equivalents, at Carrying Value Cash and cash equivalents Cash at beginning of period Cash at end of period Prepaid Expense, Current Prepaid expenses Expensed in subsequent payment Assets, Current Total current assets Total current assets Assets TOTAL ASSETS TOTAL ASSETS Liabilities and Equity [Abstract] LIABILITIES AND STOCKHOLDERS' EQUITY Liabilities, Current [Abstract] Current liabilities Accounts Payable and Accrued Liabilities, Current Accounts payable and accrued liabilities Accounts Payable, Related Parties, Current Accounts payable and accrued liabilities - related party Convertible Debt, Current Convertible note - related party, net of debt discount Carrying value Derivative Liability, Current Derivative liabilities Balance at December 31, 2017 Balance at September 30, 2018 Liabilities, Current Total current liabilities Total current liabilities Liabilities Total liabilities Stockholders' Equity Attributable to Parent [Abstract] Stockholders' equity Preferred Stock, Value, Issued Series A Preferred Shares: $0.001 par value, authorized 10,000; 2,000 shares issued and outstanding Common Stock, Value, Issued Common stock, $0.0001 par value: shares authorized 100,000,000;12,804,125 and 12,404,910 shares issued and outstanding at June 30, 2018 and December 31, 2017, respectively Common stock, $0.0001 par value: shares authorized 100,000,000; 12,826,853 and 12,404,910 shares issued and outstanding at September 30, 2018 and December 31, 2017, respectively Additional Paid in Capital Additional Paid-in Capital Retained Earnings (Accumulated Deficit) Accumulated deficit Stockholders' Equity Attributable to Parent Total stockholder's equity Total stockholder's equity Beinning balance Ending balance Liabilities and Equity TOTAL LIABILITIES & EQUITY (DEFICIT) TOTAL LIABILITIES & STOCKHOLDERS' EQUITY Preferred Stock, Par or Stated Value Per Share Preferred stock, par value Series A Preferred Shares, par value Preferred Stock, Shares Authorized Preferred stock, shares authorized Series A Preferred Shares, authorized Preferred Stock, Shares Issued Series A Preferred Shares, shares issued Preferred stock, shares issued Preferred Stock, Shares Outstanding Preferred stock, shares outstanding Series A Preferred Shares, shares outstanding Common Stock, Par or Stated Value Per Share Common stock, par value Common Stock, Shares Authorized Common stock, shares authorized Common Stock, Shares, Issued Common stock issued Common stock, shares issued Common Stock, Shares, Outstanding Common stock, shares outstanding Income Statement [Abstract] Revenues Net sales Operating Expenses [Abstract] Operating expenses: Research and Development Expense Research and development expenses Research and development costs Professional Fees Additional fees payment Professional fees General and Administrative Expense General and administrative expenses Operating Expenses Total operating expenses Operating Income (Loss) Income (loss) from operations Nonoperating Income (Expense) [Abstract] Other income (expense) Interest Expense Interest expense Interest expense Change in derivative liabilities Change in derivative liabilities Loss on change in fair value Nonoperating Income (Expense) Total Other income (expense) Net Income (Loss) Attributable to Parent Net loss Net loss for the period Net (loss) Earnings Per Share, Basic and Diluted Net (loss) per common shares (basic and diluted) Weighted Average Number of Shares Outstanding, Basic and Diluted Weighted average shares outstanding Basic and diluted Statement of Cash Flows [Abstract] Net Cash Provided by (Used in) Operating Activities [Abstract] Cash Flows From Operating Activities Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Adjustments to reconcile net loss to net cash provided from (used by) operating activities: Stock Awards Recorded As Research And Development Expense Stock awards recorded as advisory services The amount of stock awards recorded as research and development expense. Stock Option Granted And Recorded As Advisory Services Stock options granted and recorded as administrative expenses and advisory services The amount of stock option granted and recorded as advisory services. Accretion Expense Accretion of debt discount Increase (Decrease) in Derivative Liabilities Change in derivative liabilities Loss on change in fair value Increase (Decrease) in Operating Capital [Abstract] Changes in operating assets and liabilities: Increase (Decrease) in Prepaid Expense Prepaid expenses Increase (Decrease) in Other Accounts Payable and Accrued Liabilities Accounts payable and accrued liabilities Increase (Decrease) in Accounts Payable, Related Parties Accounts payable and accrued liabilities, related party Net Cash Provided by (Used in) Operating Activities Net cash provided (used by) operating activities Net Cash Provided by (Used in) Investing Activities [Abstract] Cash Flows From Investing Activities Net Cash Provided by (Used in) Investing Activities Net cash provided from (used by) investing activities Net Cash Provided by (Used in) Financing Activities [Abstract] Cash Flows From Financing Activities Proceeds from Convertible Debt Proceeds from convertible note Received proceeds totaling Proceeds from Issuance of Private Placement Proceeds from private placement Payments of Financing Costs Financing costs Net Cash Provided by (Used in) Financing Activities Net cash provided from financing activities Cash and Cash Equivalents, Period Increase (Decrease) Increase (decrease) in cash and cash equivalents Supplemental Cash Flow Information [Abstract] SUPPLEMENTAL DISCLOSURES Interest Paid, Net Interest paid Interest paid Income Taxes Paid Income taxes paid Description of Business and Basis of Presentation [Abstract] Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block] Description of Business and Basis of Presentation Summary of Significant Accounting Policies [Abstract] Significant Accounting Policies [Text Block] Summary of Significant Accounting Policies Going Concern [Abstract] Substantial Doubt about Going Concern [Text Block] Going Concern Convertible Note - Related Party and Derivative Liabilities [Abstract] Convertible Note Related Party And Derivative Liabilities [Text Block] Convertible Note - Related Party and Derivative Liabilities The entire disclosure for convertible note related party and derivative liabilities. License And Research Funding Agreements [Abstract] License And Research Funding Agreement [Text Block] License and Research Funding Agreements The entire disclosure for License and research funding agreement. Commitments [Abstract] Commitments Disclosure [Text Block] Commitments Stock Plan [Abstract] Disclosure of Compensation Related Costs, Share-based Payments [Text Block] Stock Plan Capital Stock [Abstract] Stockholders' Equity Note Disclosure [Text Block] Capital Stock Subsequent Events [Abstract] Subsequent Events [Text Block] Subsequent Events Basis of Accounting, Policy [Policy Text Block] Financial Statement Presentation Fiscal Period, Policy [Policy Text Block] Fiscal year end Use of Estimates, Policy [Policy Text Block] Use of Estimates Cash and Cash Equivalents, Policy [Policy Text Block] Cash Equivalents Research and Development Expense, Policy [Policy Text Block] Research and Development Costs Advertising Costs, Policy [Policy Text Block] Advertising and Marketing Costs Related Parties [Policy Text Block] Related parties Disclosure of accounting policy for related parties. Share-based Compensation, Option and Incentive Plans Policy [Policy Text Block] Stock-Based Compensation and Other Share-Based Payments Fair Value of Financial Instruments, Policy [Policy Text Block] Fair Value of Financial Instruments Warrants [Policy Text Block] Warrants Disclosure of accounting policy for warrants. Income Tax, Policy [Policy Text Block] Income taxes Earnings Per Share, Policy [Policy Text Block] Basic and Diluted Loss Per Share New Accounting Pronouncements, Policy [Policy Text Block] New Accounting Pronouncements Fair Value, Liabilities Measured on Recurring Basis [Table Text Block] Summary of the fair value of our derivative liabilities Schedule of Earnings Per Share, Basic and Diluted [Table Text Block] Schedule of potentially dilutive securities Convertible Debt [Table Text Block] Schedule of convertible notes Schedule Of Fair Value Of Conversion Feature [Table Text Block] Schedule of fair value of conversion feature Tabular disclosure of derivative liability fair value of conversion feature. Schedule of Derivative Liabilities at Fair Value [Table Text Block] Schedule of fair value at commitment and re-measurement dates derivative liabilities Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table Text Block] Schedule of stock award Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block] Schedule of fair value options assumptions Share-based Compensation, Stock Options, Activity [Table Text Block] Schedule of stock options Schedule Of Share Based Payment Award Stock Warrants Valuation Assumptions [Table Text Block] Schedule of fair value warrants assumptions Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock warrants, including, but not limited to: (a) expected term of share warrants and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions. Schedule Of Common Stock Purchase Warrants Outstanding [Table Text Block] Schedule of common stock purchase warrants were outstanding Tabular disclosure of common stock purchase warrants were outstanding. Fair Value Measurement Inputs and Valuation Techniques [Table] Fair Value, Hierarchy [Axis] Fair Value Hierarchy [Domain] Fair Value, Inputs, Level 1 [Member] Level 1 [Member] Fair Value, Inputs, Level 2 [Member] Level 2 [Member] Fair Value, Inputs, Level 3 [Member] Level 3 [Member] Fair Value Measurement Inputs and Valuation Techniques [Line Items] Summary Of Liabilities Measured At Fair Value On Recurring Basis [Abstract] Summary of liabilities measured at fair value on a recurring basis Financial Liabilities Fair Value Disclosure [Abstract] Liabilities Derivative Liability Derivative liabilities Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table] Antidilutive Securities [Axis] Antidilutive Securities, Name [Domain] Warrant [Member] Stock Purchase Warrants [Member] Warrant [Member] Stock purchase warrants [Member] Research Warrrants Shares [Member] Research Warrants at 3% of issued and outstanding shares [Member] Convertible Debt Securities [Member] Convertible Notes [Member] Class of Stock [Axis] Class of Stock [Domain] Series A Preferred Stock [Member] Series A Preferred shares [Member] Option Indexed to Issuer's Equity, Type [Axis] Option Indexed to Issuer's Equity, Type [Domain] Employee Stock Option [Member] Stock options, vested Stock options vested [Member] Stock Options Not Yet Vested [Member] Stock options not yet vested [Member] Stock Awards Not Yet Vested [Member] Stock awards not yet vested [Member] Stock awards are expected to vest [Member] Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Stock purchase warrants Potentially dilutive securities net loss per share Summary Of Significant Accounting Policies Textual [Abstract] Summary of Significant Accounting Policies (Textual) Marketing and Advertising Expense Advertising or marketing costs Research Warrants Issued And Outstanding Percentage Research warrants issued and outstanding, percentage Research warrants issued and outstanding percentage. Debt Instrument, Face Amount Face value of certain convertible notes Debt Instrument, Unamortized Discount Less: unamortized discount Unamortized discount Less: unamortized discount Derivative Addition Associated With Convertible Notes Derivative addition associated with convertible notes Derivative addition associated with convertible notes. Derivative, Loss on Derivative Loss on change in fair value Change in fair value Derivative [Table] Range [Axis] Range [Domain] Minimum [Member] Minimum [Member] Maximum [Member] Maximum [Member] Award Date [Axis] Award Date [Domain] Commitment Date [Member] Commitment Date [Member] Commitment date member. Derivative [Line Items] Fair Value Assumption Expected Dividend Rate Dividend yield Expected dividends Expected dividends to be paid to holders of the underlying shares or financial instruments (expressed as a percentage of the share or instrument's price). Fair Value Assumption Expected Volatility Rate Expected volatility Expected volatility Measure of dispersion, in percentage terms (for instance, the standard deviation or variance), for a given stock price. Fair Value Assumption Expected Term Expected life (years) Expected term Period the instrument, asset or liability is expected to be outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Fair Value Assumption Risk Free Interest Rate Risk-free interest rate Risk free interest rate Risk-free interest rate assumption used in valuing an instrument. Schedule of Related Party Transactions, by Related Party [Table] Related Party [Axis] Related Party [Domain] Cubesquare Llc [Member] CubeSquare, LLC [Member] Title of Individual [Axis] Relationship to Entity [Domain] President [Member] Ido Merfeld [Member] Related Party Transaction [Line Items] Convertible Note Related Party And Derivative Liabilitie Textual [Abstract] Convertible Note - Related Party and Derivative Liabilities (Textual) Equity Method Investment, Ownership Percentage Ownership percentage Debt Instrument, Interest Rate, Stated Percentage Interest rate per annum Debt Conversion, Description Conversion, description Debt Instrument, Maturity Date Maturity date Debt Instrument, Maturity Date, Description Maturity date, description Amortization of Debt Discount (Premium) Amortization of discount Debt Conversion, Original Debt, Due Date of Debt Debt instument due date License and Research Funding Agreement [Table] Indefinite-lived Intangible Assets [Axis] Indefinite-lived Intangible Assets, Major Class Name [Domain] Licensing Agreements [Member] License Agreement [Member] Ariel University [Member] EX-101.PRE 9 qron-20180930_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 10 R1.htm IDEA: XBRL DOCUMENT

Document and Entity Information - shares	9 Months Ended
Document and Entity Information - shares	Sep. 30, 2018	Nov. 14, 2018
Document and Entity Information [Abstract]
Entity Registrant Name	Qrons Inc.
Entity Central Index Key	0001689084
Trading Symbol	QRON
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Document Type	10-Q
Document Period End Date	Sep. 30, 2018
Document Fiscal Year Focus	2018
Document Fiscal Period Focus	Q3
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	true
Entity Ex Transition Period	false
Entity Common Stock, Shares Outstanding		12,849,581

XML 11 R2.htm IDEA: XBRL DOCUMENT

Condensed Balance Sheets (Unaudited) - USD ($)	Sep. 30, 2018	Dec. 31, 2017
Current assets
Cash and cash equivalents	$ 198,622	$ 57,767
Prepaid expenses	54,991	15,812
Total current assets	253,613	73,579
TOTAL ASSETS	253,613	73,579
Current liabilities
Accounts payable and accrued liabilities	14,267	14,141
Accounts payable and accrued liabilities - related party	2,915	1,410
Convertible note - related party, net of debt discount	25,000	6,665
Derivative liabilities	30,506	31,090
Total current liabilities	72,688	53,306
Total liabilities	72,688	53,306
Stockholders' equity
Series A Preferred Shares: $0.001 par value, authorized 10,000; 2,000 shares issued and outstanding	2	2
Common stock, $0.0001 par value: shares authorized 100,000,000; 12,826,853 and 12,404,910 shares issued and outstanding at September 30, 2018 and December 31, 2017, respectively	1,283	1,240
Additional Paid-in Capital	3,497,774	1,611,711
Accumulated deficit	(3,318,134)	(1,592,680)
Total stockholder's equity	180,925	20,273
TOTAL LIABILITIES & STOCKHOLDERS' EQUITY	$ 253,613	$ 73,579

XML 12 R3.htm IDEA: XBRL DOCUMENT

Condensed Balance Sheets (Unaudited) (Parenthetical) - $ / shares	Sep. 30, 2018	Dec. 31, 2017
Statement of Financial Position [Abstract]
Series A Preferred Shares, par value	$ 0.001	$ 0.001
Series A Preferred Shares, authorized	10,000	10,000
Series A Preferred Shares, shares issued	2,000	2,000
Series A Preferred Shares, shares outstanding	2,000	2,000
Common stock, par value	$ 0.0001	$ 0.0001
Common stock, shares authorized	100,000,000	100,000,000
Common stock, shares issued	12,826,853	12,404,910
Common stock, shares outstanding	12,826,853	12,404,910

XML 13 R4.htm IDEA: XBRL DOCUMENT

Condensed Statements of Operations (Unaudited) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2018	Sep. 30, 2017
Income Statement [Abstract]
Net sales
Operating expenses:
Research and development expenses	104,798	8,406	237,770	10,120
Professional fees	6,300	8,170	35,449	11,297
General and administrative expenses	423,216	31,643	1,432,980	47,252
Total operating expenses	534,314	48,219	1,706,199	68,669
Income (loss) from operations	(534,314)	(48,219)	(1,706,199)	(68,669)
Other income (expense)
Interest expense	(6,048)	(1,785)	(19,839)	(7,215)
Change in derivative liabilities	(2,979)	(47,954)	584	(47,954)
Total Other income (expense)	(9,027)	(49,739)	(19,255)	(55,169)
Net (loss)	$ (543,341)	$ (97,958)	$ (1,725,454)	$ (123,838)
Net (loss) per common shares (basic and diluted)	$ (0.04)	$ 0.00	$ (0.14)	$ 0.00
Weighted average shares outstanding Basic and diluted	12,807,584	11,552,000	12,744,561	11,544,293

XML 14 R5.htm IDEA: XBRL DOCUMENT

Condensed Statements of Cash Flows (Unaudited) - USD ($)	9 Months Ended
	Sep. 30, 2018	Sep. 30, 2017
Cash Flows From Operating Activities
Net loss	$ (1,725,454)	$ (123,838)
Adjustments to reconcile net loss to net cash provided from (used by) operating activities:
Stock awards recorded as advisory services	178,000
Stock options granted and recorded as administrative expenses and advisory services	1,183,106
Accretion of debt discount	18,335	6,599
Change in derivative liabilities	(584)	47,954
Changes in operating assets and liabilities:
Prepaid expenses	(39,179)
Accounts payable and accrued liabilities	126	6,059
Accounts payable and accrued liabilities, related party	1,505
Net cash provided (used by) operating activities	(384,145)	(63,226)
Cash Flows From Investing Activities
Net cash provided from (used by) investing activities
Cash Flows From Financing Activities
Proceeds from convertible note		15,000
Proceeds from private placement	525,000	32,000
Financing costs		(22,548)
Net cash provided from financing activities	525,000	24,452
Increase (decrease) in cash and cash equivalents	140,855	(38,774)
Cash at beginning of period	57,767	155,242
Cash at end of period	198,622	116,468
SUPPLEMENTAL DISCLOSURES
Interest paid
Income taxes paid

XML 15 R6.htm IDEA: XBRL DOCUMENT

Description of Business and Basis of Presentation	9 Months Ended
Description of Business and Basis of Presentation	Sep. 30, 2018
Description of Business and Basis of Presentation [Abstract]
Description of Business and Basis of Presentation	Note 1 – Description of Business and Basis of Presentation Organization and nature of business: Qrons Inc. ("Qrons" or the "Company") was incorporated under the laws of the State of Wyoming on August 22, 2016 under the name BioLabMart Inc. On July 6, 2017, the board of directors and a majority of the Company's shareholders approved an amendment to the Company's Articles of Incorporation to change the name of the Company from "BioLabMart Inc." to "Qrons Inc.". On August 8, 2017, the Company filed Amended Articles of Incorporation with the State of Wyoming to effectuate such name change. The Company's common stock was approved by the Financial Industry Regulatory Authority ("FINRA") for quotation on the OTC pink sheets under the symbol "BLMB" as of July 3, 2017. FINRA announced the Company's name change to Qrons Inc. on its Daily List on August 9, 2017. The new name and symbol change to "QRON" for the OTC Market was effective August 10, 2017. The Company is a preclinical stage biotechnology company developing advanced cell-based solutions to combat neuronal injuries and achieve a breakthrough in the treatment of traumatic brain injuries ("TBIs"), an unmet medical need. We believe that our approach is pushing the boundaries of science by using the latest advances in molecular biology and chemistry. The Company collaborates with universities and scientists in the fields of regenerative medicine, tissue engineering and 3D printable hydrogels to develop a treatment that integrates proprietary, engineered mesenchymal stem cells, 3D printable implant, smart materials and a novel delivery system. Our headquarters are located at 777 Brickell Avenue, Suite 500, Miami, Florida 33131. Ariel Agreements On December 14, 2016, the Company entered into a license and research funding agreement ("License Agreement") with Ariel Scientific Innovations Ltd., formerly known as Ariel University R&D Co., Ltd., ("Ariel"), a wholly owned subsidiary of Ariel University, based in Ariel, Israel. Under the terms of the License Agreement, Professor Danny Baranes, the principal investigator and his research team will carry out further research relating to cell treatment with conditioned medium for neuronal tissue regeneration and repair. In consideration for payments under the License Agreement, the Company received an exclusive worldwide royalty- bearing license in Ariel patents and know-how to develop and commercialize products based on or incorporating conditioned medium for neuronal tissue regeneration and/or repair, resulting from Ariel's research or technology or the Company's research funding (the "Products). Under the License Agreement, the Company is required to use its best efforts to develop and commercialize the Products in accordance with development milestones set forth in the Agreement. In lieu of extending the research financing and research period under the License Agreement beyond the initial 12 months, on December 14, 2017, the Company entered into a 12-month services agreement with Ariel (the "Services Agreement") pursuant to which a team at Ariel under the direction of Prof. Danny Baranes will conduct molecular biology research activities involving the testing of implant materials for the Company. On April 12, 2018, the Services Agreement was amended to provide for additional services as the Company may request. On March 6, 2018, the Company entered into an additional services agreement with Ariel for the services of Professor Gadi Turgeman and his neurobiology research team in their lab. Dartmouth Agreements On October 17, 2017, the Company entered into an Option Agreement (the "Agreement") with the Trustees of Dartmouth College which provides for, among other things, the grant to the Company of a one-year exclusive option to negotiate a worldwide, royalty bearing, exclusive license with Dartmouth for 3D printable materials in the field of human and animal health. During the option period, the Company agreed to use all commercially reasonable resources to evaluate the intellectual property and provide quarterly milestone reports and a commercialization plan upon exercise of the option. Pursuant to the Agreement, the Company agreed to finance the prosecution of patents by Dartmouth to protect its intellectual property. Further, the Agreement provides for the payment by the Company of an option fee and certain license fees and royalty payments based upon the Company's product sales, as part of a final negotiated license agreement. The Company exercised its option on March 26, 2018 to negotiate definitive license terms, as it continues further evaluation and research. On July 12, 2018, the Company entered into a one-year sponsored research agreement (the "Sponsored Research Agreement"), with the Trustees of Dartmouth College ("Dartmouth") pursuant to which the Company will support and fund the cost of research conducted by Dartmouth of mutual interest to the parties in accordance with the Agreement. Intellectual property invented or developed solely by a party shall be owned by such party and intellectual property jointly invented or developed shall be jointly owned. Dartmouth shall retain an irrevocable worldwide right to use intellectual property owned by it resulting from its research under the Agreement on a non-exclusive royalty-free basis for research and education purposes. The Agreement may be terminated earlier than one year upon written agreement of the parties, a material breach which is not cured within 30 days of notice thereof, if Professor Ke no longer conducts the research under the Agreement and a successor acceptable to both parties is not available, or in the event of an unauthorized assignment of the Company's rights and obligations under the Agreement.

XML 16 R7.htm IDEA: XBRL DOCUMENT

Summary of Significant Accounting Policies

9 Months Ended

Sep. 30, 2018

Summary of Significant Accounting Policies [Abstract]

Summary of Significant Accounting Policies

Note 2 – Summary of Significant Accounting Policies

Financial Statement Presentation: The accompanying unaudited condensed financial statements of the Company have been prepared in accordance with the rules and regulations of the Securities and Exchange Commission(the "SEC"), including the instructions to Form 10-Q and Regulation S-X. Certain information and note disclosures normally included in financial statements prepared in accordance with generally accepted accounting principles in the United States of America ("U.S. GAAP"), have been condensed or omitted from these statements pursuant to such rules and regulations and, accordingly, they do not include all the information and notes necessary for comprehensive financial statements and should be read in conjunction with our audited financial statements included in our Annual Report on Form 10-K for the year ended December 31, 2017.

Fiscal year end: The Company has selected December 31 as its fiscal year end.

Cash Equivalents: The Company considers all highly liquid investments with maturities of 90 days or less from the date of purchase to be cash equivalents.

Fair Value of Financial Instruments

Level 1 – Quoted prices in active markets for identical assets or liabilities.

The following table provides a summary of the fair value of our derivative liabilities as of September 30, 2018 and December 31, 2017:

	Fair value measurements on a recurring basis
	Level 1			Level 2			Level 3
As of September 30, 2018:
Liabilities
Derivative liabilities		$	-		$	-		$	30,506

As of December 31, 2017:
Liabilities
Derivative liabilities		$	-		$	-		$	31,090

The table below reflects the potentially dilutive securities at each reporting period which have been excluded from the computation of diluted net loss per share:

	September 30, 2018		September 30, 2017
Stock purchase warrants		52,000		566,000
Research Warrants at 3% of issued and outstanding shares		384,806		-
Convertible Notes		28,778		32,178
Series A Preferred shares		700		700
Stock options vested		30,000		-
Stock options not yet vested		690,000		-
Stock awards not yet vested		290,000		-
		1,476,284		598,878

XML 17 R8.htm IDEA: XBRL DOCUMENT

Going Concern	9 Months Ended
Going Concern	Sep. 30, 2018
Going Concern [Abstract]
Going Concern	Note 3 – Going Concern The Company has experienced net losses to date, and it has not generated revenue from operations. While the Company has recently raised proceeds, it does not believe its resources will be sufficient to meet its operating and capital needs beyond the fourth quarter of 2018. The Company expects it will require additional capital to fully implement the scope of its proposed business operations, which raises substantial doubt about its ability to continue as a going concern. The Company will have to continue to rely on equity and debt financing. There can be no assurance that financing, whether debt or equity, will always be available to the Company in the amount required at any particular time or for any particular period or, if available, that it can be obtained on favorable terms. The financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts, or amount and classification of liabilities that might cause results from this uncertainty.

XML 18 R9.htm IDEA: XBRL DOCUMENT

Convertible Note - Related Party and Derivative Liabilities

9 Months Ended

Sep. 30, 2018

Convertible Note - Related Party and Derivative Liabilities [Abstract]

Convertible Note - Related Party and Derivative Liabilities

Note 4 – Convertible Note – Related Party and Derivative Liabilities

The carrying value of these convertible notes is as follows:

	September 30, 2018		December 31, 2017
Face value of certain convertible notes	$	25,000	$	25,000
Less: unamortized discount		-		(18,335	)
Carrying value	$	25,000	$	6,665

As a result of the application of ASC No. 815 in the periods ended September 30, 2018 and December 31, 2017 the fair value of the conversion feature is summarized as follows:

Balance at December 31, 2017	$	31,090
Derivative addition associated with convertible notes		-
Change in fair value		(584	)
Balance at September 30, 2018	$	30,506

The fair value at the commitment and re-measurement dates for the Company's derivative liabilities were based upon the following management assumptions as of September 30, 2018 and commitment date:

	Commitment Date		September 30, 2018		December 31, 2017
Expected dividends		0		0		0
Expected volatility	101% ~103%		77% ~ 83%		110% ~ 115%
Expected term	0.92 ~ 1 year		0.92 ~0.99 year		0.67 ~0.74 year
Risk free interest rate		1.33%		2.59%	1.53% ~ 1.65%

XML 19 R10.htm IDEA: XBRL DOCUMENT

License and Research Funding Agreements

9 Months Ended

Sep. 30, 2018

License And Research Funding Agreements [Abstract]

License and Research Funding Agreements

Note 5 – License and Research Funding Agreements

-	Upon successful clinical FDA Phase II completion - $130,000; and
-	Upon successful clinical FDA Phase III completion - $390,000

XML 20 R11.htm IDEA: XBRL DOCUMENT

Commitments

9 Months Ended

Sep. 30, 2018

Commitments [Abstract]

Commitments

Note 6 – Commitments

(1)	Service Agreement with Ariel - Prof. Danny Baranes

(2)	Service Agreement with Ariel - Dr. Gadi Turgeman

The Services Agreement may be terminated by the non-breaching party upon a material breach that is not cured within 30 days or by the Company upon thirty days' prior written notice to Ariel. Ariel must keep confidential information of the Company confidential for six years after the term of the Services Agreement.

(3)	Science Advisory Board Member Consulting Agreements (the "Agreements")

(4)	Business Advisory Board Agreement

(5)	Investor Relations Agreement

(6)	Sponsored Research Agreement

XML 21 R12.htm IDEA: XBRL DOCUMENT

Stock Plan

9 Months Ended

Sep. 30, 2018

Stock Plan [Abstract]

Stock Plan

Note 7 – Stock Plan

2016 Stock Option and Stock Award

Stock Awards:

	For the nine months ended September 30, 2018		For the year ended December 31, 2017
Number of shares vested in period		10,000		290,000
Fair market value per share	$	2.80	$	2.80
Stock based compensation recognized	$	28,000	$	812,000

Stock Options:

(a)	Stock Options granted to Science Advisors:

On April 16, 2018, under the 2016 Stock Option and Award Plan, the Board awarded a Science Advisor, the following three-year stock options: (i) an option to purchase 10,000 shares of common stock, exercisable on April 16, 2018 at an exercise price of $2.00 per share and (ii) an option to purchase 10,000 shares of common stock exercisable on April 16, 2019 at an exercise price of $2.00 per share, and (iii) an option to purchase 10,000 shares of common stock exercisable on April 16, 2020 at an exercise price of $2.00 per share, provided the advisor is still providing services to the Company. provided the advisor is still providing services to the Company.

As of September 30, 2018, total unrecognized compensation remaining to be recognized in future periods totaled $92,671.

(b)	Stock Options granted to Officers:

During the year ended December 31, 2017, total recognized compensation of $106,029 was recorded as general and administrative expenses.

During the three and nine months ended September 30, 2018, total recognized compensation of $353,430 and $1,060,290, respectively, was recorded as general and administrative expenses.

	Measurement date
Dividend yield		0%
Expected volatility	114.69 ~ 126.34%
Risk-free interest rate	1.79% ~ 2.68%
Expected life (years)	3 ~ 5
Stock Price	$	2.00 ~ 2.80
Exercise Price	$	0.40 ~ 2.00

A summary of the activity for the Company's stock options for the nine-month period ended September 30, 2018 and for the year ended December 31, 2017, is as follows:

	September 30, 2018				December 31, 2017
			Weighted Average				Weighted Average
	Shares		Exercise Price		Shares		Exercise Price
Outstanding, beginning of period		670,000	$	1.93		-	$	-
Granted		50,000	$	2.00		670,000	$	1.93
Exercised		-	$	-		-	$	-
Canceled		-	$	-		-	$	-
Outstanding, end of period		720,000	$	1.93		670,000	$	1.93
Options exercisable, end of period		30,000	$	2.00		13,334	$	2.00
Options expected to vest, end of period		690,000	$	1.93		656,666	$	1.89
Weighted average fair value of options granted			$	2.30			$	2.36

XML 22 R13.htm IDEA: XBRL DOCUMENT

Capital Stock

9 Months Ended

Sep. 30, 2018

Capital Stock [Abstract]

Capital Stock

Note 8 – Capital Stock

Authorized:

The Company has authorized 100,000,000 shares of common stock, par value $0.0001 and 10,000 shares of preferred stock which is designated as Series A Preferred Stock, par value $0.001.

Series A Preferred Stock:

There was a total of 2,000 shares of Series A Preferred Stock issued and outstanding as at September 30, 2018 and December 31, 2017.

Common Stock issuances during the nine months ended September 30, 2018:

On January 23, 2018, the Company issued 10,000 shares for advisory services (Note 6(4)). The shares were valued at fair market value on the date of issuance for a total of $28,000 or $2.80 per share.

Common Stock issuances as of December 31, 2017:

During the year ended December 31, 2017, the Company received aggregate proceeds of $32,000 in private placement subscriptions for a total of 128,000 shares.

Share Purchase Warrants

	Measurement date
Dividend yield		0%
Expected volatility	97.90~119.33%
Risk-free interest rate	1.47~1.60%
Expected life (years)	2.71~2.92
Stock Price	$	0.25
Exercise Price	$	0.40

As of September 30, 2018, and December 31, 2017, the following common stock purchase warrants were outstanding:

	Warrants (1)			Weighted Average Exercise Price
Outstanding – December 31, 2016		502,000		$	0.40
Granted		64,000			0.40
Forfeited/Canceled		-			-
Exercised		512,000	(2)		0.40
Outstanding – December 31, 2017		54,000			0.40
Granted		-			-
Forfeited/Canceled		-			-
Exercised		2,000	(3)		0.40
Outstanding – September 30, 2018		52,000		$	0.40

(1) Each two shares of common stock purchased under the private placement provides for one warrant to acquire an additional share of common stock together with the payment of $0.40.

(2) During the year ended December 31, 2017, investors exercised 512,000 share purchase warrants and received 442,960 underlying shares for exercise on a cashless basis.

(3) During the nine-month period ended September 30, 2018, investors exercised 2,000 share purchase warrants and received 1,715 underlying shares for exercise on a cashless basis.

XML 23 R14.htm IDEA: XBRL DOCUMENT

Subsequent Events	9 Months Ended
Subsequent Events	Sep. 30, 2018
Subsequent Events [Abstract]
Subsequent Events	Note 9 – Subsequent Events On October 8, 2018 the Company sold 22,728 shares of its common stock to an investor and raised $25,000 pursuant to a subscription agreement in a private placement offering. The proceeds of the offering will be used for research and general corporate purposes. The Company has evaluated subsequent events from the balance sheet date through the date that the financial statements were issued and determined that there are no additional subsequent events to disclose.

XML 24 R15.htm IDEA: XBRL DOCUMENT

Summary of Significant Accounting Policies (Policies)

9 Months Ended

Sep. 30, 2018

Summary of Significant Accounting Policies [Abstract]

Financial Statement Presentation

Financial Statement Presentation: The accompanying unaudited condensed financial statements of the Company have been prepared in accordance with the rules and regulations of the Securities and Exchange Commission(the "SEC"), including the instructions to Form 10-Q and Regulation S-X. Certain information and note disclosures normally included in financial statements prepared in accordance with generally accepted accounting principles in the United States of America ("U.S. GAAP"), have been condensed or omitted from these statements pursuant to such rules and regulations and, accordingly, they do not include all the information and notes necessary for comprehensive financial statements and should be read in conjunction with our audited financial statements included in our Annual Report on Form 10-K for the year ended December 31, 2017.

Fiscal year end

Fiscal year end: The Company has selected December 31 as its fiscal year end.

Use of Estimates

Cash Equivalents

Cash Equivalents: The Company considers all highly liquid investments with maturities of 90 days or less from the date of purchase to be cash equivalents.

Research and Development Costs

Advertising and Marketing Costs

Fair Value of Financial Instruments

Level 1 – Quoted prices in active markets for identical assets or liabilities.

The following table provides a summary of the fair value of our derivative liabilities as of September 30, 2018 and December 31, 2017:

	Fair value measurements on a recurring basis
	Level 1			Level 2			Level 3
As of September 30, 2018:
Liabilities
Derivative liabilities		$	-		$	-		$	30,506

As of December 31, 2017:
Liabilities
Derivative liabilities		$	-		$	-		$	31,090

Warrants

Income taxes

Basic and Diluted Loss Per Share

The table below reflects the potentially dilutive securities at each reporting period which have been excluded from the computation of diluted net loss per share:

	September 30, 2018		September 30, 2017
Stock purchase warrants		52,000		566,000
Research Warrants at 3% of issued and outstanding shares		384,806		-
Convertible Notes		28,778		32,178
Series A Preferred shares		700		700
Stock options vested		30,000		-
Stock options not yet vested		690,000		-
Stock awards not yet vested		290,000		-
		1,476,284		598,878

New Accounting Pronouncements

XML 25 R16.htm IDEA: XBRL DOCUMENT

Summary of Significant Accounting Policies (Tables)

9 Months Ended

Sep. 30, 2018

Summary of Significant Accounting Policies [Abstract]

Summary of the fair value of our derivative liabilities

	Fair value measurements on a recurring basis
	Level 1			Level 2			Level 3
As of September 30, 2018:
Liabilities
Derivative liabilities		$	-		$	-		$	30,506

As of December 31, 2017:
Liabilities
Derivative liabilities		$	-		$	-		$	31,090

Schedule of potentially dilutive securities

	September 30, 2018		September 30, 2017
Stock purchase warrants		52,000		566,000
Research Warrants at 3% of issued and outstanding shares		384,806		-
Convertible Notes		28,778		32,178
Series A Preferred shares		700		700
Stock options vested		30,000		-
Stock options not yet vested		690,000		-
Stock awards not yet vested		290,000		-
		1,476,284		598,878

XML 26 R17.htm IDEA: XBRL DOCUMENT

Convertible Note - Related Party and Derivative Liabilities (Tables)

9 Months Ended

Sep. 30, 2018

Convertible Note - Related Party and Derivative Liabilities [Abstract]

Schedule of convertible notes

	September 30, 2018		December 31, 2017
Face value of certain convertible notes	$	25,000	$	25,000
Less: unamortized discount		-		(18,335	)
Carrying value	$	25,000	$	6,665

Schedule of fair value of conversion feature

Balance at December 31, 2017	$	31,090
Derivative addition associated with convertible notes		-
Change in fair value		(584	)
Balance at September 30, 2018	$	30,506

Schedule of fair value at commitment and re-measurement dates derivative liabilities

	Commitment Date		September 30, 2018		December 31, 2017
Expected dividends		0		0		0
Expected volatility	101% ~103%		77% ~ 83%		110% ~ 115%
Expected term	0.92 ~ 1 year		0.92 ~0.99 year		0.67 ~0.74 year
Risk free interest rate		1.33%		2.59%	1.53% ~ 1.65%

XML 27 R18.htm IDEA: XBRL DOCUMENT

Stock Plan (Tables)

9 Months Ended

Sep. 30, 2018

Stock Plan [Abstract]

Schedule of stock award

	For the nine months ended September 30, 2018		For the year ended December 31, 2017
Number of shares vested in period		10,000		290,000
Fair market value per share	$	2.80	$	2.80
Stock based compensation recognized	$	28,000	$	812,000

Schedule of fair value options assumptions

	Measurement date
Dividend yield		0%
Expected volatility	114.69 ~ 126.34%
Risk-free interest rate	1.79% ~ 2.68%
Expected life (years)	3 ~ 5
Stock Price	$	2.00 ~ 2.80
Exercise Price	$	0.40 ~ 2.00

Schedule of stock options

	September 30, 2018				December 31, 2017
			Weighted Average				Weighted Average
	Shares		Exercise Price		Shares		Exercise Price
Outstanding, beginning of period		670,000	$	1.93		-	$	-
Granted		50,000	$	2.00		670,000	$	1.93
Exercised		-	$	-		-	$	-
Canceled		-	$	-		-	$	-
Outstanding, end of period		720,000	$	1.93		670,000	$	1.93
Options exercisable, end of period		30,000	$	2.00		13,334	$	2.00
Options expected to vest, end of period		690,000	$	1.93		656,666	$	1.89
Weighted average fair value of options granted			$	2.30			$	2.36

XML 28 R19.htm IDEA: XBRL DOCUMENT

Capital Stock (Tables)

9 Months Ended

Sep. 30, 2018

Capital Stock [Abstract]

Schedule of fair value warrants assumptions

	Measurement date
Dividend yield		0%
Expected volatility	97.90~119.33%
Risk-free interest rate	1.47~1.60%
Expected life (years)	2.71~2.92
Stock Price	$	0.25
Exercise Price	$	0.40

Schedule of common stock purchase warrants were outstanding

	Warrants (1)			Weighted Average Exercise Price
Outstanding – December 31, 2016		502,000		$	0.40
Granted		64,000			0.40
Forfeited/Canceled		-			-
Exercised		512,000	(2)		0.40
Outstanding – December 31, 2017		54,000			0.40
Granted		-			-
Forfeited/Canceled		-			-
Exercised		2,000	(3)		0.40
Outstanding – September 30, 2018		52,000		$	0.40

(1) Each two shares of common stock purchased under the private placement provides for one warrant to acquire an additional share of common stock together with the payment of $0.40.

(2) During the year ended December 31, 2017, investors exercised 512,000 share purchase warrants and received 442,960 underlying shares for exercise on a cashless basis.

(3) During the nine-month period ended September 30, 2018, investors exercised 2,000 share purchase warrants and received 1,715 underlying shares for exercise on a cashless basis.

XML 29 R20.htm IDEA: XBRL DOCUMENT

Summary of Significant Accounting Policies (Details) - USD ($)	Sep. 30, 2018	Dec. 31, 2017
Level 1 [Member]
Liabilities
Derivative liabilities
Level 2 [Member]
Liabilities
Derivative liabilities
Level 3 [Member]
Liabilities
Derivative liabilities	$ 30,506	$ 31,090

XML 30 R21.htm IDEA: XBRL DOCUMENT

Summary of Significant Accounting Policies (Details 1) - shares	9 Months Ended
	Sep. 30, 2018	Sep. 30, 2017
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Potentially dilutive securities net loss per share	1,476,284	598,878
Stock options vested [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Potentially dilutive securities net loss per share	30,000
Stock options not yet vested [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Potentially dilutive securities net loss per share	690,000
Stock awards not yet vested [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Potentially dilutive securities net loss per share	290,000
Series A Preferred shares [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Potentially dilutive securities net loss per share	700	700
Stock purchase warrants [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Potentially dilutive securities net loss per share	52,000	566,000
Research Warrants at 3% of issued and outstanding shares [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Potentially dilutive securities net loss per share	384,806
Convertible Notes [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Potentially dilutive securities net loss per share	28,778	32,178

XML 31 R22.htm IDEA: XBRL DOCUMENT

Summary of Significant Accounting Policies (Details Textual) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2018	Sep. 30, 2017
Summary of Significant Accounting Policies (Textual)
Research and development costs	$ 104,798	$ 8,406	$ 237,770	$ 10,120
Advertising or marketing costs			$ 48,832	$ 15,657
Research warrants issued and outstanding, percentage			3.00%

XML 32 R23.htm IDEA: XBRL DOCUMENT

Convertible Note - Related Party and Derivative Liabilities (Details) - USD ($)	Sep. 30, 2018	Dec. 31, 2017
Convertible Note - Related Party and Derivative Liabilities [Abstract]
Face value of certain convertible notes	$ 25,000	$ 25,000
Less: unamortized discount		(18,335)
Carrying value	$ 25,000	$ 6,665

XML 33 R24.htm IDEA: XBRL DOCUMENT

Convertible Note - Related Party and Derivative Liabilities (Details 1)	9 Months Ended
	Sep. 30, 2018 USD ($)
Convertible Note - Related Party and Derivative Liabilities [Abstract]
Balance at December 31, 2017	$ 31,090
Derivative addition associated with convertible notes
Change in fair value	(584)
Balance at September 30, 2018	$ 30,506

XML 34 R25.htm IDEA: XBRL DOCUMENT

Convertible Note - Related Party and Derivative Liabilities (Details 2)	9 Months Ended	12 Months Ended
	Sep. 30, 2018	Dec. 31, 2017
Derivative [Line Items]
Expected dividends	0.00%	0.00%
Risk free interest rate	2.59%
Commitment Date [Member]
Derivative [Line Items]
Expected dividends	0.00%
Risk free interest rate	1.33%
Minimum [Member]
Derivative [Line Items]
Expected volatility	77.00%	110.00%
Expected term	11 months 1 day	8 months 2 days
Risk free interest rate		1.53%
Minimum [Member] \| Commitment Date [Member]
Derivative [Line Items]
Expected volatility	101.00%
Expected term	11 months 1 day
Maximum [Member]
Derivative [Line Items]
Expected volatility	83.00%	115.00%
Expected term	11 months 26 days	8 months 26 days
Risk free interest rate		1.65%
Maximum [Member] \| Commitment Date [Member]
Derivative [Line Items]
Expected volatility	103.00%
Expected term	1 year

XML 35 R26.htm IDEA: XBRL DOCUMENT

Convertible Note - Related Party and Derivative Liabilities (Details Textual) - USD ($)				1 Months Ended	3 Months Ended		9 Months Ended
	Sep. 09, 2018	Sep. 28, 2017	Sep. 27, 2017	Sep. 01, 2016	Jun. 30, 2018	Jun. 30, 2017	Sep. 30, 2018	Sep. 30, 2017
Convertible Note - Related Party and Derivative Liabilities (Textual)
Received proceeds totaling								$ 15,000
Amortization of discount					$ 5,541	$ 1,571	$ 18,335	$ 6,599
CubeSquare, LLC [Member]
Convertible Note - Related Party and Derivative Liabilities (Textual)
Received proceeds totaling			$ 15,000	$ 10,000
Interest rate per annum			8.00%	8.00%
Conversion, description			Any portion of the principal and unpaid interest under the note is convertible at any time at the option of CubeSquare into shares of common stock of the Company at a conversion price equal to a 50% discount to the average of the five lowest trading prices during the previous twenty trading days prior to the date of the notice of conversion from CubeSquare.	(i) $0.0625 per share if the Company's shares are not trading on a public market and; (ii) in the event the Company's shares are listed for trading on a public market, the conversion price shall be equal to a 50% discount to the average of the five lowest trading prices during the previous twenty trading days prior to the date of the notice of conversion from the lender.
Maturity date				Sep. 01, 2017
Maturity date, description	Note 2 was amended to extend the maturity date until September 27, 2019.	Note 1 to extend the maturity date from September 1, 2017 to September 1, 2018 and on September 9, 2018, the Company further amended Note 1 to extend the maturity date to September 1, 2019, under the same terms and conditions.
Debt instument due date			Sep. 27, 2018
CubeSquare, LLC [Member] \| President [Member]
Convertible Note - Related Party and Derivative Liabilities (Textual)
Ownership percentage				25.00%

XML 36 R27.htm IDEA: XBRL DOCUMENT

License and Research Funding Agreements (Details) - USD ($)				1 Months Ended	3 Months Ended		9 Months Ended		12 Months Ended
	Mar. 06, 2018	Dec. 13, 2017	Dec. 14, 2016	Apr. 23, 2018	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2018	Sep. 30, 2017	Dec. 31, 2017
License and Research Funding Agreements (Textual)
Research and development costs					$ 104,798	$ 8,406	$ 237,770	$ 10,120
Shares issued for advisory services, value				75,000
License and research funding agreement compensation paid, description	The Company entered into an additional service agreement with Ariel for the services of Professor Gadi Turgeman and his stem cells research team in their lab pursuant to which the Company paid Ariel $20,580 on each of March 19, 2018 and August 22, 2018.						The Company paid Ariel (i) $17,250 on December 19, 2017 and an additional $17,250 on April 26, 2018. On April 12, 2018, the Services Agreement was amended to provide for the payment by the Company of an additional monthly fee, commencing March 2018, of up to 8,000 Israeli shekels as compensation for additional costs which the Company may request.
Ariel University [Member]
License and Research Funding Agreements (Textual)
Shares issued for advisory services, value		119,950
Shares issued, value		$ 335,860
Shares issued, percentage		1.00%
License Agreement [Member]
License and Research Funding Agreements (Textual)
Total amount of fund for research during research period			$ 100,000
Warrant exercisable percentage			4.00%
Payments of completion of milestone events, description			Upon successful clinical FDA Phase II completion - $130,000; and Upon successful clinical FDA Phase III completion - $390,000
Research and development costs									$ 1,179,777
Aforementioned funding amount									119,950
Stock based compensation									812,000
Payments of completion of milestone events due			6 months
Shares issued, value									$ 335,860

XML 37 R28.htm IDEA: XBRL DOCUMENT

Commitments (Details) - USD ($)					1 Months Ended			9 Months Ended	12 Months Ended
Commitments (Details) - USD ($)	Oct. 08, 2018	Jul. 12, 2018	Jun. 23, 2018	Apr. 12, 2018	Apr. 23, 2018	Jan. 23, 2018	Nov. 15, 2017	Sep. 30, 2018	Dec. 31, 2017	Aug. 22, 2018	Aug. 15, 2018	May 01, 2018	Apr. 26, 2018	Apr. 16, 2018	Mar. 19, 2018	Dec. 14, 2017
Commitments (Textual)
Compensation for the services provided									$ 17,250			$ 17,250	$ 17,250
Compensation cost									$ 1,438
Service agreement payment, description				The Company of an additional monthly fee, commencing March 2018, of up to 8,000 Israeli shekels as compensation for additional costs which the Company may request.
Consulting fee					$ 5,000
Investor relations agreement, description			The Company gave notice of rescission of the agreement to such firm and requested the return of the consulting fee paid and the 75,000 shares of common stock. As a result, the Company has not recorded any fees for services rendered past June 23, 2018. A total of $10,000 representing April 2018 and May 2018 monthly consulting fees is reflected in the statement of operations and a total of $150,000, the fair market value of the issued shares, was expensed on issue.		The Company issued 75,000 shares of its common stock in respect of an investor relations services agreement which was rescinded on June 23, 2018 (Note 6(5)). The shares were valued at the fair market value on the date of issuance for a total of $150,000, or $2.00 per share.
Paid for additional fees								$ 14,082
Issuance of common stock payable					75,000
Service Agreement with Ariel [Member]
Commitments (Textual)
Compensation for the services provided										$ 20,580					$ 20,580	$ 17,250
Compensation cost								25,875
Prepaid expenses								41,160
Prepaid expensed during period								24,010
Outstanding expenses								17,150
Sponsored Research Agreement [Member]
Commitments (Textual)
Prepaid expenses								36,293
Prepaid expensed during period								9,073
Outstanding expenses								$ 27,220
Sponsored research agreement, description		The Company entered into a one-year sponsored research agreement (the "Sponsored Research Agreement"), with the Trustees of Dartmouth College ("Dartmouth") pursuant to which the Company will support and fund the cost of research conducted by Dartmouth of mutual interest to the parties in accordance with the Agreement. Intellectual property invented or developed solely by a party shall be owned by such party and intellectual property jointly invented or developed shall be jointly owned. Dartmouth shall retain an irrevocable worldwide right to use intellectual property owned by it resulting from its research under the Agreement on a non-exclusive royalty-free basis for research and education purposes. The Company funded $36,293 on August 20, 2018 and will fund additional $18,147 by December 1, 2018 and $18,146 by June 1, 2019, respectively.
2016 Stock Option and Award Plan [Member]
Commitments (Textual)
Advisors are granted the option						10,000	20,000
Stock option and advisor granted							30,000				20,000			30,000
Subsequent Event [Member] \| Service Agreement with Ariel [Member]
Commitments (Textual)
Compensation cost	$ 7,187

XML 38 R29.htm IDEA: XBRL DOCUMENT

Stock Plan (Details) - USD ($)	9 Months Ended	12 Months Ended
Stock Plan (Details) - USD ($)	Sep. 30, 2018	Dec. 31, 2017
Stock Plan [Abstract]
Number of shares vested in period	10,000	290,000
Fair market value per share	$ 2.80	$ 2.80
Stock based compensation recognized	$ 28,000	$ 812,000

XML 39 R30.htm IDEA: XBRL DOCUMENT

Stock Plan (Details 1) - Stock Options [Member] - Measurement Date [Member]	9 Months Ended
	Sep. 30, 2018 $ / shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Dividend yield	0.00%
Exercise Price, Minimum	$ 0.40
Exercise Price, Maximum	$ 2.00
Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected volatility	114.69%
Risk-free interest rate	1.79%
Expected life (years)	3 years
Stock Price	$ 2.00
Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected volatility	126.34%
Risk-free interest rate	2.68%
Expected life (years)	5 years
Stock Price	$ 2.80

XML 40 R31.htm IDEA: XBRL DOCUMENT

Stock Plan (Details 2) - $ / shares	9 Months Ended	12 Months Ended
Stock Plan (Details 2) - $ / shares	Sep. 30, 2018	Dec. 31, 2017
Stock Plan [Abstract]
Shares Outstanding, beginning of period	670,000
Shares, Granted	50,000	670,000
Shares, Exercised
Shares, Canceled
Shares Outstanding, end of period	720,000	670,000
Shares Options exercisable, end of period	30,000	13,334
Shares, Options expected to vest, end of period	690,000	656,666
Weighted Average Shares Exercise Price, Outstanding, beginning of period	$ 1.93
Weighted Average Shares Exercise Price, Granted	2.00	1.93
Weighted Average Shares Exercise Price, Exercised
Weighted Average Exercise Price, Canceled
Weighted Average Shares Exercise Price, Outstanding, end of period	1.93	1.93
Weighted Average Exercise Price, Options exercisable, end of period	2.00	2.00
Weighted Average Exercise Price, Options expected to vest, end of period	1.93	1.89
Weighted Average Exercise Price, Weighted average fair value of options granted	$ 2.30	$ 2.36

XML 41 R32.htm IDEA: XBRL DOCUMENT

Stock Plan (Details Textual) - USD ($)					1 Months Ended		3 Months Ended	9 Months Ended	12 Months Ended
Stock Plan (Details Textual) - USD ($)	Aug. 15, 2018	Dec. 14, 2017	Dec. 04, 2017	Dec. 14, 2016	Apr. 16, 2018	Nov. 15, 2017	Sep. 30, 2018	Sep. 30, 2018	Dec. 31, 2017	Jan. 23, 2018
Stock Plan (Textual)
Total unrecognized compensation remaining to be recognized in future periods								$ 92,671
General and administrative expenses [Member]
Stock Plan (Textual)
Stock-based compensation							$ 48,078	122,816	$ 29,000
Stock Options granted to Officers [Member]
Stock Plan (Textual)
Total unrecognized compensation remaining to be recognized in future periods								246,755
Weighted average exercise price			$ 2
Shares of common stock under certain vesting terms			5 years
Vest and exercisable date			Dec. 04, 2018
Granted an option to purchase shares of common stock			300,000
Stock Options granted to Officers [Member] \| General and administrative expenses [Member]
Stock Plan (Textual)
Stock-based compensation							$ 353,430	$ 1,060,290	$ 106,029
2016 Stock Option and Award Plan [Member]
Stock Plan (Textual)
Reserved shares for issuance				10,000,000
Stock award										10,000
Description of services agreement	Under the 2016 Stock Option and Award Plan, the Board granted a Science Advisor an option to purchase an aggregate of 20,000 shares of common stock at an exercise price of $2.00 per share. The option vests as to 6,667 shares on each of August 15, 2018 and August 15, 2019 and as to 6,666 shares on August 15, 2020 and remains exercisable as to each such installment for three years from the date of vesting.				Under the 2016 Stock Option and Award Plan, the Board awarded a Science Advisor, the following three-year stock options: (i) an option to purchase 10,000 shares of common stock, exercisable on April 16, 2018 at an exercise price of $2.00 per share and (ii) an option to purchase 10,000 shares of common stock exercisable on April 16, 2019 at an exercise price of $2.00 per share, and (iii) an option to purchase 10,000 shares of common stock exercisable on April 16, 2020 at an exercise price of $2.00 per share, provided the advisor is still providing services to the Company. provided the advisor is still providing services to the Company.	Under the 2016 Stock Option and Award Plan, the Board awarded two of its Science Advisors the following three-year stock options: (i) an immediately exercisable option to purchase 6,667 shares of common stock at an exercise price of $2.00 per share, (ii) an option to purchase 6,667 shares of common stock exercisable on November 15, 2018 at an exercise price of $2.00 per share and (iii) an option to purchase 6,666 shares of common stock exercisable on November 15, 2019 at an exercise price of $2.00 per share, provided the advisors are still providing services to the Company.
2016 Stock Option and Award Plan one [Member]
Stock Plan (Textual)
Description of services agreement						Under the 2016 Stock Option and Award Plan, the Board awarded a Science Advisor, the following three-year stock options: (i) an option to purchase 15,000 shares of common stock, exercisable on November 15, 2018 at an exercise price of $0.40 per share and (ii) an option to purchase 15,000 shares of common stock exercisable on November 15, 2019 at an exercise price of $0.40 per share, provided the advisor is still providing services to the Company.
Board of Directors Chairman [Member]
Stock Plan (Textual)
Stock award				440,000
Receive common stock vest upon grant date				150,000
Vested shares		145,000		145,000
Board of Directors Chairman [Member] \| December 14, 2018 [Member]
Stock Plan (Textual)
Vested shares								145,000
Stock awards are expected to vest [Member] \| Fourth Quarter [Member]
Stock Plan (Textual)
Vested shares								290,000

XML 42 R33.htm IDEA: XBRL DOCUMENT

Capital Stock (Details) - Measurement Date [Member] - Stock Purchase Warrants [Member]	9 Months Ended
	Sep. 30, 2018 $ / shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Dividend yield	0.00%
Stock Price	$ 0.25
Exercise Price	$ 0.40
Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected volatility	119.33%
Risk-free interest rate	1.60%
Expected life (years)	2 years 11 months 1 day
Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected volatility	97.90%
Risk-free interest rate	1.47%
Expected life (years)	2 years 8 months 16 days

XML 43 R34.htm IDEA: XBRL DOCUMENT

Capital Stock (Details 1) - Stock Purchase Warrants [Member] - $ / shares

9 Months Ended

12 Months Ended

Sep. 30, 2018

Dec. 31, 2017

Warrants

Outstanding - Beginning balance

^[1]

54,000

502,000

Granted

^[1]

64,000

Forfeited/Canceled

^[1]

Exercised

^[1]

2,000

512,000

Outstanding - Ending balance

^[1]

52,000

54,000

Weighted Average Exercise Price

Outstanding - Beginning balance

$ 0.40

Granted

0.40

Forfeited/Canceled

Exercised

0.40

^[2]

0.40

^[3]

Outstanding - Ending balance

$ 0.40

[1]	Each two shares of common stock purchased under the private placement provides for one warrant to acquire an additional share of common stock together with the payment of $0.40.
[2]	During the nine-month period ended September 30, 2018, investors exercised 2,000 share purchase warrants and received 1,715 underlying shares for exercise on a cashless basis.
[3]	During the year ended December 31, 2017, investors exercised 512,000 share purchase warrants and received 442,960 underlying shares for exercise on a cashless basis.

XML 44 R35.htm IDEA: XBRL DOCUMENT

Capital Stock (Details Textual) - USD ($)

1 Months Ended

9 Months Ended

12 Months Ended

Jun. 23, 2018

Feb. 06, 2018

Dec. 14, 2017

Dec. 13, 2017

Sep. 16, 2018

Apr. 23, 2018

Jan. 23, 2018

Sep. 30, 2018

Dec. 31, 2017

Capital Stock (Textual)

Common stock, shares authorized

100,000,000

Common stock, par value

$ 0.0001

Series A Preferred Shares, shares issued

2,000

Series A Preferred Shares, shares outstanding

2,000

Series A Preferred Shares, authorized

10,000

Series A Preferred Shares, par value

$ 0.001

Shares issued for advisory services, value

75,000

Subscriptions shares

128,000

Warrant, description

Warrants received underlying shares for exercise on a cashless basis

442,960

Investor relations agreement, description

The Company gave notice of rescission of the agreement to such firm and requested the return of the consulting fee paid and the 75,000 shares of common stock. As a result, the Company has not recorded any fees for services rendered past June 23, 2018. A total of $10,000 representing April 2018 and May 2018 monthly consulting fees is reflected in the statement of operations and a total of $150,000, the fair market value of the issued shares, was expensed on issue.

The Company issued 75,000 shares of its common stock in respect of an investor relations services agreement which was rescinded on June 23, 2018 (Note 6(5)). The shares were valued at the fair market value on the date of issuance for a total of $150,000, or $2.00 per share.

Additional share of common stock per share

$ 0.40

License Agreement Terms [Member]

Capital Stock (Textual)

Share issued for agreement

119,950

Conversion value

$ 335,860

Conversion of stock par value

$ 2.80

Investors [Member]

Capital Stock (Textual)

Warrant exercise

2,000

Warrants received underlying shares for exercise on a cashless basis

1,715

Scientific Advisors [Member]

Capital Stock (Textual)

Share issued for agreement

290,000

Conversion value

$ 812,000

Conversion of stock par value

$ 2.80

Private Placement [Member]

Capital Stock (Textual)

Sale and issuance of common stock

22,728

312,500

Total proceeds of subscriptions amount

$ 25,000

$ 500,000

$ 32,000

Investor relations agreement, description

The Company issued 10,000 shares for advisory services (Note 6(4)). The shares were valued at fair market value on the date of issuance for a total of $28,000 or $2.80 per share.

Warrant [Member]

Capital Stock (Textual)

Warrant exercise

^[1]

2,000

512,000

Series A Preferred Stock [Member]

Capital Stock (Textual)

Preferred stock, conversion basis, description

[1]	Each two shares of common stock purchased under the private placement provides for one warrant to acquire an additional share of common stock together with the payment of $0.40.

XML 45 R36.htm IDEA: XBRL DOCUMENT

Subsequent Events (Details) - Subsequent Event [Member]	Oct. 08, 2018 USD ($) shares
Subsequent Events (Textual)
Sale and issuance of common stock \| shares	22,728
Total proceeds of subscriptions amount \| $	$ 25,000

EXCEL 46 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 47 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 48 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 50 FilingSummary.xml IDEA: XBRL DOCUMENT 3.10.0.1 html 114 191 1 true 34 0 false 4 false false R1.htm 001 - Document - Document and Entity Information Sheet http://www.biolabmart.com/role/DocumentAndEntityInformation Document and Entity Information Cover 1 false false R2.htm 002 - Statement - Condensed Balance Sheets (Unaudited) Sheet http://www.biolabmart.com/role/CondensedBalanceSheetsUnaudited Condensed Balance Sheets (Unaudited) Statements 2 false false R3.htm 003 - Statement - Condensed Balance Sheets (Unaudited) (Parenthetical) Sheet http://www.biolabmart.com/role/CondensedBalanceSheetsUnauditedParenthetical Condensed Balance Sheets (Unaudited) (Parenthetical) Statements 3 false false R4.htm 004 - Statement - Condensed Statements of Operations (Unaudited) Sheet http://www.biolabmart.com/role/CondensedStatementsOfOperationsUnaudited Condensed Statements of Operations (Unaudited) Statements 4 false false R5.htm 005 - Statement - Condensed Statements of Cash Flows (Unaudited) Sheet http://www.biolabmart.com/role/CondensedStatementsOfCashFlowsUnaudited Condensed Statements of Cash Flows (Unaudited) Statements 5 false false R6.htm 006 - Disclosure - Description of Business and Basis of Presentation Sheet http://www.biolabmart.com/role/DescriptionOfBusinessAndBasisOfPresentation Description of Business and Basis of Presentation Notes 6 false false R7.htm 007 - Disclosure - Summary of Significant Accounting Policies Sheet http://www.biolabmart.com/role/SummaryOfSignificantAccountingPolicies Summary of Significant Accounting Policies Notes 7 false false R8.htm 008 - Disclosure - Going Concern Sheet http://www.biolabmart.com/role/GoingConcern Going Concern Notes 8 false false R9.htm 009 - Disclosure - Convertible Note - Related Party and Derivative Liabilities Sheet http://www.biolabmart.com/role/ConvertibleNoteRelatedPartyAndDerivativeLiabilities Convertible Note - Related Party and Derivative Liabilities Notes 9 false false R10.htm 010 - Disclosure - License and Research Funding Agreements Sheet http://www.biolabmart.com/role/LicenseAndResearchFundingAgreements License and Research Funding Agreements Notes 10 false false R11.htm 011 - Disclosure - Commitments Sheet http://www.biolabmart.com/role/Commitments Commitments Notes 11 false false R12.htm 012 - Disclosure - Stock Plan Sheet http://www.biolabmart.com/role/StockPlan Stock Plan Notes 12 false false R13.htm 013 - Disclosure - Capital Stock Sheet http://www.biolabmart.com/role/CapitalStock Capital Stock Notes 13 false false R14.htm 014 - Disclosure - Subsequent Events Sheet http://www.biolabmart.com/role/SubsequentEvents Subsequent Events Notes 14 false false R15.htm 015 - Disclosure - Summary of Significant Accounting Policies (Policies) Sheet http://www.biolabmart.com/role/SummaryOfSignificantAccountingPoliciesPolicies Summary of Significant Accounting Policies (Policies) Policies http://www.biolabmart.com/role/SummaryOfSignificantAccountingPolicies 15 false false R16.htm 016 - Disclosure - Summary of Significant Accounting Policies (Tables) Sheet http://www.biolabmart.com/role/SummaryofSignificantAccountingPoliciesTables Summary of Significant Accounting Policies (Tables) Tables http://www.biolabmart.com/role/SummaryOfSignificantAccountingPolicies 16 false false R17.htm 017 - Disclosure - Convertible Note - Related Party and Derivative Liabilities (Tables) Sheet http://www.biolabmart.com/role/ConvertibleNoteRelatedPartyAndDerivativeLiabilitiesTables Convertible Note - Related Party and Derivative Liabilities (Tables) Tables http://www.biolabmart.com/role/ConvertibleNoteRelatedPartyAndDerivativeLiabilities 17 false false R18.htm 018 - Disclosure - Stock Plan (Tables) Sheet http://www.biolabmart.com/role/StockPlanTables Stock Plan (Tables) Tables http://www.biolabmart.com/role/StockPlan 18 false false R19.htm 019 - Disclosure - Capital Stock (Tables) Sheet http://www.biolabmart.com/role/CapitalStockTables Capital Stock (Tables) Tables http://www.biolabmart.com/role/CapitalStock 19 false false R20.htm 020 - Disclosure - Summary of Significant Accounting Policies (Details) Sheet http://www.biolabmart.com/role/SummaryOfSignificantAccountingPoliciesDetails Summary of Significant Accounting Policies (Details) Details http://www.biolabmart.com/role/SummaryofSignificantAccountingPoliciesTables 20 false false R21.htm 021 - Disclosure - Summary of Significant Accounting Policies (Details 1) Sheet http://www.biolabmart.com/role/SummaryOfSignificantAccountingPoliciesDetails1 Summary of Significant Accounting Policies (Details 1) Details http://www.biolabmart.com/role/SummaryofSignificantAccountingPoliciesTables 21 false false R22.htm 022 - Disclosure - Summary of Significant Accounting Policies (Details Textual) Sheet http://www.biolabmart.com/role/SummaryOfSignificantAccountingPoliciesDetailsTextual Summary of Significant Accounting Policies (Details Textual) Details http://www.biolabmart.com/role/SummaryofSignificantAccountingPoliciesTables 22 false false R23.htm 023 - Disclosure - Convertible Note - Related Party and Derivative Liabilities (Details) Sheet http://www.biolabmart.com/role/ConvertibleNoteRelatedPartyAndDerivativeLiabilitiesDetails Convertible Note - Related Party and Derivative Liabilities (Details) Details http://www.biolabmart.com/role/ConvertibleNoteRelatedPartyAndDerivativeLiabilitiesTables 23 false false R24.htm 024 - Disclosure - Convertible Note - Related Party and Derivative Liabilities (Details 1) Sheet http://www.biolabmart.com/role/ConvertibleNoteRelatedPartyAndDerivativeLiabilitiesdetails1 Convertible Note - Related Party and Derivative Liabilities (Details 1) Details http://www.biolabmart.com/role/ConvertibleNoteRelatedPartyAndDerivativeLiabilitiesTables 24 false false R25.htm 025 - Disclosure - Convertible Note - Related Party and Derivative Liabilities (Details 2) Sheet http://www.biolabmart.com/role/ConvertibleNoteRelatedPartyAndDerivativeLiabilitiesDetails2 Convertible Note - Related Party and Derivative Liabilities (Details 2) Details http://www.biolabmart.com/role/ConvertibleNoteRelatedPartyAndDerivativeLiabilitiesTables 25 false false R26.htm 026 - Disclosure - Convertible Note - Related Party and Derivative Liabilities (Details Textual) Sheet http://www.biolabmart.com/role/ConvertibleNoteRelatedPartyAndDerivativeLiabilitiesDetailsTextual Convertible Note - Related Party and Derivative Liabilities (Details Textual) Details http://www.biolabmart.com/role/ConvertibleNoteRelatedPartyAndDerivativeLiabilitiesTables 26 false false R27.htm 027 - Disclosure - License and Research Funding Agreements (Details) Sheet http://www.biolabmart.com/role/LicenseAndResearchFundingAgreementsDetails License and Research Funding Agreements (Details) Details http://www.biolabmart.com/role/LicenseAndResearchFundingAgreements 27 false false R28.htm 028 - Disclosure - Commitments (Details) Sheet http://www.biolabmart.com/role/CommitmentsDetails Commitments (Details) Details http://www.biolabmart.com/role/Commitments 28 false false R29.htm 029 - Disclosure - Stock Plan (Details) Sheet http://www.biolabmart.com/role/StockPlanDetails Stock Plan (Details) Details http://www.biolabmart.com/role/StockPlanTables 29 false false R30.htm 030 - Disclosure - Stock Plan (Details 1) Sheet http://www.biolabmart.com/role/StockPlanDetails1 Stock Plan (Details 1) Details http://www.biolabmart.com/role/StockPlanTables 30 false false R31.htm 031 - Disclosure - Stock Plan (Details 2) Sheet http://www.biolabmart.com/role/StockPlanDetails2 Stock Plan (Details 2) Details http://www.biolabmart.com/role/StockPlanTables 31 false false R32.htm 032 - Disclosure - Stock Plan (Details Textual) Sheet http://www.biolabmart.com/role/StockPlanDetailsTextual Stock Plan (Details Textual) Details http://www.biolabmart.com/role/StockPlanTables 32 false false R33.htm 033 - Disclosure - Capital Stock (Details) Sheet http://www.biolabmart.com/role/CapitalStockDetails Capital Stock (Details) Details http://www.biolabmart.com/role/CapitalStockTables 33 false false R34.htm 034 - Disclosure - Capital Stock (Details 1) Sheet http://www.biolabmart.com/role/CapitalStockDetails1 Capital Stock (Details 1) Details http://www.biolabmart.com/role/CapitalStockTables 34 false false R35.htm 035 - Disclosure - Capital Stock (Details Textual) Sheet http://www.biolabmart.com/role/CapitalStockDetailsTextual Capital Stock (Details Textual) Details http://www.biolabmart.com/role/CapitalStockTables 35 false false R36.htm 036 - Disclosure - Subsequent Events (Details) Sheet http://www.biolabmart.com/role/SubsequentEventsDetails Subsequent Events (Details) Details http://www.biolabmart.com/role/SubsequentEvents 36 false false All Reports Book All Reports qron-20180930.xml qron-20180930.xsd qron-20180930_cal.xml qron-20180930_def.xml qron-20180930_lab.xml qron-20180930_pre.xml http://fasb.org/srt/2018-01-31 http://xbrl.sec.gov/dei/2018-01-31 http://fasb.org/us-gaap/2018-01-31 true true ZIP 52 0001594062-18-000183-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001594062-18-000183-xbrl.zip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